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CHAPTER 1: GENERAL INTRODUCTION AND 
CHAPTER OUTLINE
THE IMMUNE SySTEM
The immune system has evolved to protect the body against pathogens. It comprises both 
humoral and cellular components that act in concert to eliminate pathogens. Cells of the 
immune system are classically divided into innate and adaptive immune cells. Innate immune 
cells are regarded as a first line of defense because they can immediately respond to pathogens 
in a generic way, whereas adaptive immune cells recognize individual antigens with specialized 
antigen receptors, leading to a delayed but highly specific immune response. Innate immune cells 
comprise macrophages, dendritic cells (DC), neutrophils, eosinophils, basophils, mast cells and 
natural killer (NK) cells. T and B cells are part of the adaptive immune system, each cell carrying 
a unique T cell receptor (TCR) or B cell receptor (BCR), respectively. While the BCR can directly 
interact with the antigen, the TCR recognizes sequences derived from foreign molecules bound 
to major histocompatilibity complex (MHC) proteins. T cells can carry either CD4 or CD8 as a 
co-receptor for the TCR. CD4+ T cells respond to peptides bound to MHC-class II and CD8+ T cells 
are targeted towards MHC-class I-peptide complexes. In general, CD8+ T cell responses lead to 
elimination of (infected) target cells while CD4+ T cells provide help for such cytotoxic CD8 T cells 
and facilitate the production of immunoglobulins by antigen specific B cells. In addition, subsets 
of T cells, such as natural killer T cells (NKT) and mucosa-associated invariant T (MAIT) cells, can 
respond to non-peptide antigens bound to non-classical MHC molecules. A unique feature of 
the adaptive immune response is immunological memory: once exposed to a certain pathogen, 
pathogen-specific T and B cells expand and form a memory pool that can mediate accelerated 
and stronger responses towards the same pathogen upon re-exposure.
T CELLS 
Leukocytes originate in the bone marrow and either develop and mature there or migrate to 
the thymus for further differentiation. Whereas NK cells mainly complete their differentiation 
in the bone marrow, T cells generally mature in the thymus. Nevertheless, recent evidence for 
NK and T cell development in secondary lymphoid organs such as the spleen, lymph nodes 
or the liver have also been presented 1, 2. In the thymus distinct T cell lineages are generated: 
T cells carrying a TCRαβ or TCRγδ, which can express the co-receptors CD4 or CD8. Through 
somatic recombination T cells randomly rearrange TCR genes, creating a unique and diverse TCR 
repertoire.  Recombination is carried out by enzymes encoded by recombination activating genes 




deoxynucleotidyl transferase (TdT), which randomly inserts nucleotides during the recombination 
event, generating further diversity in the T cell receptor repertoire. Developing T cells go through 
a series of developmental stages, which have been thoroughly characterized. Immature T cells 
sequentially pass through a CD3-CD4-CD8- double-negative (DN), a CD3low double-positive (DP), 
and a CD3+ single-positive CD4 or CD8+ stage, which eventually yields committed and fully 
matured specialized T cell subsets. Moreover; in the thymus four stages of DN cells (DN1-4) can 
be discriminated by a combination of markers, including CD25, CD44, c-kit (CD117) and CD34. 
While DN1 and DN2 cells still have the potential to differentiate into other lineage such as DC or 
NK cells (Figure 1), at the DN2 and DN3 stages T cell commitment is initiated and completed. It 
is generally believed that upon commitment to a certain lineage, the cell fate is set due to the 
expression of particular  transcription factors and epigenetic changes (T cell differentiation is 
reviewed in 1, 3). Throughout the T cell maturation process, the expression of the CD3ε, CD3γ, 
CD3δ and ζ chains are gradually upregulated resulting in the protein expression of all CD3 chains 
intracellularly before their association with the T cell receptor dimer and translocation to the 
surface of mature T cells 4.  The expression of the T cell receptor on the surface is therefore 
dependent on the presence of the CD3 chains. 
During the past few years several factors that are essential for thymic T cell maturation have 
been characterized. Receptor-ligand interactions such as notch and notch-receptors are now 
recognized to be crucial in T cell commitment (reviewed in 5). Knowledge about such factors has 
laid the groundwork for the development of in vitro T cell differentiation culture systems, such as 
the generation of the mouse bone-marrow cell line OP9 transduced with the notch-ligand delta-
like 1 (OP9DL1). Progenitor cells that are seeded on these OP9DL1 stroma cells (with the addition 
of cytokines such as FLT3L, SCF and IL-7) can develop into mature TCRαβ or TCRγδ T cells 6. 
To effectively recognize pathogen-derived antigens while maintaining tolerance to self-antigens, T 
cells that have rearranged the T cell receptor (TCR) undergo an extensive selection process in the 
thymus.  To ensure that the TCR generated will recognize foreign but not self-antigens presented 
by MHC, T cells with a TCR capable of recognizing self-antigens with a low affinity are positively 
selected in the thymus while T cells carrying a T cell receptor recognizing MHC/self-peptide with 
too strong of an affinity are deleted (negative selection). This process results in CD8+ T cells, able 
to detect ‘non-self’ peptides in the context of MHC class I and CD4+ T cells recognizing ‘non-self’ 
peptides on MHC class II. Despite this strict selection process, not all TCR with high affinity for 
self-antigens are successfully eliminated. T cells carrying an autoreactive TCR can still be deleted 
or silenced in the periphery. Failure of central (thymic) and pheripheral regulatory mechanisms 
contributes to the development of autoimmunity in diseases like rheumatoid arthritis (RA), type 1 
diabetes (T1D) and multiple sclerosis (MS).
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Only a minority of T cells survives the positive and negative selection in the thymus and 
subsequently leaves the thymus in anticipation of its specific antigen. During an infection, 
activation of these naïve T cells occurs in lymph nodes, where recirculating T cells come in close 
contact to antigen-presenting cells (APC) such as DC, that have encountered pathogens in the 
periphery. Before moving to draining lymph nodes, these DC have been activated by pathogens 
via conserved receptors recognizing damage-associated molecular patterns (DAMPs) or 
pathogen-associated molecular patters (PAMPs) and engulfed the pathogen in order to present 
pathogen-derived peptides via MHC. Upon MHC-restricted recognition of the presented antigens 
on APC in lymph nodes, T cells are either silenced or turned into effector cells, depending on the 
level of costimulation provided by the APC and the local cytokine milieu.  
Upon activation effector T cells clonally expand and most cells die once the pathogen is cleared, 
but a small fraction survives as memory cells, responsible for immunological memory. Effector 
CD8+ T cells are cytotoxic T cells lymphocytes (CTL), capable of lysing infected cells, while CD4+ T 
cells (T-helper cells) produce various cytokines, help B cell antibody class switching and activate 
other immune cells. In contrast to other tissues, the intestine is overrun with foreign antigens 
from food, pathogenic or harmless commensal bacteria, emphasizing the need to preserve 
tolerance and prevent systemic immune reactions.
NK CELLS 
NK cells are cytolytic effector cells that play an essential role in immune defense, particularly 
in the first week of primary infections with intracellular pathogens. Individual NK cells 
express multiple inhibitory and activating receptors and depending on the triggering either 
become activated or not (reviewed in 7). Inhibitory receptors, such as a subset of killer-cell 
immunoglobulin-like receptors (KIR) and the CD94/NKG2A heterodimer, recognize MHC class I 
and suppress NK cell responses upon recognition. Cells that have downregulated MHC-I either 
as a result of virus infection or malignant transformation are targets for activated NK cells, which 
then lyse these cells. This mechanism has been described as ‘missing-self’. NK cells also express 
activating receptors, such as CD16, Nkp46, Nkp44, NKG2D, CD244 (2B4) and several activating 
KIR, which tend to recognize ligands that are upregulated on infected and transformed cells 8. 
Upon activation NK cells can kill target cells and produce pro-inflammatory cytokines such as IFNγ 
and TNFα. In addition, they are able to activate DC.
NK cells develop in the bone marrow and in secondary lymphoid organs. As for T cells, distinct 
NK cell developmental stages have been defined in detail (reviewed in 2). NK and T cells share a 
common CD34+ T/NK cell progenitor that is found in the bone marrow and also in the thymus.  




Nevertheless, it is generally believed that the thymic microenvironment favors T over NK cell 
differentiation 9. In humans, committed NK cell precursors are defined as CD34+CD7+CD3- cells 
that express CD122 (IL-15/IL-2Rβ) transcripts, an essential component of the IL-15-receptor 10. 
Upon IL15-dependent maturation, NK cell progenitors lose CD34 expression and mature NK cells 
are characterized by the expression of CD56 and NKp46, among others (Figure 1). 
Occasionally individual lymphocytes can undergo malignant transformation and develop into 
systemic leukemias or tissue-resident lymphomas. Based on morphological criteria, genetic 
evaluation and immunophenotyping, it has become clear that such malignancies can arise at 
any stage of lymphocyte development. They are classified accordingly in the WHO classifications 
of leukemias and lymphomas 11. Examples of immature T cell leukemias are the common acute 
lymphoblastic leukemia, or the acute lymphoblastic leukemia (T-ALL) and more mature T cell 
leukemias include Sezary syndrome or the adult T cell leukemia. The distinct types of lymphomas 
are subdivided according to the cell type a lymphoma arises from (B, T, NK cells) and the 
grade of proliferation (low or high grade). Examples of high-grade lymphomas are peripheral 
T cell lymphomas including anaplastic large cell lymphoma and enteropathy-associated T-cell 
lymphoma (EATL). 
THE INTESTINAL IMMUNE SySTEM
Mucosal surfaces of the gastrointestinal, respiratory or urogenital tract, but also their associated 
glands (such as salivary glands) or the lactating breast are in close contact to both harmful 
invading pathogens and commensal bacteria from the environment. At the same time they 
serve essential functions, such as nutrient absorption in the intestine or exchange of oxygen 
and carbon dioxide in the lung. Altogether mucosal surfaces form an enormous surface area to 
protect. To meet these demands, the intestine possesses specialized anatomical features and 
harbors an elaborate compartment of innate and adaptive immune cells, with distinct features 
compared to their counterparts in other organs or the blood. Immune cells from mucosal sites 
can circulate from any mucosal site to the other via the expression of specific epithelial adhesion 
and chemokine receptors, a mechanism referred to as lymphocyte homing. This facilitates the 
coordinated immune responses towards pathogens at various mucosal sites and the protection 
of the entire mucosal surfaces. Even though immune cells at mucosal sites show an activated 
phenotype, inhibitory mechanisms downregulate the local immune response to non-pathogenic 
antigens such as food-derived antigens or commensal bacteria. In fact, oral administration of 
antigens leads to the peripheral suppression of immune responses against these same antigens 
at non-mucosal sites -a principle known as oral tolerance 12. The intestine for instance harbors 
trillions of microbes, which are introduced early in childhood during birth and by weaning, as 
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FIGURE 1. HUMAN T AND NK CELL DEvELOPMENT. The cartoon shows the main 
developmental stages of T and NK cells, which for NK cells mainly take place in the bone marrow 
and for T cells mainly in the thymus 1, 2. Nevertheless, NK and T cell differentiation has been 
described for secondary lymphoid organs such as lymph nodes, spleen, liver  1, 2 or NK cell 
differentiation for the thymus 9 (not depicted here). At immature developmental stages (marked 
by the grey box), cells can still switch developmental paths either towards T or NK cells and a 
common T/NK cell progenitor (PG-progenitor) is characterized by the expression of CD34 and/
or CD117. Upon maturation NK cells express CD56, NKp46 and KIR, whereas mature T cells are 
characterized by surface CD3 (along with the TCR) and CD5 expression (grey triangle indicates 




food may carry microbes. The presence of such enormous amounts of microbes in the intestine 
renders it the most densely populated organ in the body. Yet, under physiological conditions, a 
mutual beneficial interplay between microbes and the host persists (reviewed in 13).   
Anatomically, the intestine is composed of the small and the large intestine. The small intestine 
consists of the duodenum, which connects to the stomach, the jejunum and the ileum, which 
attaches to the large intestine. The main function of the small intestine is the digestion of food 
and the absorption of nutrients and water. At the same time the small intestine is the first line of 
defense against various pathogens entering via the same route. The small and the large intestine 
show large structural and functional differences with regards to the composition and size of the 
microbial community -of which the vast majority is present in the large intestine-, ion and nutrient 
concentration, pH, oxygen tension and retention time or composition of the surface structure, 
among others. The small intestine has a larger surface area compared to the large intestine as it 
is composed of finger-like structures which protrude into the lumen, shaping a landscape of villi 
(extrusions) and crypts (intrusions). This network of villi and the expression of additional microvilli 
on enterocytes increases the overall surface for optimized absorption of nutrients and results 
in an immense surface area of 200-400m2  14. Even though the barrier between the lumen -the 
content of the gut- and the body consists only of a single layer of epithelial cells, this barrier has to 
maintain both absorption of essential nutrients and contribute to the defense against pathogens. 
To perform these tasks, the intestinal epithelium consists of enterocytes which absorb nutrients, 
while secretory cells, such as goblet cells produce a sophisticated matrix of mucus supporting the 
barrier function against pathogens. Furthermore, the epithelium consists of hormone-producing 
(endocrine) cells, anti-bacterial lysozyme-producing paneth cells and stem cells replenishing 
these specialized cell types. These stem cells provide continuous, rapid cell renewal of the entire 
epithelial population, with a turnover rate of approximately 60h and a strict regulation of cell 
birth, differentiation and cell death. As proliferating stem cells differentiate, they move upwards 
from the crypt towards the villi, where they are shed into the lumen and are discarded with the 
feces (reviewed in 15). These epithelial cell types are situated on a basal membrane which serves 
as a boundary to the underlying lamina propria (LP).  
    
The epithelium and the lamina propria contain distinct populations of immune cells. CD8+ T 
cells comprise the major proportion of the intraepithelial lymphocytes (IEL) which are located 
between the enterocytes in the epithelium while in the lamina propria both CD8 and CD4 positive 
T cells are present, as well as B cells and an abundance of antibody secreting plasma cells. In 
addition dendritic cells reside mainly in the lamina propria, but can sample luminal antigens via 
protrusion of dendrites through the epithelium 16 or via interaction with goblet cells 17. In addition, 
various innate immune cell populations are located in the lamina propria, such as macrophages, 
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mast cells, basophils, eosinophils and innate lymphoid cells (ILC), which play important roles 
in tissue remodeling and immunity against viruses and bacteria (reviewed in 18). These innate 
immune cells, which also include NK cells, rapidly sense and initiate immune reactions towards 
pathogens while tolerance to harmless antigens is maintained. It is becoming increasingly clear 
that also enterocytes and goblet cells actively participate in these processes by expressing 
pattern-recognition receptors (PRRs) amongst others, which can detect conserved motives from 
pathogens (reviewed in 19). Furthermore, organized lymphoid structures in the LP harbor various 
lymphocyte subsets whose function it is to induce and synchronize a tailored immune response. 
These structures are classified as gut-associated lymphoid tissue (GALT) and include peyer’s 
patches with microfold cells (M cells), which are specialized in antigen-uptake, cryptopatch (CP)-
like structures 20 and isolated lymphoid follicles (reviewed in 21). 
Deregulation of intestinal immune responses can contribute to a variety of inflammatory bowel 
diseases like Crohn’s disase, ulcerative colitis and celiac disease. Whereas Crohn’s disease can 
affect the entire intestine, ulcerative colitis only affects the large intestine (colon) and celiac 
disease generally affects the small intestine. 
INTRAEPITHELIAL LyMPHOCyTES
Intraepithelial lymphocytes (IEL) are situated at the basolateral side of the epithelium, dispersed 
in between the epithelial cells. In the small intestine IEL are mainly located in the crypts, with 
decreasing frequencies of IEL towards the tip of the villi. The healthy small intestine displays a 
characteristic IEL distribution pattern 22, 23. As IEL are in close contact with enterocytes, they are 
generally believed to contribute in preserving the mucosal barrier integrity, as well as inhibiting 
pathogen entry and distribution by lysing infected epithelial cells. Furthermore, IEL possess 
immune-regulatory functions, dampening unwanted immune reactions and limiting potent 
immune responses directed against pathogen entry to the site of infection (reviewed in 24).  
 
The majority of small intestinal IEL in humans and mice are TCRαβ and TCRγδ T cells (T-IEL). Most 
of these express CD8, whereas CD4+ T-IEL form a minority population in the epithelium.  All IEL 
constitutively express the epithelial adhesion marker CD103 (αE chain) in association with the 
β7 chain, thus forming the αEβ7 heterodimer. CD103 expression distinguishes IEL from blood-
derived lymphocytes, where only a minority is CD103 positive. The αEβ7 heterodimer specifically 
interacts with E-Cadherin which is expressed on epithelial cells and is therefore essential to 
the gut homing and retention of IEL 25-27. Furthermore, the majority of IEL express antigen-
experienced/memory T cell markers, the T/NK cell maker CD7 28 (Thy-1 in mice 24) and a variety 




mice and men demonstrate that the repertoire is polyclonal after birth but becomes oligoclonal in 
adults (reviewed in 35), likely the result of the expansion of particular T-IEL. 
MICE 
In mice the majority (60%) of T-IEL is composed of TCRγδ+ cells 36, 37 which express CD8αα 
homodimers. CD8αα serves as an activation marker, being expressed either by itself or in 
combination with CD4 or CD8αβ and binds to thymus leukemia antigen (TLA), a non-classical 
MHC-I molecule which is abundantly expressed in the small intestine 24.  The composition of IEL 
can be influenced by the intestinal environment such as by colonization with microbes or by 
dietary antigens. Studies in mice for example, show that the IEL pool is reduced in an antigen-
deprived environment 38, 39 and is influenced by dietary compounds, such as aryl hydrocarbon 
receptor (AhR)-ligands in cruciferous vegetables 40 and vitamin D 41. As the small intestine harbors 
considerably fewer microbes than the colon, but contains many more IEL, it is therefore possible 
that the response to dietary antigens in the small intestine is more pronounced than in the colon.  
  
In mice two subtypes of IEL can be classified according to their phenotype and origin of 
development: induced (type a) and natural (type b) T-IEL. Whereas induced IEL in mice are 
derived from conventional T cells, which become activated by peripheral antigens, natural IEL 
are assumed to develop in the thymus in the presence of self-antigens (referred to as agonist 
selection) or complete their development in the intestine 24. In fact, pre-committed T cell 
precursors have been found in the thymus, which can complete their maturation under the 
influence of the local intestinal cytokine IL-15 in the gut 42, 43.  If extrathymic T cell differentiation 
from early progenitor cells exists in the intestine, is a subject of a long-standing debate (reviewed 
in 44). Evidences against and in favor of intestinal T cell development have been adduced for mice 
and humans. The absence of detectable RAG proteins in the intestine 45 and the complexity of the 
thymic environment necessary for TCR selection are prominent reasons to oppose extrathymic 
T cell development. Nevertheless, athymic mice show reduced, but non eliminated TCRαβ and 
TCRγδ T-IEL populations, which increase with age 46, 47. This could indicate that the majority of 
T-IEL develops in the thymus, but a minority could develop locally. Furthermore, in the intestine 
evidence of ongoing T cell differentiation has been presented for lineage-negative (Lin-) cells, thus 
for cells lacking surface markers of all known lineages. Molecular evidence of T cell development 
in Lin- cells include preTα expression 48, 49, initiation of TCR rearrangements and the presence of 
intracellular CD3 chains 50. Moreover, CD8+ T-IEL could be reconstituted from Lin- cells in athymic 
RAG2/γc- mice 50 as well as CD8αα+ T-IEL from Lin- cells derived from CP 51, 52. It is therefore 




Considerably less is known about human IEL development. In humans only a minority of the 
T-IEL express CD8αα 28, 53, 54 and due to the limitations of studies with human primary tissue only 
indirect evidence for in situ IEL development is available 55, 56. Nevertheless evidence for the 
presence of T cell precursors within a CD3- IEL population exists 55, 56. Others have shown that 
enzymes necessary for TCR rearrangements such as RAG-1 are expressed in the small intestine 
57-59, while only a minor proportion of cells were found positive for TdT 54. The exact phenotype of 
the putative T cell precursors was not determined. It is also unknown if these cells have a thymic 
origin and which factors are crucial for their local development.   
In humans IEL are composed of about 70-80% of TCRαβ+ CD8αβ+ and the remaining are TCRγδ+ 
(either CD4-CD8- or CD8+) (5-20%), or CD4+ TCRαβ+ (10-15%) 60. Human TCRγδ+ predominantly 
express Vδ1 61-63 which recognizes non-classical MHC-I-related molecules such as CD1c 64 and MIC 
proteins 65-67. Furthermore, 10% of the IEL are CD3- IEL, some of which are functional NK cells 68, 
69. In fact, T-IEL also express several NK cell receptors such as NKG2D 31, 32, 70, CD94 34, 69 71, CD56 34, 72 
and CD161 34, 69.  Furthermore, T-IEL can be activated without engagement of the TCR 31, 32, 70. 
Thus, in mice and men T-IEL show an activated -yet resting- innate-like phenotype. IEL therefore 
represent unique types of activated lymphocytes, which are tightly regulated under physiological 
conditions and likely play an important role in the maintenance of intestinal homeostasis.
CELIAC DISEASE
Celiac disease (CD) is a gluten induced enteropathy of the small intestine, caused by the ingestion 
of gluten compounds in genetic susceptible individuals. The prevalence of CD is around 1 % in 
the western population and is therefore one of the most common intestinal disorders 73. CD can 
affect both children and adults. It is still unclear why some individuals develop CD during infancy 
or childhood, while others acquire the disease at a later stage in adulthood. Classical clinical 
manifestations such as diarrhea, failure to thrive and abdominal distention are mostly found in 
children. CD can also present with diverse symptoms such as anemia, osteoporosis, dermatitis 
herpetiformis and neurological symptoms which are part of a complex spectrum of clinical 
manifestations associated with celiac disease due to malabsorption and autoimmune phenomena 
73, 74.      
Celiac disease is generally diagnosed by the detection of auto-antibodies against tissue 
transglutaminase (tTG) in the serum 75. If tTG auto-antibodies are detected, duodenal biopsies 
are taken and analyzed by histology. Celiac lesions demonstrate typical histological features, such 




the epithelium. Collectively these histological abnormalities are included in a diagnostic scoring 
system for disease severity which is reflected in the Marsh criteria 76 77. After diagnosis patients are 
treated with a life-long gluten free diet (GFD), avoiding any gluten intake from wheat, barley and 
rye.  
Celiac disease has a strong autoimmune component, as auto-antibodies against tTG are detected 
in active CD patients. Furthermore, epidemiological studies show a strong link between CD and 
other autoimmune diseases such as type-1 diabetes and autoimmune thyroiditis 78.  In fact, such 
autoimmune comorbidities affect about 20% of adult CD patients 79. In the last decades it has 
been demonstrated that HLA-DQ2 and HLA-DQ8 are the major genetic predisposing factors in 
CD, as 90-95% of CD patients express HLA-DQ2 and the remaining 5-10% HLA-DQ8 (reviewed 
in 80). Besides HLA, other genes have been linked to CD by genome-wide association studies 
(GWAS), but these explain only approximately 5% of the genetic heritability 81. Therefore HLA 
itself is the strongest disease-associated gene in CD, accounting for about 35% of the genetic 
heritability 82. The nature of the remaining genetic heritability still has to be determined and could 
be explained by gene-gene interactions, or rare genetic variants (reviewed in 80). As about 25% of 
the western population is HLA-DQ2+, but only 4% of DQ2 carriers develop the disease, additional 
environmental or genetic factors also play a crucial role in disease development that still need to 
be determined 83.  
Environmental factors influencing CD development could be the amount of gluten intake, the age 
of gluten introduction into the diet of an infant 84, or viral infections, such as rotaviruses which 
lead to an increased risk of CD development 85. Nevertheless, more work is needed in order to 
understand the complex interplay of gene variations, gene networks and gene-environmental 
interactions, ultimately leading to CD development.  
The molecular basis for the association of CD with HLA-DQ2 and HLA-DQ8 was revealed when 
it was demonstrated that CD4+ T cells in the lamina propria (LP) can recognize gluten presented 
in a HLA-DQ2/8-restricted fashion 86, 87, 88-93. Such gluten-specific T cells have a pro-inflammatory 
phenotype characterized by the secretion of IFNγ 94 and IL-21 95. Moreover, generally such CD4+ 
T cells are found in small intestinal biopsies of patients but not in healthy controls and they are 
therefore generally held responsible for the intestinal inflammation of CD lesions due to gluten 
consumption. 
Gluten is unusually rich in the amino acids proline and glutamine, and the abundance of proline 
makes it relatively resistant to digestion by gastrointestinal enzymes, as compared to other food-
derived proteins 96. After partial digestion immunostimulatory gluten fragments can reach the 
intestine and trigger a cascade of immune reactions in the small intestinal LP in CD patients, which 
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has been extensively characterized in the last years. The local tissue-repair enzyme tTG can modify 
such gluten fragments by deamidation of particular glutamine residues into a negatively charged 
glutamic acid. This increases the binding affinity of gluten peptides to HLA-DQ2 and HLA-DQ8, 
thus amplifying the gluten-specific immune response 97, 98. Various immunodominant epitopes 
have been characterized for HLA-DQ2 and HLA-DQ8 and placed CD4+ T cells as key players in the 
gluten-mediated immune response 86, 87, 99, 100.       
The inflammatory reaction to gluten in the lamina propria has been shown to be absolutely 
necessary for the development of celiac disease, but might not be sufficient, as additional factors 
such as the activation and expansion of IEL most likely contribute to tissue destruction. In order to 
study the pathogenesis of CD one relies on limited patient material, as currently no mouse model 
is available that shows all key features of CD: the adaptive response to gluten, the innate response 
in the epithelium and LP and the autoimmunity component by the generation of tTG antibodies 
(reviewed in 101). In fact, mice engineered to express human HLA-DQ8 or HLA-DQ2 and a gluten-
specific TCR, mainly produced the anti-inflammatory cytokines IL-10 and TGFβ upon gluten 
challenge 102, 103, indicating that multiple factors are required in order to break the strong oral 
tolerance towards gluten. In another mice model, oral tolerance to gluten could be abrogated by 
the administration of both IL-15 and retinoic acid (a vitamin A metabolite) 104, implicating a great 
improvement in the development of murine CD models. If there is a causal relationship of retinoic 
acid intake and CD is currently unknown and the factors leading to the break of oral tolerance 
against gluten in CD patients remain to be elucidated.
REFRACTORy CELIAC DISEASE
Most celiac patients show remission from CD symptoms when following a gluten-free diet (GFD). 
Nevertheless a small percentage of patients do not respond to a GFD initially or relapse despite 
a strict GFD and are therefore diagnosed with refractory celiac disease (RCD). Refractory celiac 
disease is considered a rare disorder, with an estimate prevalence of 2-5 % in adult onset CD 
patients, which are generally above the age of 50 74.   
The diagnosis of RCD is based on exclusion criteria, where other pathological intestinal diseases 
such as autoimmune enteropathy, common variable immunodeficiency and tropical sprue 
are ruled out, as these diseases can mimic (R)CD symptoms 105. According to the phenotype, 
composition and clonality of IEL, RCD can further be subdivided in type I and type II, with 
substantial differences in clinical outcome. RCDI presents with oligoclonal, phenotypically normal 
IEL, composed mainly of T cells (T-IEL). RCDII on the other hand shows a massive expansion 
of clonal aberrant IEL, lacking surface markers characteristic for T cells such as CD4, CD8, CD3 
and the TCR, but expressing  CD3 intracellularly (ic) 106-108. The diagnosis of RCDI and RCDII is 




flow cytometry. To detect aberrant IEL, intestinal samples are stained for CD3ε in combination 
with T cell receptor or CD8 by immunohistochemistry 109 or - more accurately- IEL are isolated from 
biopsies and analyzed by flow cytometry 110. Clonal aberrant IEL are further analyzed by PCR and 
the presence of clonal rearrangements confirms the diagnosis of RCDII 106. As in CD, RCD shows 
a strong association with HLA-DQ2 and HLA-DQ2 homozygosity is particularly frequent in RCDII 
patients 111. 
No standardized therapeutic strategy has been defined for the treatment of RCDI and RCDII, 
except for parental nutrition in cases of severe malnutrition. Whereas RCDI can be treated 
effectively with immunosuppressant drugs 112, moderate success rate have been described 
for the treatment of RCDII with various chemotherapeutic drugs 108, 113 or autologous stem cell 
transplantation 114. 
Consequently, about 50% of RCDII patients progress and can develop an overt enteropathy-
associated lymphoma (EATL), thereby defining RCDII as a serious premalignant condition 107, 
108, 115. This is further illustrated by chromosomal aberrations found in aberrant IEL, which are 
particularly frequent within the chromosome 1q22-44 region 116. Upon transformation aberrant 
IEL can disseminate to other tissues such as the LP, blood and other organs 108, 117. As the 5-year 
survival rate in patients with RCDI is 80-96 % but only 44-58 % for patients with RCDII, this clearly 
demonstrates the necessity to further differentiate the diagnosis of RCDI and II to predict the 
clinical outcome 108, 112, 115.
INTRAEPITHELIAL LyMPHOCyTES IN CELIAC AND REFRACTORy CELIAC 
DISEASE
A classical feature of active CD is the expansion of IEL in the small intestine (IEL lymphocytosis), 
which is also used as a diagnostic criterion for CD. Histological studies on healthy biopsy material 
and CD lesions have set an IEL count for the upper limit of normal at 25 IEL/100 enterocytes, 
whereas >30 IEL/100 enterocytes is considered pathological 118. The distribution pattern of IEL 
also changes in CD, from a crypt-enriched pattern under physiological conditions, to a more 
scattered, continuous distribution mainly caused by elevated numbers of IEL in the tip of the villi 
22 (Figure 2). IEL lymphocytosis is a consequence of a significant increase of TCRγδ T-IEL, as well as 
TCRαβ T-IEL, whereas TCRαβ T-IEL counts decrease on a GFD to physiological levels -in contrast to 
persistently high numbers of TCRγδ T-IEL 119-121 (Figure 2). The GFD therefore leads to a moderate 
decrease in IEL counts, but already 12 hours after oral or rectal gluten challenge elevated IEL 
numbers can be detected, demonstrating a rapid epithelial response to gluten which precedes 
the onset of epithelial damage 76, 122. IEL lymphocytosis is not specific to CD as it is also found 
in gastric infections with h. pylori, bacterial overgrowth in the small intestine 123, tropical sprue 
22
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23 and can be caused by the use of nonsteroidal anti-inflammatory drugs 23, 124, but not in other 
gastroinflammatory diseases such as Crohn’s disease or autoimmune enteropathy. Like in CD the 
latter two diseases share a marked infiltration of lymphocytes in the LP, but do not reveal such a 
characteristic IEL expansion 23. Whether the increase of IEL in intestinal inflammation, such as in 
CD is caused by an expansion of local IEL, an influx of (mature or semi-mature) lymphocytes from 
extra-intestinal sites or by lymphocytes generated by local development from immature IEL is not 
known. 
However, several studies have demonstrated that in CD IEL can be highly cytotoxic 125, 126 and can 
kill epithelial cells via Fas, granzyme and perforin-mediated pathways 127, 128 and via the NK cell 
receptor NKG2D which binds to its ligand MICA on stressed enterocytes 31, 32, 70 (Figure 2). These 
studies also demonstrated a prominent role for the inflammatory cytokine IL-15 in NKG2D up-
regulation, therefore contributing to cytotoxicity. IL-15 plays an important role in the pathogenesis 
of CD 129, as it has been shown to be up-regulated both in the LP and the epithelium of CD 
patients, in comparison to controls 128, 130. 
Besides T-IEL, the epithelium also contains an ill-defined CD3- population which harbors functional 
NK cells 68, 69 and is decreased in CD patients in comparison to controls 69, 72, 131-133. Studies carried 
out on this enigmatic CD3- population further indicate that it is heterogeneous 69, 72, 131-133, most 
likely harboring various IEL subsets, amongst others also NK cells. Therefore the exact phenotype 
of the different CD3-IEL subsets is not determined, neither is the function of these CD3- cells under 
physiological and pathological conditions, nor the mechanisms leading to its reduction in CD. As 
aberrant IEL in RCDII patients show a similar phenotype of CD3-CD4-CD8-TCR- but intracellular 
CD3+, it was proposed that CD3- IEL could harbor the physiological precursors for aberrant IEL in 
RCDII 133. On the contrary it was also postulated that aberrant IEL could be derived from derailed 
T-IEL, which have down-regulated their TCR due to overstimulation 106.  
As previously mentioned, in RCDII more than 80% of IEL can display an aberrant phenotype, which 
distinguishes RCDII from RCDI where no to <20% of IEL have such a CD3- phenotype 106, 110. In RCDI 
patients IEL show the same characteristic phenotypes as active or treated CD, with increased or 
physiological levels of TCRγδ T-IEL 108. In RCDII aberrant IEL lack the T-IEL markers CD3, CD4, CD8 
and TCR, but express the common IEL markers CD45, CD7 and CD103 106-108, 134. Furthermore, 
aberrant IEL as T-IEL in CD express NKG2D 32, but lack the NK cell marker CD56 and CD16 106 and 
show clonal TCR rearrangement, which are mostly TCRγ -but also TCRδ or β rearrangements have 
been detected. Importantly, TCR rearrangements in aberrant IEL are almost always non-functional, 
out-of-frame or even completely absent 106, 108, 135, 136. Similar to T-IEL in CD, aberrant IEL show 
strong cytotoxicity towards epithelial cells and aberrant IEL cell lines (derived from RCDII biopsies) 




also shown to be up-regulated in the LP and the epithelium of RCDII patients, compared to 
controls 128. Different cell types such as enterocytes can present IL-15 via the IL-15Rα to adjacent 
cells (such as IEL) which respond via the IL-2/15Rβ (CD122). This mode of activation is called trans-
presentation and can take place in the intestinal epithelium (reviewed in 138). Aberrant IEL in RCDII 
patients have been shown to express CD122 128 and to be very sensitive to IL-15 by responding to 
low concentrations of IL-15 128, 134, 139. IL-15 can further induce IFNγ expression and cytotoxicity 32 
and the anti-apoptotic pathyway of Jak3, Stat5 and Bcl-xl in aberrant IEL 139. IL-15 therefore plays a 
crucial role in the accumulation of aberrant IEL in RCDII. As IL-15 strongly induces proliferation and 
exerts anti-apoptotic effects on aberrant IEL, it has been proposed that RCDII and EATL patients 
should be treated with IL-15-specific antibodies, neutralizing the detrimental effects of IL-15 on 
aberrant IEL 139.  
Whether or not elevated IL-15 is sufficient in inducing expansion and transformation of aberrant 
IEL, or in other words if blocking of IL-15 is sufficient in preventing the expansion or induction of 
cell death in an already enlarged aberrant IEL pool is not known. In fact, the expansion of aberrant 
IEL could be the result of multiple factors. It is furthermore important to determine the origin of 
aberrant IEL in order to understand how aberrant IEL develop and what makes them susceptible 







FIGURE 2. INTRAEPITHELIAL LyMPHOCyTES IN HEALTH AND CELIAC DISEASE
The cartoon depicts the key features of the epithelium and the role of intraepithelial lymphocytes 
(IEL) under physiological, celiac (CD) and refractory celiac (RCD) conditions. The frame enlarges 
the interaction of IEL with enterocytes and depicts the current understanding of receptor-ligand 
interactions resulting in cytotoxicity towards epithelial cells. IEL are mainly situated in the crypts 
and made up of mainly T cells (T-IEL) and some NK cells (NK-IEL). Under physiological conditions 
T-IEL consist mainly of CD8+TCRαβ+ and <15% TCRγδ+, whereas the latter increase to around 
30% in celiac disease patients (CD). In CD patients, gluten ingestion leads to villous atrophy thus 
decreasing the distance between the tip of the villi and the crypts. Moreover, the distribution 
pattern of IEL changes, as IEL are scattered throughout the whole mucosa and can therefore 
also be found at the (remaining) tips of the villi. The treatment for CD is a life-long gluten-free 
diet (GFD) which in most patients leads to a complete mucosal repair. Nevertheless, a few 
percent of patients develop refractory celiac disease (RCD), with no remission despite a GFD. 
Whereas RCD type I mimics CD pathology, RCDII is characterized by the expansion of so called 
aberrant IEL (surface TCR-CD4-CD8-CD3- intracellular CD3+), which present with non-functional 
TCR rearrangements. These aberrant IEL are considered pre-malignant and can transform into 
a malignant entropathy-associated T cell lymphoma (EATL). IEL can actively promote tissue 
damage which leads to the macroscopic mucosal changes characteristic for CD and RCD. Under 
physiological conditions epithelial cells lack the expression of CD94- and NKG2D-ligands, whereas 
in CD the ligands for NKG2D and CD94 (MICA and HLA-E) are upregulated, resulting in enhanced 
epithelial cell lysis. The pro-inflammatory cytokine IL-15, which can be produced by enterocytes, 
further enhances epithelial lysis via NKG2D upregulation on IEL. This cytotoxicity is mediated by 
Fas, Granzyme or Perforin-mediated pathways. Aberrant IEL are also highly cytotoxic and can 
lyse epithelial cells via NKG2D- or via DNAM-mediated pathways. As in CD, IL-15 also plays an 
important role in the pathogenesis of RCDII, as IL-15 is upregulated in RCDII lesions and aberrant 
IEL strongly respond to IL-15 via the IL-15Rβ, leading to uncontrolled expansion of such cells. IEL- 
intraepithelial lymphocytes; GDF- gluten free diet. 
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SCOPE OF THE THESIS:
Over the last few decades several studies have shed light on the complex network of immune 
reactions triggered by gluten in the small intestine of celiac disease patients and the cytotoxic 
mechanisms of T-IEL in CD. In recent years it has also been demonstrated how aberrant IEL 
in RCDII patients can participate in tissue damage. Nevertheless, several features of RCD are 
still poorly understood. How does RCD develop and why do some patients develop the severe 
condition of RCDII and EATL? Our studies have focused on two main questions: 
WHAT DRIvES THE ExPANSION OF AbERRANT IEL IN RCDII PATIENTS?  
From studies previously carried out by the group of Cerf-Bensussan et al. we have learned that in 
vitro IL-15 can drive the expansion of aberrant IEL through proliferation and anti-apoptotic effects. 
We hypothesized that the expansion could be also influenced by other factors present in the small 
intestine.  
WHAT IS THE ORIGIN OF AbERRANT IEL? 
In order to understand the pathological mechanisms leading to the massive expansion of aberrant 
IEL and ultimately the transformation into an overt lymphoma, one has to understand the origin 
of the disease. If there is a physiological cell population that could be the counterpart of aberrant 
IEL, what can we learn about their phenotype and physiological function? This information could 
be used to draw conclusions about the mechanisms on how aberrant IEL develop, expand and 
ultimately transform into a lymphoma. This knowledge is essential to develop more effective 
therapeutic approaches. 
THIS CHAPTER (CHAPTER 1) provided an overview of key players and mechanisms in 
immunity, especially in mucosal immunology of the small intestine. The structure, cell types and 
networks of immune cells that are unique to the small intestine in particular have been described. 
Subsequently the current knowledge of celiac and refractory celiac disease was summarized, 
with an emphasis on intraepithelial lymphocytes in health and under celiac and refractory celiac 
conditions. 
IN CHAPTER 2 we investigate which other factors can drive the expansion of aberrant IEL, 
besides the well characterized IL-15. We therefore made use of aberrant IEL lines, generated 
from RCDII patients and study the interaction of these aberrant IEL lines with possible bystander 




WHAT IS THE ORIGIN OF AbERRANT IEL?
 
It was postulated that aberrant IEL could either be derived from a derailed T-IEL population, which 
down-regulates CD3 and the TCR, or that it originates from a physiological IEL subsets within the 
existing CD3- population.   
   
IN CHAPTER 3 we tested the latter hypothesis by comparing aberrant IEL lines and T-IEL 
lines, using transcriptomic and detailed phenotypic analysis to initially define a distinct common 
phenotype of aberrant IEL. This information was then used to identify their possible physiological 
counterpart in situ in non-RCDII individuals. 
The comparison of aberrant IEL lines with T-IEL lines in CHAPTER 3, generated a broad knowledge 
of the phenotype of aberrant IEL, but also about the existence of a heterogeneous physiological 
innate IEL population, which harbors the putative precursor for aberrant IEL. This led to several 
questions: What is the phenotype, relationship and function of this innate IEL population? What 
are the parallels with a similar thymic population? 
     
IN CHAPTER 4 we further characterize this heterogeneous small intestinal innate IEL 
compartment in depth with multicolor flow cytometry and studied its plasticity in different 
patient cohorts. As we have learned in CHAPTER 3 aberrant IEL lines and their putative 
physiological precursor cells reflect features of T and NK cells, we now investigated the hypothesis 
that these cells function as immature IEL which could mature in situ. We therefore test the 
ability and the requirements of these cells to develop into mature NK and T cells, comparing the 
developmental capacity of IEL derived from non-CD, CD and RCDII patients in vitro.
IN CHAPTER 5 the thymic counterpart of the small intestinal cell population is studied, which 
is described in CHAPTER 3 and 4. We now investigate the phenotype and developmental capacity 
of the thymic cell population with parallels to the well-described CD34+ T/NK cell precursor 
population in the human thymus.  
IN CHAPTER 6 the implications of our studies described in Chapter 2-5 for our understanding 
of CD and RCDII pathogenesis in particular are discussed. Furthermore, we discuss the relevance 
of these studies in the context of IEL development under physiological and pathological conditions 
and suggest directions for future research.
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AbSTRACT 
Celiac disease (CD) patients who fail to respond to a gluten-free diet suffer from refractory celiac 
disease (RCD). A marked expansion of intraepithelial lymphocytes (IEL) lacking surface TCR/
CD3 expression characterizes the RCD subtype II. In up to 50% of RCDII patients these so-called 
aberrant IEL (a-IEL) develop into lymphoma and can disseminate into other tissues. Elevated 
levels of Interleukin-15 (IL-15) in the intestine of CD and RCD patients likely contribute to the 
expansion of a-IEL. Here, we investigated if interactions with other cells might also influence 
a-IEL expansion. Similar to IL-15, cells from the monocyte lineage, particularly mature dendritic 
cells (DCs), promoted proliferation, prevented apoptosis and induced IFNγ secretion of a-IEL 
derived from RCDII biopsies (RCDII cell lines), which in turn induced CXCL10. In contrast to IL-15, 
mature DCs did not induce proliferation of regular TCR+IEL lines, generated from CD biopsies and 
IL-15-blocking antibodies did not inhibit DC-induced proliferation of RCDII cell lines. Furthermore, 
proliferation was dependent on cell-cell contact, but independent of the HLA-genotype of the 
stimulating cells. Our results suggest that contact with DC, either in the epithelium or upon 
dissemination, contributes to uncontrolled expansion of a-IEL in RCDII, independent of HLA-
genotype and IL-15. 
AbbREvIATIONS
CD- Coeliac Disease, RCD- Refractory Coeliac Disease, EATL- Enteropathy associated T cell 
Lymphoma, IEL- Intraepithelial Lymphocytes, T-IEL- TCR+/CD3+ Intraepithelial Lymphocytes, a-IEL- 
aberrant IEL
CHAPTER 2 
DENDRITIC CELLS PROMOTE ExPANSION 
AND SURvIvAL OF AbERRANT TCR-NEGATIvE 
INTRAEPITHELIAL LyMPHOCyTE LINES FROM 





Celiac disease (CD) is an enteropathy of the small intestine, caused by a strong immune 
response to dietary gluten that occurs in HLA-DQ2+ and/or HLA-DQ8+ individuals. Histological 
findings include villous atrophy, crypt hyperplasia 1, increased numbers of TCR-αβ+ and TCR-γδ+ 
intraepithelial lymphocytes (T-IEL) 2, 3 and elevated interleukin-15 (IL-15) levels in the epithelium 
and lamina propria 4. Clinical symptoms include anemia, diarrhea and failure to thrive. CD is 
treated with a gluten-free diet, which usually leads to remission and amelioration of histological 
and serological findings. However, 2-5% of adult-onset CD patients develop refractory CD (RCD) 
with persisting epithelial damage and increased numbers of IEL 5, 6, despite adherence to a gluten-
free diet. 
RCD can be further subdivided into RCD type I (RCDI) and RCD type II (RCDII), based on the 
quantity and phenotype of IEL in duodenal biopsies. RCDII patients have >20% surface T-cell 
receptor-negative -also called aberrant- IEL (a-IEL) of the total IEL population 7. In approximately 
50% of RCDII patients these a-IEL gradually replace the normal IEL population and undergo 
malignant transformation 8. These patients develop a severe life threatening condition, called 
enteropathy-associated T cell lymphoma (EATL) with a 2 year survival of less than 30% 5, 9. a-IEL in 
RCDII contain clonal TCR rearrangements 6, 8, 10 and display a unique phenotype: they express no 
lineage markers (CD3, CD14, CD19, CD56) (Lin-) nor CD34 or CD127, but are positive for the T/NK 
cell marker CD7 and express intracellular CD3 (icCD3). a-IEL also express multiple NK cell markers 
and therefore share features with T and NK cells  7, 8, 10, 11.
While in non-celiac adults less than 10 % of IEL possess this ‘aberrant’ phenotype 11, in RCDII 
patients a-IEL can make up more than 80% of the IEL population. The combination of elevated 
IL-15 levels in the duodenal epithelium of RCD patients and greater IL-15 sensitivity of a-IEL 
compared to other IEL is likely to contribute to the selective expansion and survival of aberrant 
cells in RCDII 4, 12, 13. The fact that cells with this ‘aberrant’ phenotype from non-celiac duodenal 
biopsies express the IL-2/15Rβ and become positive for the proliferation marker Ki67 upon 
incubation with IL-15 11 suggests that the precursors of a-IEL in RCDII patients are also IL-15 
sensitive. 
Aberrant IEL in situ are located in the intraepithelial compartment and are therefore likely to 
closely interact with epithelial cells. In addition, contact with dendritic cells (DCs) could be made 
via DC protrusions extending into the epithelium 14-16 and contact to DCs and other types of blood-
borne cells could take place upon dissemination of a-IEL. We therefore investigated proliferation, 
apoptosis and cytokine production of a-IEL derived from RCDII biopsies (RCDII cell lines) after co-
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culture with intestinal epithelial cell lines and several blood-borne cell types, including DCs.
MATERIALS AND METHODS
Small intestinal biopsy specimen
During upper endoscopy, large spike forceps biopsy specimens (Medi- Globe, Tempe, AZ) were 
taken from the second part of the duodenum. All biopsy specimens were obtained after given 
informed consent in accordance with the local ethical guidelines of the VU Medical Center in 
Amsterdam and the Declaration of Helsinki.
Cell lines and cell culture
RCDII lines P1 and P2 were isolated from duodenal biopsies of RCDII patients and maintained 
as described 13. TCR+IEL (T-IEL) lines were isolated from 4 CD patients, as described for RCDII 
lines. PBMC were isolated from buffy coats using standard ficoll gradient (PBMC layer). After 
ficoll separation the PBMC layer was removed, remaining cells were separately collected from 
the layer above the erythrocytes and termed neutrophils if CD16 was expressed or eosinophils if 
CD16 expression was not detected.  Monocytes were isolated from fresh PBMC using CD14 beads 
(Miltenyi, Bergisch Gladbach, Germany) using LS MACS columns and the standard separation 
protocol (Miltenyi). Dendritic cells (DC) were generated by culture of these monocytes in 
RPMI/10% FCS medium supplemented with 1000 U/ml GM-CSF (R&D Systems, Abingdon, UK), 
500 U/ml IL-4 (R&D Systems, Abingdon, UK)  and macrophages were generated by culture in 
RPMI/10% FCS medium supplemented with 50 U/ml GM-CSF. On day 7, DC and/or macrophages 
were matured by incubation of 100 ng/ml LPS (Sigma-Aldrich, Zwijndrecht, The Netherlands) in 
10% FCS/ IMDM medium for 48h. HT-29 cells were cultured in IMDM/10% FCS medium. 
Cytotoxicity assay
One million target cells were labeled with 100 γCi [51Cr] for 1 h at 37˚C. After extensive washing, 
labeled target cells were incubated with the RCDII lines as effector cells at an effector: target (E:T) 
ratio between 50:1 and 1.5:1 for 4 h at 37˚C. Spontaneous chromium release and maximum 
chromium release by target cells was determined by addition of medium or 1% Triton X-100 
(Pierce, Rockford, IL), respectively. The percentage of specific cytotoxicity was as follows: ([cpm 






Responder cells were rested by culturing them in the absence of IL-15 for 4 days. 20 000 
responder cells per well were subsequently cultured in triplicate in 96-well plates in the presence 
or absence of 10 ng/ml IL-15 or with irradiated (3000 Rad) stimulator cells for 3 days at 37°C, 
after which 0.5 μCi 3H-thymidine was added to every well. Stimulator cells were 1x105/well PBMC, 
2x104/well DC/macrophages/monocytes, 2x104/well HT29 and responder cells were 2x104/well 
RCDII lines or T-IEL lines, unless stated otherwise. For the transwell experiments the inserts were 
discarded after 3 days co-culture and 0.5 μCi 3H -thymidine was added directly to the 96 well plate 
(HTS Transwell-96 system, 0,4μm pore size, Corning, MA, USA). 3H-thymidine incorporation was 
determined during the final 17h of the incubation.
Flowcytometry and antibodies
After co-culture, cells were harvested, washed in 0,5% FCS/PBS and stained with 7-AAD and 
Annexin PE using the apoptosis detection kit according to the BD Biosciences protocol (BD 
Biosciences, San Jose, CA). In short, 7-AAD and Annexin PE incubation was done for 15 min at 
room temperature (RT) in the supplied binding buffer and the labeled cells were acquired within 
1h on a LSR II or FACS-Calibur (both from BD Biosciences). PBMC subsets were stained with CD14-
PeCy7, CD19-PE, CD56-FITC, CD16-FITC (all BD Biosciences, San Jose, CA) and CD3-AlexaF750 
(Invitrogen, NY, USA) and sorted with FACSAriaIII (BD Biosciences). For proliferation assays 10 μg/
ml IL-15 antibodies MAB 647 and 2 μg/ml MAB247 (both R&D systems Europe, Abingdon, UK) 
were used.
Cytokine production 
IFNg and CXCL10 concentrations were measured using the Bio–Plex assay (BioRad, Hercules, CA, 
USA) according to the manufacturer’s protocol (www.biorad.com).
Data analysis
Flow cytometry results were analyzed with FACS DIVA 6.1.2 software. Data from cytotoxicity, 




MONOCyTES INDUCE PROLIFERATION bUT NOT CyTOTOxICITy OF RCDII 
CELL LINES
In vivo, a-IEL are in direct contact with epithelial cells and likely also with blood-borne cells, either 
locally or upon dissemination. In vitro, a-IEL derived from RCDII biopsies (RCDII cell lines) efficiently 
lyse epithelial cell lines via the NK cell receptor DNAM-I 17, but it was not known whether the 
interaction between RCDII cell lines and other cell types could contribute to proliferation. To 
test this, we co-cultured RCDII lines with PBMC and the epithelial cell line HT-29. We observed 
that RCDII cell lines proliferated upon co-culture with PBMC, but not when co-cultured with the 
intestinal epithelial cell line HT-29 (Figure 1A). To investigate which cell type among PBMC induced 
RCDII line proliferation, we purified PBMC subpopulations by flow cytometry and co-cultured 
these with the RCDII lines. Monocytes (CD3-CD14+) induced proliferation of RCDII lines, but B cells 
(CD3-CD19+), NK cells (CD3-CD56+), T cells (CD3+), neutrophils (CD3-CD56-CD16+) and eosinophils 
(CD3-CD56-CD16-) did not (Figure 1B). In contrast, RCDII lines lysed HT-29 but not monocytes 
(Figure 1C). Thus, monocytes induced proliferation but not cytotoxicity of RCDII lines, while the 
opposite was true for intestinal epithelial cells.
MATURE MONOCyTE-DERIvED DENDRITIC CELLS ARE SUPERIOR TO 
MONOCyTES IN INDUCING PROLIFERATION OF RCDII CELL LINES
Monocytes are recruited from peripheral blood to tissues, where they differentiate into 
macrophages and dendritic cells (DC). Macrophages and DC are found in the intestinal lamina 
propria and DC protrusions can be found in the epithelium 14-16 . We therefore investigated the 
induction of proliferation by macrophages and DC differentiated in vitro from purified peripheral 
blood monocytes. While macrophages, monocytes, immature DC and LPS-matured DC induced 
proliferation of RCDII lines, the strongest responses were found with mature DC (Figure 2A). In 
contrast, T-IEL lines derived from CD patients did not proliferate when co-cultured with DC (Figure 
2B). The interaction between RCDII lines and DC did not alter the expression of the maturation 
markers CD1a, HLA-DR, CD86, CD80, CD83 and DC-SIGN on DC (data not shown). Thus, RCDII lines 





DERIvED CELLS INDUCED 
PROLIFERATION, bUT NOT 
CyTOTOxICITy OF RCDII 
LINES.
(A) Proliferation was measured 
after 3 days of co-culture with 
PBMC or HT-29 and RCDII 
cell lines. On the y-axis the 
3H-incorporation (CPM) is 
depicted. (B) Proliferation 
(cpm) was measured after 3 
days of co-culture with RCDII 
lines and monocytes, T cells, 
B cells, NK cells, eosinophils or 
neutrophils. Black bars indicate 
the proliferation when co-
cultured with the RCDII line, white 
bars represent the background 
proliferation of the corresponding 
PBMC population. (C) Monocytes 
were sorted from fresh healthy 
PBMC by CD14+ MACS sort and 
used in a cytotoxicity assay. An 
effector:target ratio of 50:1 
is depicted. On the y-axis the 
percentage of lysis is shown. 
Results are depicted for RCDII 
line P2. Similar results were 
obtained with RCDII line P1 for all 
tests. Graphs are representative 




FIGURE 2. DENDRITIC CELLS INDUCED STRONGEST PROLIFERATION OF RCDII 
LINES WHEREAS T-IEL LINES SHOWED NO RESPONSE. (A) MACS sorted CD14+ 
monocytes (mono), monocyte-derived in vitro cultured macrophages (macro), immature dendritic 
cells (iDC) or 48h LPS-matured DC (mDC) were co-cultured with RCDII cell line P2 and proliferation 
(cpm) was measured after 3 days. Control 1 represents the mean background proliferation of 
monocyte-derived cells, control 2 the background proliferation of the RCDII line with an LPS-
treated EBV line. Results were representative of 3 experiments. On the y-axis the 3H-incorporation 
(CPM) is depicted. (B) Proliferation (cpm) was measured after 3 days of co-culture with DC and 
a RCDII line P2 (white bars), or with DC and a representative T-IEL line (black bars). A plus or 
minus indicates whether DC or IL-15 as a control was added. The result is representative of 2 
experiments. The T-IEL line used in this experiment is representative for four T-IEL lines tested, 




PROLIFERATION OF RCDII LINES WAS INDEPENDENT OF IL-15 OR HLA 
GENOTyPE, bUT DEPENDENT ON CELL-CELL CONTACT 
Since monocytes, macrophages and DC are known to produce Interleukin-15 (IL-15) 18, we tested 
whether the proliferative effect seen in co-culture experiments was due to the IL-15 production 
and/or presentation by cells of the monocyte lineage. Blocking of IL-15 with a combination of 
IL-15 antibodies showed no effect on proliferation in monocyte RCDII line co-cultures, while 
they effectively blocked the response to soluble IL-15 (Figure 3A). These results indicate that it 
is unlikely that IL-15 is the factor responsible for the monocyte- and DC-induced proliferation of 
RCDII lines. 
Activation of T and NK cells is modulated by receptors binding to Human Leucocyte Antigens 
(HLA). Since many of these receptors bind only to a selected set of HLA allele products, we 
investigated whether the proliferation of RCDII lines was affected by the HLA genotype of the 
stimulating cells. To address this, we used a panel of PBMC with divergent HLA-genotypes as a 
convenient source of monocytes. PBMC from 10 donors selected for divergence in HLA allotypes 
induced similar proliferation of RCDII lines (Figure 3B). What’s more, RCDII line P1 proliferated 
in response to autologous PBMC (Figure 3C). As observed for DC (Figure 2B), a control T-IEL 
line showed no response to PBMC. The HLA genotype of the stimulator cells therefore did not 
detectably influence the proliferative response of RCDII lines.
To address whether cell-cell contact was required for the induction of proliferation by DC, a 
transwell experiment was performed. In the absence of cell-cell contact, the proliferation of RCDII 
lines was severely reduced but did not disappear completely (Figure 3D). Therefore, cell-cell 
contact played a major role in the induction of proliferation, but soluble factors also contributed. 
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FIGURE 3. PROLIFERATION OF RCDII LINES WAS INDEPENDENT OF IL-15 OR 
HLA GENOTyPE, bUT DEPENDENT ON CELL-CELL CONTACT. Proliferation was 
measured by 3H incorporation (CPM) after 3 days of co-culture. (A) Co-culture of RCDII line P2 
with monocytes (CD14), 10 ng/m IL-15, IL-15 antibodies MAB647 (10 μg/ml) and MAB247 (2 μg/
ml) (αIL-15) or 12 μg/ml of the isotype control (IgG1). (n=2) 
(B) Co-culture of RCDII line P2 and PBMC of divergent HLA-typed donors. The HLA-type is 
depicted for HLA-A, B and C on the x-axis to reflect the random HLA-type of the donors. Control 
1 is the background of the representative RCDII line, control 2 stands for the representative 
background proliferation of PBMC used in the experiment. (C) Co-culture of RCDII line from 
patient 1 (P1) (black bar) and patient 2 (P2) (gray bar) or of a representative T-IEL (white bar) 
with PBMC from patient 1 (PBL(P1)). The legend on the x-axis indicates if autologous PBMC 
from patient 1 (PBL(P1)), or the corresponding cell lines P1,P2 or T-IEL (cells) were added to the 
co-culture experiment. IL-15, taken along as a positive control is not depicted here (162000 cpm 
for P1, 63000 cpm for P2 and 80000 cpm for T-IEL). (D) A transwell experiment was combined 
with a proliferation (cpm) assay. Cell-cell contact is depicted by the open triangle symbol, no 




2DENDRITIC CELLS INHIbIT APOPTOSIS OF RCDII LINES
IL-15 is known to induce proliferation and inhibit apoptosis of RCDII lines and other lymphoid cell 
types such as T-IEL 4, 12. Since DC induced proliferation of RCDII lines, we also investigated whether 
apoptosis was inhibited. After 6 days of incubation in the absence of DC, the majority of RCDII 
lines underwent early (AnnexinV+/7-AAD-) and late (AnnexinV+/7-AAD+) stage apoptosis (Figure 
4A). In the presence of DC the percentage of apoptotic cells was drastically reduced (Figure 4B). 
In line with previous observations 12, IL-15 also drastically reduced apoptosis of RCDII lines. These 
data demonstrated that, similar to IL-15, DC prevented apoptosis of RCDII lines. 
w
proliferation of the RCDII line P2 and the DC. On the x-axis the amount of DC added to each well is 
depicted as x103 cells. Results are representative of two independent experiments. RCDII line P1 
and P2 showed similar results in all tests.
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FIGURE 4. ANTI-APOPTOTIC EFFECTS OF DC ON RCDII LINES. Apoptosis induction 
was measured by 7-AAD and Annevin V staining by flow cytometry. (A) After 6 days incubation 
of RCDII line P2 with medium alone (Medium), after DC co-culture (+DC) or after 10 ng/ml IL-15 
(+IL-15) cells were analyzed by flow cytometry. The percentages of Annexin V+ and 7-AAD+ cells 
are depicted in the graph. (B) Summarizing the data from co-culture experiments of 4, 6 and 7 
days for RCDII line P2, as percentages of AnnexinV+ and 7-AAD+ RCDII cells with medium alone (-), 






DENDRITIC CELL-RCDII LINE CO-CULTURES PRODUCE IFNγ AND CxCL10
Previous studies showed that IL-15 triggered interferon-γ (IFNγ) production by RCDII lines 4. We 
therefore measured IFNγ secretion after co-culture of RCDII lines with DC or IL-15. In co-culture 
experiments with DC higher concentrations of IFNγ were measured in the supernatants compared 
to IL-15 incubation (Figure 5A). A control T-IEL line generated from a CD patient showed no IFNγ 
response to either stimulus, but did proliferate in response to IL-15 (Figure 5A). IFNγ is known to 
induce the secretion of CXCL10 from monocytes, macrophages and DC 19, 20. Indeed, supernatants 
of DC and RCDII co-cultures contained high concentrations of CXCL10 (Figure 5B), which was 
mainly detected when cells had direct cell-cell contact (Figure 5C) and was not secreted after IL-15 
incubation (Figure 5B). In contrast, co-culture of DC with a T-IEL line resulted in very little CXCL10 
secretion, consistent with the absence of IFNγ in such co-cultures (Figure 5A and B). 
In short, IFNγ is produced by RCDII lines upon co-culture with DC, which induces CXCL10 secretion 





FIGURE 5. IFNγ WAS DETECTED IN THE SUPERNATANTS OF DC-RCDII 
CO-CULTURES AND INDUCED THE SECRETION OF THE IFNγ-DEPENDENT 
CHEMOKINE CxCL10. Supernatants of co-culture experiments were analyzed after 3 
days by Bioplex Human Cytokine assay. (A) In the upper graph the concentration of IFNγ in 
the supernatants of DC co-culture is depicted on the x-axis in pg/ml.  Proliferation of cells was 
measured by 3H-incorporation (CPM) from the same experiment as depicted in the lower panel. 
Black bars indicate DC co-culture with RCDII line P2, gray bars with a representative T-IEL cell line. 
A plus or a minus in the legend on the x-axis indicates if DC, 10 ng/ml IL-15 or the corresponding 
cell line (cells) was added to the co-culture experiment. (B) The concentration of CXCL10 (in pg/
ml) in supernatants of DC co-culture with RCDII line P2 (black bar) or T-IEL control lines (gray bar) 
is shown. The legend on the x-axis indicates whether DC, 10 ng/ml IL-15 or the corresponding cell 
lines (cells) was added. (C) The concentration of CXCL10 (in pg/ml) in supernatants of transwell 
experiments with DC and RCDII line P2 is depicted. The legend on the x-axis indicates if cell-cell 
contact was permitted (YES) or not (NO) and if the RCDII line or DC were added (+) or not (-). 






Interleukin-15 is generally believed to contribute to the outgrowth of a-IEL seen in RCDII patients, 
and its proliferation-inducing and anti-apoptotic effects on RCDII lines are well documented 4, 
12. Here we demonstrate that not only IL-15 but also monocytes, macrophages and especially 
dendritic cells (DC), prominent cell types of the innate immune system, can induce proliferation 
and inhibit apoptosis of RCDII lines. This effect on proliferation was specific to RCDII lines as 
regular T-IEL lines did not proliferate when co-cultured with monocyte-derived cells.
Although we were unable to identify the receptor-ligand interactions between DC and RCDII lines 
triggering proliferation, several important candidates could be excluded. First, since proliferation 
was drastically reduced in the absence of cell-cell contact, soluble mediators are unlikely to play a 
major role. Second, since RCDII lines (like a-IEL, their in vivo counterparts in RCDII) do not express 
TCR/CD3 complexes on the cell surface, TCR-dependent recognition of HLA-class I or II cannot 
be responsible for proliferation induced by DC. Third, co-culture experiments with a diverse 
panel of HLA-typed PBMC- including autologous PBMC- demonstrated that the HLA-genotype 
of the stimulator cells did not influence the observed proliferative response. This argues against 
HLA-allotype-specific recognition by NK cell receptors such as Killer-cell Immmunoglobulin-like 
Receptors (KIR), which are expressed by the RCDII lines 11. Finally, IL-15-specific antibodies did not 
inhibit the induction of proliferation by DC, while they did block the response induced by soluble 
IL-15. In conclusion, recognition is most likely mediated by receptors on the RCDII lines that bind 
to non-polymorphic surface-expressed ligands on DC.    
Contact between cells of the monocyte lineage and a-IEL can occur either in the epithelium in 
RCD patients or after dissemination into the lamina propria 21, the blood and other intestinal 
tissues 6, 22 reflecting ongoing malignant transformation and development into an enteropathy-
associated T cell lymphoma. DC normally reside in the lamina propria, but can extend 
protrusions into the epithelial layer 14, 15 and thereby could contact a-IEL. Raki et al. reported 
increased numbers of dendritic cell subsets and macrophages in the lamina propria and in the 
basolateral membrane of epithelial cells in lesions of active celiac patients, reflecting the ongoing 
inflammatory responses of the untreated disease 23. While this has not been investigated in RCD 
patients, DC cell numbers may be similarly increased in these patients due to the ongoing severe 
inflammation in the intestine. 
Our results indicate that  IFNγ produced by RCDII lines leads to the secretion of CXCL10 by DC. 
In vivo, this  would attract CXCL10-sensitive macrophages and DC to the lesion 24, thus creating a 
self-augmenting inflammatory process. It has been described that CXCL10 (Chirdo et al., personal 
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communication) and its receptor CXCR3 25 are more abundantly expressed in the mucosa of 
CD patients than in non-CD individuals, suggesting that this chemokine-receptor interaction 
is involved in ongoing inflammation in active celiac disease. Thus far, no data are available for 
refractory celiac disease. Nevertheless, high expression levels of CXCL10 have also been found 
in the mucosa of IBD patients 26, 27 and increased serum levels of CXCL10 have further been 
described in several autoimmune diseases and could be of value as a biomarker for inflammation 
28-30. Thus, contact-dependent production of IFNγ and subsequently CXCL10 as a result of DC-
lymphocyte interactions could help sustain persistent inflammation in refractory celiac disease 
and other intestinal and autoimmune diseases.
In conclusion, contact between a-IEL and cells of the monocyte lineage can protect the a-IEL from 
apoptosis and induce proliferation and IFNγ production. Since both IL-15 and DC quantities are 
increased in duodenal lesions 4, 12 , and since a-IEL are more sensitive to these stimuli than regular 
T-IEL, together they may contribute to the uncontrolled expansion of a-IEL in RCDII and support 
the development of an invasive lymphoma.
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Refractory coeliac disease type II (RCDII) is a severe complication of coeliac disease (CD) 
characterized by aberrant intraepithelial lymphocytes (IEL) of unknown origin that display an 
atypical CD3-CD7+icCD3+ phenotype. In approximately 40% of RCDII patients these lymphocytes 
develop into an invasive lymphoma. In the current study we aimed to identify the physiological 
counterpart of these cells. 
RCDII cell lines were compared to TCR+ IEL (T-IEL) lines by microarray analysis, RT-qPCR and flow 
cytometry. This information was used to identify cells with an RCDII-associated phenotype in 
duodenal biopsies from non-refractory individuals by multicolour flowcytometry.
RCDII lines were transcriptionally distinct from T-IEL lines and expressed higher levels of 
multiple NK cell receptors. In addition to the CD3-CD7+icCD3+ phenotype, the RCDII lines were 
distinguishable from other lymphocyte subsets by the absence of CD56, CD127 and CD34. 
Cells matching this surface lineage-negative (Lin-) CD7+CD127-CD34- phenotype expressed a 
functional IL-15 receptor and constituted a significant proportion of IEL in duodenal specimens 
of non-coeliacs, particularly children, and were also found in the thymus. In non-coeliacs, the 
Lin-CD7+CD127-CD34- subset was one of four subsets within the CD3-CD7+icCD3+ population that 
could be distinguished on the basis of differential expression of CD56 and/or CD127. 
Our studies indicate that the CD3-CD7+icCD3+ population is heterogeneous and reveal the 
existence of a Lin- subset that is distinct from T, B, NK and Lymphoid tissue-inducer cells. We 
speculate that this IL-15 responsive population represents the physiological counterpart of 
aberrant cells expanded in RCDII and transformed in RCDII-associated lymphoma. 
AbbREvIATIONS
CD- Coeliac Disease, RCD- Refractory Coeliac Disease, EATL- Enteropathy associated T cell 
Lymphoma, IEL- Intraepithelial Lymphocytes, T-IEL- TCR+/CD3+ Intraepithelial Lymphocytes, 





Coeliac disease (CD) is an enteropathy of the small intestine induced in HLA-DQ2+ and/or HLA-
DQ8+ individuals by a polyclonal CD4+ T cell response to gluten, leading to villous atrophy and crypt 
hyperplasia 1. In addition, the number of TCR-αβ+ and TCR-γδ+ intraepithelial lymphocytes (IEL) is 
strongly increased 2 and interleukin 15 (IL-15) is highly upregulated in the epithelium and in the 
lamina propria 3, 4. Elimination of gluten from the diet usually restores the intestinal architecture, 
accompanied by a reduction in TCR-αβ+ IEL but not TCR-γδ+ IEL. However, 2-5% of adult-onset CD 
patients develops refractory CD (RCD) with persisting epithelial damage and increased numbers of 
IEL 5, despite strict adherence to a gluten-free diet.
Based on immunophenotyping of the IEL population, RCD is subdivided into two types: RCD type 
I (RCDI) and RCD type II (RCDII). RCDI presents with < 20% aberrant IEL, whereas in RCDII > 20% of 
the IEL have an aberrant phenotype 6. For diagnostic purposes, aberrant IEL are defined as surface 
TCR-CD3-CD4-CD8-CD7+ but intracellular CD3+ cells that commonly display monoclonal TCR-γ gene 
rearrangements 6, 7. In RCDII, the aberrant IEL gradually replace the normal IEL population and can 
undergo malignant transformation into lymphoma 8. 
The cellular origin of the aberrant CD3-CD7+icCD3+ population that expands in RCDII is still unclear. 
One view is that aberrant IEL originate from mature TCR+CD3+ IEL (T-IEL) that downregulate 
the TCR-CD3 complex due to overstimulation 7. This view is supported by the observation 
that aberrant IEL have intracellular expression of the CD3γ-, CD3δ, CD3ε- and ζ-chains and 
commonly display monoclonal TCR-γ gene rearrangements 7-9. Intracellular CD3 expression, 
however, is not exclusive to mature T cells as pre-T cells and some NK cells also express all 
CD3 chains intracellularly 10, 11. Therefore, an alternative view is that aberrant IEL derive from 
a surface CD3-CD7+ IEL population that is already present in the healthy small intestine. By 
immunohistochemical analysis 12 and 3 colour flow cytometry 13 the CD3-CD7+ IEL population 
was studied in coeliac and non-coeliac patients, demonstrating a reduction of this population 
in coeliac compared to non-coeliac patients. Later studies focused on the composition and 
characterization of this IEL population in the intestine of non-coeliac individuals 12, 14-18. The CD3-
CD7+ IEL population proved to contain NK cells 17 and immature T cells 14-16, 18. Due to limitations of 
the techniques applied and the small amount of cells available from biopsy material an accurate 
identification and quantification of rare (sub)populations within the IEL population is challenging. 
In the present study we therefore combined microarray analysis, real time quantitative PCR 
and multicolour flow cytometry to extensively characterize aberrant RCDII cell lines from RCDII 
patients. Subsequently, we have used this information to design a multicolour staining protocol 




coeliacs and non-coeliacs as a first step to determine the cellular origin of aberrant IEL. 
MATERIALS AND METHODS
Human specimens
Duodenal biopsies were obtained as previously described 9. Fetal tissues were obtained from 
elective abortions and gestational age was determined by ultrasonic measurement of the 
diameter of the skull or the femur. Thymic material was obtained as surgical tissue discards from 
four children without immunological abnormalities (2, 5, 7 and 8 months old) undergoing cardiac 
surgery. Thymocytes were isolated as described 19 and stored at  -80○C until further analysis. All 
specimens were obtained after informed consent, medical ethical commission approval and 
in accordance with the local ethical guidelines of the VU Medical Center in Amsterdam (adult 
duodenal biopsies), the Leiden University Medical Center (paediatric duodenal biopsies) or the 
Erasmus MC in Rotterdam (fetal intestine, thymuses) and in accordance with the declaration of 
Helsinki. 
Cell lines and cell culture
RCDII cell lines P1, P2, P3 and P4 were isolated from duodenal biopsies of RCDII patients and 
maintained as described 9. Control cell lines for P1 were a CD4+ T cell line (P1-CD4) and a CD8+ T 
cell line (P1-CD8) isolated from the same biopsy as RCDII cell line P1. A CD4+ T cell clone (P3-CD4) 
and a CD8+ T cell line (P1-CD8) was isolated from the same biopsy as RCDII cell line P1 or P3, 
respectively. T-IEL lines (CD4+ and CD8+ T: IEL1-5) were isolated from 4 CD patients and one patient 
with Crohn’s disease, as described for RCDII lines. IEL1-CD4 was derived from IEL1, IEL5-CD8 from 
IEL5. NK cells were negatively selected from PBMC by depletion using MACS beads (Miltenyi, 
Bergisch Gladbach, Germany). RCDII lines and T cells were restimulated with mixed irradiated 
allogeneic PBMC, 1 μg/ml phytohemagglutinin, 20 Cetus u/ml IL-2 (Proleukin, Chiron corporation, 
Emeryville, CA) and 10 ng/ml IL-15 (R&D systems Europe, Abingdon, UK) approximately every 4 
or 2 weeks, respectively and maintained on 10% normal human serum (NHS) containing 10 ng/
ml IL-15 and 20 Cetus units/ml IL-2. After isolation, NK cells were cultured for 2 weeks in AMV-I 
Medium containing 10% NHS and IL-15 (10 ng/ml). 
Isolation of cells from duodenal biopsies specimen for flowcytometry
Cells were isolated from two or three duodenal biopsies by treatment with 1mM DTT (Fluka, 
Buchs, Switzerland) for 20 minutes followed by the addition of 1mM EDTA (Merck, Darmstadt, 
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Germany) under rotation for 2 hours at 37○C. Since DTT incubation decreases CD103 expression 20 
all CD45+ cells were considered IEL. The IEL were then washed with PBS containing 0,5% FCS and 
fixed for 10 min at 4°C with PBS containing 0,1% paraformaldehyde and 0,5% FCS. After washing 
the cells were kept at 4°C until flow cytometric analysis. 
Antibodies and flowcytometry
Fluorochrome-labeled antibodies specific for CD1a, CD2, CD3, CD4, CD5, CD6, CD7, CD8α, CD11a, 
CD16, CD18, CD25, CD27, CD28, CD30, CD31, CD33, CD34, CD38, CD40, CD44, CD45RA, CD45RO, 
CD54, CD56, CD62L, CD94, CD103, CD117, CD122, CD152, CD154, CD161, CD226, integrin β7, 
KIR3DL1 and NKG2D were purchased from BD Biosciences (San Jose, CA). Fluorochrome-labeled 
antibodies specific for CD8β, KIR2DL2/DL3/DS2, KIR2DL1/2DS1, KIR2DS4, KIR3DL1, CD244, NKp30, 
NKp44 and NKp46 were purchased from Beckman Coulter (Fullerton, CA). Fluorochrome-labeled 
Antibodies specific for IL-15Rα, KIR2DL3, KIR2DL4, NKG2A and NKG2C were purchased from R&D 
systems (Abingdon, UK). Anti-CD19 was from Exbio (Vestec, Czech Republic), anti-CD14 from 
Immunotools (Friesoythe, Germany), anti-CD7, CD127, CD45 and Ki-67 were from eBioscience 
(San Diego, CA) and anti-CD52 was from Genzyme, Cambridge. The anti-KIR2DS2/2DL3 antibody 
was a kind gift from Dr. C. Retiere 21, the anti-KIR3DL2 antibody from Dr. D. Pende 22 and the anti-
KIRDL5 antibody from Dr.C.Vilches 23. For antibody clone names see Table 2.  For surface staining, 
cells were incubated for 30 minutes with fluorochrome-conjugated antibodies. For intracellular 
CD3- or Ki-67-staining, the cells were subsequently lysed with BD lysing solution for 10 min at 
room temperature (RT) then washed thoroughly and treated with permeabilising solution 2 (BD)  
for 10 min at RT, after which the cells were incubated with anti-CD3 or anti-Ki-67 for an additional 
30 minutes and washed again. Antibody-stained cells were acquired on an LSR II or FACS-Calibur 
(both from BD biosciences) and the results were analyzed with FACSDIVA 6.1.2 or FlowJo 7.6.3 
software. Relative mean flourescence intensity (MFI) was calculated as follows: (MFI staining 
antibody)/(MFI isotype control). Percentages obtained from FACS analysis were computed in 
4-GraphPad. 
RNA isolation and preparation 
Total RNA was extracted from cell lines using the RNeasy Mini Kit (Qiagen, Venlo, the Netherlands) 
followed by DNAse digestion using the RNase-free DNAse kit (Qiagen, Venlo, the Netherlands). 
The RNA samples were labeled in duplicate with the Ambion Illumina TotalPrep RNA-amplification 
kit (Illumina, Son, The Netherlands) for the microarray study.




Biotinylated cRNA samples were hybridized on 2 Illumina HumanHT-12 V3 Expression BeadChips 
according to the Illumina BeadArray protocol. Samples were randomly distributed among the two 
BeadChips. The intensities of the expression results were parsed into the R statistical computing 
environment using the beadarray package 24. Gene expression values were log2 transformed 
and normalized using the quantile method across all samples. Samples were grouped into 
lymphoma and control for a two-sample comparative study, fold changes and adjusted p-values 
were calculated using the limma package 25. The Benjamini and Hochberg method was used to 
adjust p-values for mulitple-testing errors. The cut-off criteria for differential expression was set 
at a relative difference of > 7 fold change and adjusted P-value < 0.001. Unsupervised hierarchical 
clustering of the samples was done, using the complete clustering method with the euclidean 
distance metric. The result was plotted using the heatmap.2 function from the R plots package.  
Gene ontology clusters were determined with PANTHER (http://www.pantherdb.org/).
Real-time quantitative PCR (RT-qPCR)
cDNA was synthesized using superscript reverse transcriptase III (Invitrogen, USA), following the 
manufacturer’s instructions. Gene-specific PCR primers were designed using the Roche web-
based universal probefinder software tool, version 2.45 (www.roche-applied-science.com). 
RT-qPCR was performed in a Step One Plus Real Time PCR System (Applied Biosystems, USA). The 
reactions were set up in a Microamp 96 well plate (Applied Biosystems, USA), using the forward 
and reverse primers (each at 400 nM) in Fast Start Universal SYBR Green Master Mix solution 
(Roche, Germany). The thermal profile for all reactions was 10 min at 95°C, followed by 40 cycles 
of 15 seconds at 95°C and 1 min at 60°C. All RT-qPCR measurements were done in triplicate. The 
ΔCT values were determined using GAPDH as the reference gene.
Statistics





MOLECULAR ANALySIS REvEALS HIGHER ExPRESSION LEvELS OF NK CELL-
ASSOCIATED GENES ON RCDII LINES COMPARED TO TCR+ IEL LINES
To define the differences between aberrant IEL and regular T-IEL in detail, aberrant cell lines from 
RCDII patients (RCDII lines) and control T-IEL cell lines were subjected to microarray analysis. 
The RCDII cell lines were isolated from small intestinal biopsies of RCDII patients (P1, P2 and P3) 
and displayed the characteristic phenotype of aberrant IEL: surface TCR-, CD3-, CD4-, CD8-, CD7+, 
CD103+, intracellular (ic) CD3+ 9. The controls included (I) five polyclonal CD103+ CD4+ and CD8+ 
TCRαβ+ T-IEL lines (T-IEL), (II) a CD4+TCR+ cell line from patient P1(P1-CD4), (III) a CD4+TCR+ clone 
from patient P3 (P3-CD4) and (IV) a CD8+TCR+ IEL line from patient P1 (P1-CD8).
Unsupervised hierarchical clustering analysis revealed two main branches: one contained the 
RCDII lines while the other contained all control TCR+ cell lines, including those from patients 
P1 and P3 (Figure 1A). Therefore, the RCDII lines were transcriptionally distinct from TCR+ cell 
lines, yet similar to each other. The RCDII lines had relatively high expression values of NK cell-
associated genes. The amount of Killer-cell Immunoglobulin-like Receptors (KIR) transcripts was 
roughly 5- to 20-fold higher in RCDII lines versus controls. Furthermore, the RCDII lines showed 
higher expression levels of  PLCG2 (phospholipase C γ2), which plays a pivotal role in secretion 
of cytotoxic granules in NK cells 26. The RCDII lines also had higher expression levels of SH2 
domain containing 1B (SH2D1B/EAT-2) which can act as an adapter molecule for the cell surface 
receptors CD84, CD244 and CD150 (SLAMF1) 27. All RCDII cell lines expressed CD244 (Table 1), 
a receptor expressed by NK cells and effector/memory T cells 28, while SLAMF1 expression was 
downregulated in the RCDII cell lines. 
In addition, several other genes that are associated with T cell mediated immunity according to 
the PANTHER classification were downregulated in the RCDII lines compared to the T cell lines, in 
particular granulysin (GNLY), lymphotoxin β (LTB) and tumor necrosis factor receptor 4 (TNSFRSF4) 
(Figure 1A, B). The differential expression of 7 genes (TNS3, SLAMF1, FoxD1, SH2D1B, PLCG2, LAT, 
LTB) was confirmed by RT-qPCR (Figure 1B and data not shown). An additional 12 surface markers 
(CD154, CD278, CD6, CD44, CD7, CD244, CD82, CD160, CD127, CD18, CD5, CD158d) were 
analyzed by flow cytometry (Figure 2 and data not shown) and also corroborated the microarray 
results. Furthermore, analysis of TCR rearrangements revealed that none of the RCDII lines 
possessed functionally rearranged TCRα/β or TCRγ/δ loci 29. Together, these data showed that 





FIGURE 1. RCDII LINES ExPRESS HIGHER LEvELS OF NK CELL-ASSOCIATED 
GENES WHEN COMPARED WITH REGULAR TCR+ CELL LINES. (A) Unsupervised 
hierarchical clustering analysis of the gene expression profiles of RCDII lines P1, P2 and P3 and 
TCR+ cell lines P1-CD4, P1-CD8, P3-CD4 and IEL 1-5. The heat map depicts the log intensity 
values of differentially expressed genes with a false discovery rate (FDR) of P<0.01 and a fold 
change difference of >7. Darker grey corresponds to higher log intensity values.  KIR allocation 
was imprecise as KIR probes anneal to transcripts of multiple KIR genes. (B) Quantification of 
differential gene expression by RT-qPCR. Relative expression of SH2D1B, PLCG2, LAT and LTB in 
RCDII lines (P1-P4), T-IEL lines (IEL1-4) as well as CD4+ T cell lines (CD4T: P1-CD4, P3-CD4, IEL1-
CD4), CD8+ T cell lines (CD8T: P1-CD8, P3-CD8, IEL5-CD8) and NK cell lines from 4 independent 




FIGURE 2. CONFIRMATION OF DIFFERENTIALLy ExPRESSED GENES FROM 
FIGURE 1 by FLOW CyTOMETRy ANALySIS. RCDII lines (P1-P4) and T-IEL (IEL1-5, IEL1-
CD4, P1-CD8, P3-CD8, IEL5-CD8) were analyzed for expression of (A) CD158d (KIR2DL4), (B) 
CD5, (C) CD18 (ITGB2) and (D) CD127 (IL7RA) by flowcytometry. On the left, a histogram of a 
representative staining for one RCDII and one T-IEL line (grey filling= isotype, no filling= antibody) 
is shown. The scatter plots on the right depict the relative mean fluorescence intensities (relative 




RCDII LINES DISPLAy A PREvIOUSLy UNDESCRIbED LyMPHOCyTE PHENOTyPE
To confirm and extend the results of the microarray analysis, we determined the expression of a 
large set of cell surface markers on RCDII lines P1, P2, P3 9 and on RCDII line P4 by flow cytometry 
(Table 1). RCDII line P4 (supplementary Figure 1) was derived from an additional RCDII patient. 
Like T-IEL, all RCDII lines expressed the pan-leucocyte marker CD45 but lacked expression of B cell 
marker CD19 and monocyte marker CD14 (Table 1). Although the RCDII lines did not express the 
NK cell marker CD56 (with the exception of a small CD56+ fraction within RCDII line P3, see Table 
1), they each expressed a unique selection of NK cell receptors (Table 1). Consistent with the 
microarray results (Figure 1A), all RCDII lines but not the control T cell lines expressed KIR2DL4/
CD158d (Figure 2A), which has thus far been detected on mature NK cells and memory T cells 
only. In addition, these cells expressed the IL-2/15Rβ chain (CD122), normally found on NK cells 
and memory T cells (Table 1). These results confirm and extend previous studies 30-32 and indicate 
that RCDII lines share features with both T and NK cells. 
The absence of the main lineage (Lin) markers (CD3, CD14, CD19, CD56) in combination with 
intracellular CD3 would be consistent with an immature lymphocyte phenotype. However, the 
RCDII lines did not express CD34, CD1a or CD117 (Table 1), markers associated with T cell and NK 
cell precursors 33, 34. Furthermore, RCDII lines P1, P2, P3 expressed no ROR-C transcripts (data not 
shown), nor the CD127/IL-7 receptor on the cell surface (Table 1, Figure 2D). RCDII line P4 was 
partly CD127 (IL-7Rα)-positive, but ROR-C negative (data not shown). The RCDII lines did therefore 
also not match the phenotype of LTi cells, a Lin-CD127+ROR-γ+ cell population present in the small 
intestine 35, 36.
Together, these results demonstrate that the RCDII lines share features with both T and NK cells 
and display a previously undescribed IEL phenotype: Lin-CD7+CD127-CD34-.
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Cell Type Marker Antibody clone name P1 P2 P3 P4
Leucocyte CD11a G43-25B     
Leucocyte CD18 L130     
Leucocyte CD54 LB-2     
Leucocyte CD62L SK11-EMPTY     
Leucocyte CD31 WM59     
Leucocyte CD52 Campath 1-H     
Leucocyte CD45 2D1     
Monocyte CD14 MEM-15     
Monocyte CD33 HIM3-4     
B (pre-B) CD10 ALB2     
B CD40 5C3     
B CD19 LT19     
T/B CD6 MT605     
T/B CD5 L17F12     
T/B/NK CD38 HB7     
T/B/NK CD30 BerH8     
T/B/NK CD45 RA L48     
T CD3 S4.1     
T/NK CD3 ic SK7     
T CD4 SK3     
T/NK CD8-α SK1     
T CD8-β 2ST8.5H7     
T CD45 RO UCHL1     
T CD152 BN13     
T CD154 TRAP1     
T CD44 G44-26     
T CD28 CD28.2     
T/LTI CD127 ebioRDR5    40%.
T/NK CD2 S5.2     
T/NK CD25 M-A251     
T/NK CD27 M-T271     
T/NK CD7 6B7     
T/NK Integrin beta-7 F1B504     
IEL T/NK CD103 Ber-ACT8     
NK/T CD122 TU27     
NK/T IL15 Rα 151303.     
NK/T CD56 MEM-188   2%.  
NK/T CD161 DX12     
NK/T CD16 GO22     
NK/T CD226 DX11     
NK/T KIR2DL1/S1 EB6     
NK/T KIR2DL2/L3/S2 GL183     
NK/T KIR2DL4 181703.     
NK/T KIR2DL5 UP-R1     
NK/T KIR2DS2/L3 1F12     
NK/T KIR2DS4 FES172     
NK/T KIR3DL1 DX9     
NK/T KIR3DL2 Q66     
NK/T CD94 HP-3D9     
NK/T NKG2A 131411.     
NK/T NKG2C 134591.     
NK/T NKG2D 149810.     
NK/T CD244 (2B4) C1.7     
NK/T NKp30 210845.     
NK/T NKp44 253415.     
NK/T NKp46 195314.     
NK/T NKp80 4A4.D10     
pre T/NK CD1a HI149     
pre T/NK CD117 104D2     
lymphoid precursor CD34 8G12     
TAbLE 1. FLOWCyTOMETRy ANALySIS OF RCDII CELL LINES P1-P4. White: no 
expression of the marker; Black: uniform expression of the marker; Gray: partial expression of the 




LIN-CD7+CD127-CD34- IEL ARE ALSO FOUND IN NON-COELIAC INDIvIDUALS
Next we investigated if cells with a Lin-CD7+CD127-CD34- phenotype were also present in non-
coeliacs. Multicolour flow cytometric analysis of IEL from duodenal biopsies from children and 
adults without CD showed that cells with this phenotype were indeed present (Figure 3A). These 
cells constituted on average 4% (range 0-8%, n=10) of the CD45+SSClow population in adults 
without CD and were more abundant (average 13%, range 4-32%, n=10) in children without CD 
(Figure 3B). In pediatric CD patients, this subset formed on average 0.7% (range 0-2%, n=11) of 
the CD45+SSClow population while this was on average 1.8 % (range 0-10%, n=16) in adult CD 
patients. Thus, Lin-CD7+CD127-CD34-  IEL are present in the duodenum of non-coeliac individuals 
as well as in CD patients. 
In contrast to the duodenum, few Lin-CD7+CD127-CD34- IEL were found in the ileum (average 
0.3%, n=2; data not shown) and colon (average 0.1%, n=3; data not shown). Furthermore, Lin-
CD7+CD127-CD34- IEL were were not detected in two fetal intestinal samples (data not shown). 
Most CD3-CD7+ cells in the fetal intestinal samples were CD56+ or CD127+ cells (data not shown). 
In human thymic cell suspensions, Lin-CD7+CD127-CD34- cells expressing CD103 constituted on 
average 0.1% (range 0.0-0.3%, n=4) of CD45+SSClow thymocytes (Figure 3C). These findings indicate 
that the postnatal duodenum is the preferential intestinal site for Lin-CD7+CD127-CD34- IEL, and 
suggest that this population may be thymus-derived.
The classical definition of aberrant IEL in RCDII includes the presence of intracellular CD3ε. Indeed, 
the large majority (average 88%, range 66-99% n=4) of Lin-CD7+CD127-CD34- IEL in RCDII duodenal 
biopsies expressed CD3 intracellularly (Figure 3 D, E), while this was on average 51% (range 8-91 
n=11) in coeliac and 31% (range 27-37 n=9) in non-coeliac individuals (Figure 3 D, E). On average 
23% (range 11-37%, n=3) of Lin-CD7+ CD127- CD34- IEL in the thymus showed intracellular CD3 
expression (Figure 3 D, E). 
In conclusion, a sizeable fraction of the Lin-CD7+ CD127- CD34-  cells in the duodenum and in the 




FIGURE 3. LIN-CD7+CD127-CD34- IEL: A PHySIOLOGICAL LyMPHOCyTE 
POPULATION IN NON-COELIAC AND COELIAC INDIvIDUALS.  (A) FACS analysis of 
cells isolated from the epithelium of duodenal biopsies from a non-coeliac child. Each plot shows 
the cells gated in the previous plot with the calculated percentages from the previous gate. The 
experiment shown is qua gating and populations representative of non-coeliac adults (n=10) 
and children ( n=10).(B) Fraction of Lin-CD7+CD127-CD34- IEL in duodenal biopsies expressed as 
a percentage of the CD45+SSClow population. This graph summarizes data from 11 children with 
CD (CD), 10 non-coeliac children (no CD), 16 adults with CD (CD) and 10 adults without CD (no 
CD). (C) FACS analysis of a healthy thymus (8 months old child) using the same gating strategy 
and calculations as described in Fig. 3A. Plots are representative of 4 donors. (D) Representative 
FACS plot depicts intracellular CD3 staining of Lin-CD7+CD127-CD34- IEL in an RCDII patient, a 
non-RCD individual, and a thymus sample. (E) Percentages of intracellular (ic) CD3+ cells within 
Lin-CD7+CD127-CD34- IEL in RCDII patients (n=4), CD (n=11), non-CD (n=9) individuals and thymus 




LIN-CD7+CD127-CD34- FORM A SUbPOPULATION OF CD3-CD7+icCD3+ CELLS
As the diagnosis of RCDII and EATL is made on the basis of the identification of a CD3-CD7+icCD3+ 
cell population either by histological or flow cytometric means 6-8, 37, we inverted our gating 
strategy to determine the specific phenotype of the CD3-CD7+icCD3+ population. 
Using this strategy we observed that in non-RCD patients (CD patients and non-coeliac individuals) 
this duodenal CD3-CD7+icCD3+ cell population was composed of four distinct populations: 
CD56+CD127-, CD56+CD127+, CD56-CD127- and CD56-CD127+ (Figure 4A). In RCDII patients (n=4) 
only two populations: CD56-CD127- and CD56-CD127+ cells were observed (Figure 4B). In the 
thymus the CD3-CD7+icCD3+ cells predominantly expressed CD56+ or were CD56-CD127- (Figure 
4C). 
These findings revealed that the duodenal CD3-CD7+icCD3+ IEL population is heterogeneous and 




FIGURE 4. CD3-CD7+icCD3+ CELLS FORM A HETEROGENOUS POPULATION. 
FACS analysis of CD45+SSClowCD14-/CD19- intraepithelial cells isolated from duodenal biopsies of 
(A) non-RCD individuals (no CD: n=9, CD: n=11), (B) RCDII patients (n=4) and of (C) from healthy 
thymuses (n=3). Representative dot plots are shown on the left; each plot depicts the cells gated 
in the previous plot. The graphs on the right summarize the results: the average (+/- SD) size 





LIN-CD7+CD127-CD34- IEL ExPRESS THE IL-2/15 RECEPTOR β -CHAIN AND 
PROLIFERATE IN RESPONSE TO IL-15
Expression of the cytokine IL-15 is elevated in the duodenum of CD and RCD patients 3. As IL-15 
is critical for the survival and expansion of RCDII cell lines 3, 38 we examined the expression of the 
IL-2/15 receptor β-chain (CD122) on IEL subsets from non-coeliac (n=5) coeliac (n=2) and RCDII 
(n=1) duodenal biopsies (Figure 5A, B). Lin-CD7+CD127-CD34- IEL expressed CD122 (Figure 5A). In 
fact, CD122 expression levels on these cells were higher than on NK cells, which are known to be 
IL-15 responsive. CD122 expression levels on Lin-CD7+CD127-CD34- cells on the other hand were 
lower than on NK cells and no CD122 was detected on T cells (Figure 5B). CD122 expression by 
PBMC from the same patients, on the other hand, showed a different pattern as Lin-CD7+CD127-
CD34- cells in blood had a lower CD122 expression than NK cells, while T cells, like in biopsies, 
were negative for CD122 expression (Figure 5C). 
As Lin-CD7+CD127-CD34-  IEL expressed the IL-2/15 receptor β-chain (CD122) in the absence of 
the IL-2 receptor α-chain (CD25, data not shown), they expressed a receptor for IL-15 but not a 
high-affinity IL-2 receptor. To test whether these cells were indeed IL-15 responsive, IEL released 
from paediatric non-celiac biopsies were incubated with IL-15 for three days. In the presence of 
IL-15, approximately 25% of Lin-CD7+CD127-CD34-  IEL were positive for the nuclear proliferation 
marker Ki-67, compared to approximately 5% in the absence of IL-15 (Figure 6). A similar picture 
was observed for the NK cells among the IEL (Figure 6), which also expressed CD122 (Figure 5). 
In contrast, no increase in Ki-67+ cell numbers was detectable for Lin-CD7+CD127-CD34-  cells and 
CD3+T cells (Figure 6), which did not express CD122 (Figure 5). 
Together, these results indicate that duodenal Lin-CD7+CD127-CD34- IEL proliferate in response to 




FIGURE 5. CD122 (IL2/IL-15Rβ) ExPRESSION ON T, LIN-CD7+CD127-CD34- IEL, 
LIN-CD7+CD127+CD34- AND NK CELLS. (A) Representative experiment of the CD122 
expression of IEL subsets of a non-coeliac child. The mean fluorescence intensity (MFI) of surface 
CD122 expression of T cells (CD3+), Lin-CD7+CD127-CD34- IEL, Lin-CD7+CD127+CD34- IEL and NK 
cells (CD3-CD56+CD127+/-) is depicted between square brackets. The CD122 expression is shown 
on the x-axis and the cell count on the y-axis. All IEL depicted here are CD45+SSClowCD14-CD19-
CD7+CD34-. (B) CD122 MFI expression of IEL subsets. Expression of CD3, 56 and CD127 is used to 
differentiate the sub populations as explained for (A) within CD45+SSClowCD14-CD19-CD7+CD34- 
cells from biopsies. (C) CD122 MFI expression of PBMC subsets. Expression of CD3, 56 and CD127 
is used to differentiate the sub populations within CD45+SSClowCD14-CD19-CD7+CD34- cells in 
PBMC from the same donors as in (B). Figure (B) and (C) summarize data from 8 donors (no-CD 





FIGURE 6. LIN-CD7+CD127-CD34- IEL PROLIFERATE IN RESPONSE TO IL-15. IEL 
released from a non-celiac paediatric biopsy were incubated for three days with 10ng/ml IL-15 
and subsequently analyzed by flow cytometry. Intracellular Ki-67 staining upon incubation in the 
absence (left) or presence (right) of IL-15 is shown for T cells (CD3+), NK cells (CD3-CD56+CD127+/-), 
Lin-CD7+CD127-CD34- cells and Lin-CD7+CD127+CD34- cells among IEL, gated as in Fig.5. One 




In this study we performed an in-depth analysis of aberrant RCDII lines isolated from biopsies 
of RCDII patients to uncover the cellular origin of these aberrant cells. Compared to TCR+CD3+ 
IEL, these RCDII lines expressed more NK-cell associated transcripts, including KIR. The RCDII 
lines lacked surface expression of lineage markers, as well as the expression of CD127 and CD34 
(Lin-CD7+CD127-CD34- IEL), but highly expressed the IL-15/2Rβ chain (CD122). Cells with this 
phenotype were also found in duodenal biopsies of non-coeliacs and in the healthy thymus, but 
were less frequent in ileal and colonic epithelium and undetectable in the fetal intestine. 
Characteristic for aberrant cells in RCDII, Lin-CD7+CD127-CD34-  IEL do not match any previously 
described physiological (non-pathological) IEL subset. In the duodenum of non-coeliac individuals, 
particularly children, these cells constituted up to 30% of CD45+SSClow cells. Strikingly, these cells 
were 18-fold more frequent in non-coeliac children compared to children with CD. This difference 
in numbers between coeliac and non-coeliac individuals mirrors previous studies regarding the 
CD3-CD7+ population 12, 13. Even after correction for the 2-4 fold increase in total IEL numbers in 
active celiac disease 39-42, absolute numbers of Lin-CD7+CD127-CD34-  IEL remain reduced in CD 
compared to non-CD children. 
Lin-CD7+CD127-CD34-  cells that also expressed the gut-homing receptor CD103 43 were 
also present in the human thymus. This may point to a thymic origin of these cells in the 
gastrointestinal epithelium. The low frequency of these cells in the ileum and colon compared 
to the duodenum suggests that the latter would be a preferential site for homing of such thymic 
emigrants. Strikingly, Lin-CD7+CD127-CD34-  IEL were not detected in the fetal intestine. Therefore, 
if these cells in the duodenum are indeed of thymic origin, this suggests migration from the 
thymus later in life. Together, the data fit a scenario in which the frequencies of these intestinal 
cells peak when the thymus is highly active, i.e. during the first postnatal decade. 
Data from this study support and extend further studies focusing on the intestinal CD3-CD7+ cell 
population, which included immature T cells and NK cells 12-18, 44.Using multicolour flow cytometry 
we could further define the different subpopulations in this heterogeneous CD3-CD7+ cell 
population. Additional markers such as icCD3, CD56, CD127 and CD34 proved that Lin-CD7+CD127-
CD34- IEL are distinct from T cells, NK, LTi and early CD34+ precursor cells. It is tempting to 
speculate that the Lin-CD7+CD127-CD34- IEL represent intermediate NK/T-lymphocyte precursors 
that undergo extrathymic differentiation, as was shown for other intestinal IEL subsets 18, 45-47.




with a pre-T cell phenotype, RCDII cell lines P1, P2 and P4 (but not P3) contained partial TCR 
rearrangements 29. Lin-CD7+CD127-CD34- IEL may therefore be identical to the immature T cells 
contained within the CD3-CD7+ cell population. On the other hand, the RCDII lines as well as 
duodenal Lin-CD7+CD127-CD34- IEL in vivo expressed the IL-2/15 receptor β-chain (CD122)  which 
could be detected on CD3-CD7+ cells in the epithelium 13, but is normally found on NK but not 
T cell precursors 33. Thus it will be important to test the ability of Lin-CD7+CD127-CD34-  IEL to 
differentiate into T or NK cells in in vitro differentiation systems. This will be the subject of further 
investigation. 
The presence of copious amounts of IL-15 in RCD is likely to contribute to the expansion and 
survival of (aberrant) IEL 3, 9, 38. In CD it induces NK- programming of TCRαβ+CD8+ IEL 30, 31, 48, 
49.  Lin-CD7+CD127-CD34- IEL, regardless of the disease status, expressed the IL-2/15 receptor 
β-chain in the absence of the IL-2 receptor α-chain. In line with this finding, in non-CD children 
Lin-CD7+CD127-CD34- IEL proliferated in response to IL-15, providing a potential link between the 
upregulation of IL-15 and the outgrowth of cells with a Lin-CD7+CD127-CD34- phenotype. 
Microarray analysis showed that, compared to regular T-IEL lines, the RCDII lines expressed 
lower levels of several T cell-associated genes, but higher levels of NK cell-associated genes. 
Notably, the  lines each expressed a unique combination of KIR, normally expressed after the 
appearance of NKp46 (present on P3 only) and CD56 (present on a small fraction of P3 only) in 
NK cell development or well after the completion of TCR rearrangements in T cells. It is therefore 
conceivable that IL-15, a critical cytokine in NK cell development, induces not only the expansion 
and survival, but also the acquisition of NK cell receptors on aberrant IEL in RCDII. 
Quantification of the CD3-CD7+icCD3+ population provides the basis for diagnosis of RCDII 6-8, 
37. Our results demonstrate that in non-coeliac individuals, as well as in CD patients, the CD3-
CD7+icCD3+ cells are heterogeneous and composed of four subsets based on the expression 
of CD127 and CD56, one of which displays the Lin-CD7+CD127-CD34-  IEL phenotype. In RCDII 
patients, CD56-CD127- and CD56-CD127+  subsets were observed, which fits the observation 
that lymphomas arising in RCDII patients are usually CD56- 50. This diverse phenotype of CD3-
CD7+icCD3+ cells in vivo, however, was mirrored in the RCDII cell lines, as a sizeable fraction of P4 
expressed CD127 and a minor fraction of P3 expressed CD56. Proliferation and a (pre)malignant 
transformation of aberrant IEL in RCDII and EATL could therefore take place at different time 
points of cellular development, potentially ranging from pre-T/NK cells to nearly mature T cells 
with near-complete TCR rearrangements. 
78
3
In conclusion, our studies indicate that ‘aberrant’ IEL in RCDII may be derived from a preexistent 
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Active celiac disease (CD) is characterized by an oligoclonal expansion of intraepithelial T cells 
(T-IEL), whereas refractory celiac disease type II (RCDII), a severe complication of CD, is defined 
by the clonal expansion of Lineage-negative (Lin-) IEL that can transform into overt lymphoma. 
Previously we demonstrated that CD3-negative IEL could be divided into 4 phenotypically distinct 
subsets based on the expression of CD56 and CD127. To gain insight into their function and 
relationship we here determined the phenotype, composition and differentiation potential of this 
innate IEL compartment in non-celiac controls as well as in patients with CD and RCDII. 
Unsupervised hierarchical clustering analysis of the expression of 14 NK and T cell surface markers 
demonstrated that the innate IEL subsets cluster together and separate from T-IEL. Moreover, 
co-expression of the IL-7R, IL-21R and IL-15Rα was a hallmark of CD127+ innate IEL while CD127- 
innate IEL expressed the IL-2/15Rβ. Age and disease dependent alterations in both the T-IEL and 
innate IEL compartments were observed, in particular a significant increase in the proportion of 
Lin-CD127- and Lin-CD127+ IEL expressing intracellular CD3ε and CD3γ in patients with CD. In vitro, 
in the presence of IL-15, Lin-CD127-IEL from controls and patients with CD, but not from RCDII 
patients, could differentiate into NK and T cells, the latter largely dependent on notch-signaling. 
Together our data reveal complexity and plasticity of the innate IEL compartment that is 
influenced by age and disease and provide evidence that innate IEL have the ability to give rise to 
NK and T cells. This developmental plasticity may allow rapid responses to local cues in health and 
disease.
AbbREvIATIONS
IEL- Intraepithelial Lymphocytes, Lin- Lineage, ILC- innate lymphoid cells, PBL- Peripheral Blood 
Lymphocytes, PBMC- Peripheral Blood Mononuclear Cells, RAG- Recombination Activating Gene, 





In the intestine, a single-layer epithelium provides a barrier against potentially harmful entities 
and mediates the uptake of nutrients. Intraepithelial lymphocytes (IEL) scattered throughout the 
epithelium form one of the largest lymphocyte populations in the body and are thought to be 
essential for maintaining the integrity of this barrier 1. 
IEL consist mainly of TCRαβ and TCRγδ T cells (T-IEL). Frequently disregarded, a CD3-negative 
innate IEL compartment exists, which was first described by Spencer et al. 2, 3 and Jarry et al. 4. 
Later studies revealed that this innate IEL compartment harbors cells expressing  a variety of 
NK cell receptors 5-9,  functional NK cells 9 and NK cell-like type 1 Innate Lymphoid Cells (ILC1) 
10. However, the composition, function and origin of this innate IEL compartment is still poorly 
understood. While it has been described that human innate IEL contain T cell precursors, their 
exact phenotype or developmental requirements have not been established 11, 12. As yet there is 
no evidence for intraepithelial NK cell development.
Previous studies reported that ILC subsets are increased in the lamina propria 13, 14, as well as in 
the epithelium of IBD patients 10 while in celiac disease (CD) patients a decrease in the CD3- innate 
IEL population 3, 7-9, 15, as well a decline in NK cell numbers is found 16. A severe complication of 
CD is refractory celiac disease (RCD), defined by a lack of remission despite a gluten free diet. 
RCD type II patients present with a massively expanded innate IEL population. This innate IEL 
population, characterized by the presence of intracellular CD3ε, was termed aberrant IEL 17. 
We recently showed that cells matching this phenotype were also present in healthy individuals 
and proposed that these cells were the physiological counterparts of aberrant IEL in RCDII 
18. Moreover, we observed that four innate IEL populations could be distinguished based in 
the expression of CD56 and CD127, indicating substantial heterogeneity within the innate IEL 
compartment. 
We now have conducted an extensive phenotypic analysis of innate IEL and compared them 
with T-IEL and their counterparts in blood. Furthermore we investigated the influence of aging 
and disease on the composition of the T-IEL and innate IEL compartment. Finally, we investigated 
if CD3- IEL could be precursors to mature T-IEL and /or NK cells. Our results indicate that innate 
IEL are heterogeneous and that the composition of the innate IEL and T-IEL compartments is 
influenced by both age and disease. What’s more, our results provide evidence that innate 








Fetal intestine from elective abortions and duodenal biopsies were obtained as described 
previously 18, 52. Informed consent was given for all human specimens after medical ethical 
commission approval and in accordance with the local ethical guidelines of the VUmc (duodeni) 
and the LUMC (duodeni, fetal intestines) and in accordance with the declaration of Helsinki. 
Cell isolation
IEL were isolated from fetal intestinal material and duodenal biopsies as described 18. Briefly, 
the material was treated with 1 mM DTT (Fluka, Buchs, Switzerland)/HBSS (Life Technologies, 
Bleiswijk, NL) and subsequently 1 mM EDTA (Merck, Darmstadt, Germany)/HBSS. IEL from fetal 
intestines cells were further purified using a percoll (GE Healthcare, Hoevelaken, NL) gradient. 
Isolated cells were either kept on ice in PBS/0.5 % FCS, fixed for 10 min at 4°C with PBS containing 
0.1% paraformaldehyde and 0.5% FCS, or viably frozen and stored at -80°C. 
Flow cytometry
Fluorochrome-labelled antibodies for CD3ε, CD4, CD5, CD7, CD16, CD25, CD45, CD56, CD103, 
CD117, CD122, CD14, CD19, CD34, KIR3DL1 (DX9), IL-21R, IFNγ and TCRγδ were from BD 
Biosciences (San Jose, CA, USA). KIR2DL2/DL3/DS2 (GL183), KIR2DL1/2DS1 (EB6), CD244, and 
NKp46 were from Beckman Coulter (Fullerton, CA, USA). IL-15Rα, TCRαβ, Granzyme B and 
goat-anti hamster (secondary antibody for HMT3-2) were from Biolegend (San Diego, CA, USA). 
Anti-CD127, CD45, CD3ζ and CD160 were from eBioscience (San Diego, CA, USA) and CD8 from 
Invitrogen (Bleiswijk, The Netherlands). CD3γ [HMT3-2] was from Millipore (Billerica, MA, USA) 
and TCRδ [TCS-1] from ThermoScientific (Etten-Leur, The Netherlands). Cells were incubated 
for 30 minutes with fluorochrome-conjugated antibodies for surface staining, and subsequent 
intracellular staining was done using the permabilisation kit from eBioscience. Cells were acquired 
on a LSRII or on a FACSAriaIII (BD Biosciences) for cell sorting. T cell contamination for sorts of 
Lin-IEL was calculated as 0%, CD56Low cell contamination 2,5% (n=3, reanalysis of 500 sorted 
cells/well).  Results were analyzed using FlowJo V10 software, and 4-GraphPad.  Unsupervised 
hierarchical clustering of flow cytometric measurements was done using the complete clustering 
method with the Euclidean distance measurement. The result was plotted in a heatmap using the 
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heatmap.2 function from the R gplots package.
Differentiation assays and cell culture
OP9-DL1 cells 53 were irradiated (1500 RAD) and plated at 5000 cells/well in 96-well plates. 
Lineage-negative (Lin-) cells were sorted from intestinal IEL as CD45+CD14-CD19-CD3-CD7+CD56-
CD127-CD4- and plated at 1 or 100 cells/well onto OP9-DL1. These co-cultures were maintained 
in Iscove’s modified Dulbecco’s medium (IMDM; LonzaVerviers, Verviers, Belgium) containing 10 
% pooled normal human serum (NHS), 5 ng/ml human IL-7 (Peprotech, Rocky Hill, NJ, USA), 10 
ng/mL human SCF, 10 ng/ml Flt3L and 10 ng/ml IL-15 (all R&D systems Europe, Abingdon, UK) 
for two weeks. Lin-IEL from duodenal biopsies were plated at 1 cell/well and feeder-cell mixture 
was added after two weeks of OP9-DL1 culture. This feeder-cell mixture contained 100.000 
mixed irradiated allogeneic PBMC, 1 μg/ml phytohemagglutinin, 20 Cetus u/ml IL-2 (Proleukin, 
Chiron corporation, Emeryville, CA) and 10 ng/ml IL-15. Clones were maintained on IMDM/10% 
NHS containing 10 ng/ml IL-15 and 20 Cetus units/ml IL-2.  In all cases, the phenotypes of the 
resulting cell populations were determined by flow cytometry. NK cells were obtained from PBMC 
by negative selection using MACS beads (Miltenyi, Bergisch Gladbach, Germany) and cultured 
for 2 weeks in AMV-I Medium containing 10% NHS/IL-15. K562 and Daudi cells were cultured in 
IMDM/8 % FCS and split at regular intervals.
Cytotoxicity assay
K562 and Daudi were labeled with 100 γCi [51Cr] for 1 h at 37˚C and washed. Target cells were 
incubated with a Lin-IEL-derived NK cell clone or blood-derived polyclonal NK cells at an effector: 
target (E:T) ratio of 25:1 for 4 h at 37˚C. Spontaneous and maximum 51Cr-release was assessed 
by the addition of medium or 1% Triton X-100 (Pierce, Rockford, IL), respectively. The percentage 
of specific lysis was determined by: (cpm experimental release - cpm spontaneous release)/(cpm 
maximum release - cpm spontaneous release) x 100 %.
Functional cell activation assays
Non tissue cultured plates (BD Microtest Plates)  were coated over night with anti-CD3 and anti-
CD28 (both at 2,5 µg/ml) and IgG1 (5 µg/ml) all from Biolegend in PBS, washed with PBS and 
incubated with 10% NHS/ IMDM Medium for 1h subsequently. Alternatively, cells were activated 
with PMA (20ng/ml) and Ionomycin (1µg/ml) both from SigmaAldrich (St. Luis, MO, USA), IL-15 
and IL-12 (both 10ng/ml from R&D systems Europe, Abingdon, UK) for 1h and Brefeldin A (10 µ/




analyzed by flow cytometry.
Statistical Analysis
Differences in percentages of IEL subsets were first calculated for an overall statistical significance 
with a Kruskal-Wallis test, and then using the Mann-Whitney U test with the Bonferroni 
Correction for multiple testing.
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RESULTS
INNATE IEL FORM A HETEROGENEOUS POPULATION WHICH IS 
DISTINCT FROM T-IEL 
In a previous study we identified multiple innate IEL subsets that could be distinguished on the 
basis of CD127 and CD56 expression: conventional CD56+CD127- NK cells (cNK), CD56+CD127+ 
NK cells, Lin-CD127- IEL and Lin-CD127+ IEL (Figure 1A and 18). In the current study, we determined 
the phenotypes of these innate IEL subsets by flow cytometry in a large number of duodenal 
samples. We used a panel of 14 T and NK cell surface markers known to be expressed at various 
stages of NK and T cell development: CD160, IL-21R, CD18, NKp80, CD94, CD16, KIRs, CD122, 
CD117, LAT, CD5, NKp46, IL-15Ra, CD244. For comparison, PBL samples were stained using the 
same antibody mixtures. Representative FACS-histograms of three cell surface markers are shown 
in Figure 1B. An overview of all data obtained is shown in supplementary Figure 1. While all IEL 
subsets expressed CD160, the IL-21R was expressed by a small subset of T-IEL and CD127+ innate 
IEL but not by CD127- innate IEL (Figure 1B). Similarly, the integrin CD18 showed a distinct pattern 
of expression, as a fraction of T-IEL, cNK and CD127+ NK were CD18 positive, while both Lin-IEL 
subsets lacked CD18 expression (Figure 1B). 
Unsupervised hierarchical clustering analysis (Figure 1C) of the entire set of flow cytometric 
data (supplementary Figure 1) using IEL and PBL samples revealed three distinct clusters of 
phenotypically similar cells: 1) a T cell cluster, 2) an NK cell cluster and 3) an innate IEL cluster with 
the four innate IEL subpopulations (Figure 1C). As the T-IEL clustered with T cells from PBL and 
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the NK cells from PBL clustered together, this indicates that the innate IEL populations are distinct 
from conventional NK cells and T cells including T-IEL. 
Within the innate IEL the CD127+ and CD127- subsets clustered together and are distinguished by 
the co-expression of the IL-7R, the IL-21R and the IL-15Rα by CD127+ but not CD127- cells and the 
much more prominent expression of IL-2/15Rβ (CD122) by CD127- cells compared with CD127+ 
cells (Figure 1C). Strikingly, the unsupervised clustering groups the cNK IEL with the Lin-CD127- IEL 
and the CD127+NK IEL with the Lin-CD127+ IEL so that neither the innate NK subpopulations nor 
the innate Lin- subpopulations cluster together. 
Taken together, these data confirmed the notion that the innate IEL compartment consists of 4 
phenotypically distinct subsets and indicates that while the CD127+ subsets could respond to IL-7 
and IL-21, the CD127- subsets would be more sensitive to IL-15. 
FIGURE 1. INNATE IEL ARE FORMED by DISTINCT SUbSETS THAT ARE 
DISSIMILAR TO T-IEL. (A) IEL were isolated from duodenal biopsies, stained with 
antibodies to CD45/CD14/CD19/CD3/CD7/CD56/CD127 and analyzed by flow cytometry. A 
representative plot for the gating strategy for T cells (T-IEL) (1) innate IEL including conventional 
NK (cNK) (2) CD127+NK (3) Lineage-negative (Lin-) CD127- (4) and Lin-CD127+ (5) cells is depicted. 
Each plot shows the cells gated in the previous plot. (B) IEL were isolated from duodenal biopsies 
and stained as described in (A) and analyzed by flow cytometry. The percentage of CD160, 
IL-21R and CD18 expression for IEL within the different subsets is depicted in the histograms 
and the corresponding marker on the y-axis. (C) Pediatric and adult duodenal IEL and PBL from 
peripheral blood were stained with a standard panel of antibodies (against CD45/CD14/CD19/
CD3/CD7/CD56/CD127), combined with antibodies detecting Nkp80, CD94, CD16, KIRs (a 
cocktail recognizing KIR2DL1/KIR2DL2/KIR2DL3/KIR2DS1/KIR2DS2/KIR3DL1), CD122, CD117, 
LAT, CD5, CD160, Nkp46, IL21R, IL15Rα, CD244 and CD18 and analyzed by flow cytometry. T 
cells, conventional NK (cNK), CD127+NK, Lineage-negative CD127- (Lin-CD127-) and Lin-CD127+ 
cells from IEL or PBL were gated as described in (A). A heatmap was generated from the data by 
unsupervised hierarchical clustering. The heatmap depicts the z score generated by the average 
percentages of cells expressing the above-mentioned markers or the average mean fluorescence 






AGE- AND CELIAC DISEASE-ASSOCIATED CHANGES IN INNATE IEL
As the entire innate IEL population is decreased in celiac disease patients compared with non-
celiac controls, 3, 7-9, 15, 16 and children show higher frequencies of Lin-CD127- IEL than adults 18, we 
considered the possibility that the composition of the innate IEL compartment is influenced by 
disease and/or ageing. 
We therefore determined the relative abundances of the IEL subpopulations in the fetal intestine, 
duodenal biopsies of healthy children and adults, children and adults suffering from CD, and 
adults with complicated celiac disease (RCDII). T-IEL were the least abundant in fetal IEL and most 
prominent in adults with an intermediate percentage in children (Figure 2A). Conversely, both cNK 
and CD127+NK populations were most abundant in the fetal IEL and significantly lower in IEL of 
both children and adults. As reported earlier 18 Lin-CD127- IEL were significantly higher in children 
compared to adults. Similarly, cNK IEL were higher in children compared to adults.  
In CD, both in children and in adults, the percentage of T-IEL were increased, in agreement with 
previous reports 3, 19, 20. Conversely, the percentages of the innate IEL populations were lower, 
particularly in children in which all four subsets were significantly affected, while in adults only 
the CD127+ subsets were lowered (Figure 2A). In striking contrast, in RCDII patients both the 
percentages of Lin-CD127- and Lin-CD127+ IEL were significantly increased, accompanied by a 
decrease in the percentage of T-IEL when compared with adults with CD (Figure 2A). The latter 
observation confirms the diagnosis of RCDII on the basis of the percentage of CD3-negative 
aberrant IEL 21. 
Previously, it was not recognized that the CD3-negative aberrant IEL population could contain 
both CD127- and CD127+ cells. Analysis of these subpopulations in the cohort of 10 patients 
included in the present study indicates that the relative contribution of these subsets is patient 
dependent: while all patients harbored a sizable, but variable proportion of CD127- and CD127+ 
cells, in three patients only the CD127- subset was detected (Supplementary Figure 2). As these 
subsets can be distinguished on the basis of the expression of distinct cytokine receptors, the local 
cytokine milieu in the intestine may determine the selective outgrowth of one of these innate IEL 
subsets. 
Premalignant aberrant Lin-CD127- IEL expanded in RCDII patients 18 express intracellular CD3 
(icCD3). We therefore analyzed the intracellular expression of the ζ-chain, CD3ε and CD3γ 




T-IEL from both controls and patients with CD and in PBL expressed both CD3ε and CD3γ (Figure 
2B, C) and the ζ-chain (not shown). In patients and non-CD controls all four innate IEL subsets 
expressed the ζ-chain (data not shown). In controls the large majority of cells in all four IEL 
subpopulations lacked expression of both icCD3ε and icCD3γ while the remainder were either 
icCD3ε single positive or icCD3εγ double positive. In contrast, in CD patients the majority of 
both Lin-CD127+ and Lin-CD127- IEL populations expressed both icCD3ε and icCD3γ, while the 
percentage of icCD3εγ positive cNK and CD127+ NK IEL was decreased (Figure 2B,C). In PBL high 
frequencies of icCD3εγ+ cells were only detected in Lin-CD127+ cells (Figure 2C). Furthermore, 
Lin-CD127- IEL and Lin-CD127+ IEL in RCDII patients showed enormous levels of icCD3ε expression, 
which was on average 3x higher than T-IEL (Figure 2D).
Thus, the composition of both the T-IEL and innate IEL compartment is influenced by age and 
disease and in CD there is a significant increase in the intracellular expression of CD3εγ within 





FIGURE 2. PLASTICITy OF THE INNATE IEL COMPARTMENT: SHAPED by 
AGE AND DISEASE. (A) IEL were isolated from duodenal biopsies from children and adults 
with celiac disease (CD) or without CD (no CD) and refractory celiac disease type II (RCDII). IEL 
were stained with antibodies to CD45/CD14/CD19/CD3/CD7/CD56/CD127 and analyzed by flow 
cytometry. The percentages of T cells (1), Lineage-negative CD127-(Lin-CD127-) (2), Lin-CD127+ IEL 




CD45+ cells measured. A star indicates statistical significance as calculated by the Mann-Whitney 
U test with Bonferroni Correction. *1 compares percentages of IEL subsets from: the fetus with 
children (no CD), *2 children with adults (both no CD), *3 children without CD (no CD) with 
children with CD (CD), *4 adults no CD versus adults CD and *5 adults CD with RCDII. N=17 fetus, 
n=51 children no CD, n=10 adults no CD, n=28 children CD, n=30 adults CD, n= 10 RCDII. (B) IEL 
were isolated from pediatric biopsies from celiac patients (IEL CD) and non CD patients (IEL no CD) 
and stained for surface CD45/CD14/CD19/CD3/CD7/CD56/CD127 as well as intracellular CD3ε 
(icCD3ε) and CD3γ (icCD3γ). Representative dot plots of the intracellular CD3ε and CD3γ staining 
of T cells, Lineage-negative CD127- (Lin-CD127-) and Lin-CD127+ IEL, conventional NK (cNK) and 
CD127+NK cells, gated as in Fig1A are shown. (C) IEL isolated from biopsies of CD, no CD and PBL 
were stained and analyzed as described in (A). The bar graphs depict the percentages (mean ± SD) 
of intracellular (ic) CD3ε and CD3γ (icCD3γε+) cells (y-axis) within the subpopulations (x-axis). N=3 
for IEL CD and no CD, N=6 for PBL. (D) IEL isolated from RCDII patients were stained as in (A) and 
for icCD3ε. The mean fluorescence intensity (MFI) of the icCD3ε+ cells (x-axis) is depicted for the 
different IEL subsets (y-axis). N=4
LIN-CD127- IEL FROM NON-CD CONTROLS AND CD PATIENTS, bUT NOT 
FROM RCDII PATIENTS, CONTAIN NK AND NOTCH-DEPENDENT T CELL 
PRECURSORS
As both Lin- IEL subsets contained cells that expressed multiple CD3 chains intracellularly, we 
investigated if these subsets might contain precursors to mature T and/or NK cells. For this 
purpose we determined the in vitro differentiation potential of cells isolated from controls, CD 
and RCDII patients in the OP9 stroma-based co-culture system 22. As duodenal biopsy material 
yielded only small numbers of Lin-IEL (usually up to 100 cells), we decided to focus on the Lin-
CD127- IEL subset as in the majority of biopsies this subset was the largest innate subset and 
we have previously shown that they are responsive to IL-15 18, a key cytokine in CD and RCDII 
pathogenesis. For all experiments we isolated Lin-CD127-  IEL by flow cytometric sorting. 
First, we investigated if IL-15 was required for the outgrowth of Lin-CD127- IEL in stromal co-
cultures. For this purpose Lin-CD127- IEL were isolated and co-cultured with OP9-DL1 in the 
absence or presence of IL-15. After two weeks, significant numbers of CD45+ cells were detected 
only in co-cultures to which IL-15 had been added (Figure 3A) showing, that IL-15 was required for 
the survival and expansion of Lin-CD127- IEL in this culture system. 
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As notch ligands are expressed in the intestinal epithelium 23, 24 and notch receptor triggering has 
been shown to drive icCD3 expression 25 and T cell development in developing lymphocytes, we 
next investigated the differentiation potential of Lin-CD127- IEL on stroma cells lacking (OP9) or 
expressing the notch ligand DLL1 (OP9DL1) 26. For this purpose we used Lin-CD127-  IEL isolated 
from CD biopsies. While Lin-CD127- IEL co-cultured with OP9 developed mainly into cNK cells, 
co-cultures with OP9DL1 resulted in the outgrowth of both cNK and T cells (Figure 3B, left two 
panels). The differential outgrowth of T cells on notch-ligand DLL1 indicated, that Lin-CD127-  IEL 
contained notch-dependent T cell precursor cells. Therefore this outgrowth was unlikely due to 
contaminating mature T cells. 
Subsequently, we determined the differentiation capacity of Lin-CD127-  IEL isolated from biopsies 
of controls and patients with RCDII. Similar to Lin-CD127-  isolated from CD patients, co-cultures of 
OP9DL1 with Lin-CD127-  IEL from controls yielded cNK and T cells, but the outgrowth of cNK cells 
dominated (Figure 3B, middle panels). In contrast, Lin-CD127-  IEL isolated from RCDII biopsies 
did not differentiate into NK or T-IEL in OP9DL1 co-cultures (Figure 3B, right panel). As T-IEL were 
still present in RCDII patients, yet no T-IEL outgrowth was detected from RCDII Lin-CD127-  IEL on 
OP9DL1, this further underlies the validity of our previous studies.
Next we determined the cell surface phenotype of the cells generated in the co-cultures. An 
overview of the results is shown in Figure 3C and examples for the phenotype of cells generated 
from a patient with CD and a patient with RCD are shown in Figure 3D. T cells from non-CD 
and CD patients consisted mainly of CD8+TCRαβ+ cells and some TCRγδ+ cells. NK cells showed 
a variable level of CD8 expression, but lacked CD127 and were therefore considered cNK 
cells (Figure 3C,D). On the contrary, Lin-CD127- IEL from RCDII biopsies retained their original 
phenotype after culture (Figure 3D).
Thus, Lin-CD127-  IEL from controls and CD patients could give rise to cNK and T cells, where 
increased T cell differentiation was detected in co-cultures with cells from CD patients, compared 
to non-CD patients, which may relate to the increased icCD3εγ expression in Lin-CD127- IEL from 
CD patients (Figure 2). In contrast Lin-CD127-  IEL from RCDII patients did not differentiate into 




FIGURE 3. LIN-CD127-IEL FROM NON-CD CONTROLS AND CD 
PATIENTS, bUT NOT FROM RCDII PATIENTS, CONTAIN NK AND NOTCH-
DEPENDENT T CELL PRECURSORS. (A) IEL isolated from adult biopsies (adult Lin-
CD127- IEL) were sorted (gated as in Figure 1) at 100 cells/well on OP9-DL1. After 14 days of 
co-culture in the presence of Flt3L/IL-7/SCF with (+IL-15) or without IL-15 (-IL-15), cells were 
harvested and analyzed by flow cytometry. The amount of CD45+ (y-axis) cells after co-culture is 
depicted. (B) Lin-CD127-IEL from biopsies of CD patients (CD), non-CD controls (no CD) and from 
RCDII biopsies were sorted at 100 cells/well on OP9 or OP9DL1 and cultured in the presence of 
Flt3L/IL-7/SCF and IL-15. After two weeks, the cultures were analysed by flowcytometry, and 
the percentage of NK (CD3-CD7+CD56+) and T cells (CD3+CD7+) was calculated as a percentage 
of CD45+ cells. Each data point represents the result of a single culture from a total of 7 non-CD 
controls, 4 CD patients and 7 RCDII patients. While for non-CD and CD patients Lin-CD127- IEL 
were sorted directly from biopsies, for the RCDII patients Lin-CD127- IEL were sorted directly 
from biopsies (n=1), sorted from short-term cultures of biopsies in IL-15-containing medium 
(n=2),  or plated from cultured RCDII lines, which were homogeneously Lin-CD127- (n=4). (C) 
These graph gives an overview of the phenotype of T and NK cells generated as described in (B). 
The percentages of cells staining positive for TCRαβ, TCRγδ, CD4, CD8 or CD4-CD8- (DN= double 
negative) is depicted for T cells (CD3+CD7+) and NK cells (CD3-CD7+). 
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(D) Representative FACS plots of Lin-CD127- IEL at the time of sort (sort) and after 14 days of 
culture on OP9DL1 (with FLT3L, SCF, IL-7, IL-15). This graph shows a representative example of Lin-
CD127-  IEL isolated from a CD patient and a RCDII patient (both after IEL isolation from biopsies, 
staining and sorting as described in Figure 1A). Cells were stained for CD3, CD7, CD56, CD127, 
CD4, CD8, and additionally TCRαβ and TCRγδ if applicable.
CLONAL LIN-CD127-IEL GENERATED FUNCTIONAL TCRαβ, TCRγδ AND NK 
CELLS 
Subsequently, we investigated whether single Lin-CD127- IEL isolated from duodenal biopsies 
could give rise to T and/or NK cells. However, single Lin-CD127- IEL seeded on OP9DL1 did not 
yield sufficiently large cell numbers for phenotypic analysis (data not shown). We therefore 
cultured single cells on OP9DL1 cells for 14 days for differentiation, after which a ‘feeder mix’ 
consisting of irradiated allogeneic PBL was added for expansion of the differentiated cells. After an 
additional 10-20 days, three types of cells arose from single duodenal Lin-CD127- IEL: Vδ1+TCRγδ T 
cells, CD8+TCRαβ T cells and NK cells (Figure 4A). 
To investigate if the generated T and NK cell clones were functional, we stimulated these 
clones with plate-bound antibodies directed against CD3 and CD28 or with a mixture of PMA/
Ionomycin/IL-15 and IL-12 - designed to achieve optimal activation of the clones - and tested for 
the induction of IFNγ and Granzyme B production. In the T cell clones, anti-CD3/CD28 triggering 
induced moderate IFNγ production in the T cell clones and the PMA/Ionoycin/IL15/IL2 mix 
strongly upregulated both IFNγ production and Granzyme B (Figure 4B). In the NK cell clone, 
anti-CD3/CD28 triggering had no effect and the PMA/Ionomycin/IL15/IL2 mix induced a strong 
IFNγ response, but had no effect on the already very high levels of Granzyme B expression prior 
to stimulation (Figure 4B). In addition, this NK cell clone lysed classical NK cell targets K562 and 
Daudi, albeit to a lesser extent than peripheral-blood-derived NK cells (Figure 4C). 
In summary, the generated T cell clone was sensitive to TCR crosslinking and able to produce IFNγ 
and Granzyme B upon stimulation, while the NK cell clone expressed high levels of Granzyme B, 




FIGURE 4. LIN-CD127- IEL DERIvED CLONES SHOW FUNCTIONAL 
PROPERTIES OF T OR NK CELLS. (A) Lin-CD127- IEL were sorted from pediatric 
duodenal biopsies and plated at 1 cell/well on OP9DL1 in the presence of Flt3L/IL-7/SCF and IL-15. 
After 14 days of co-culture, cultures were expanded with mixed irradiated allogeneic PBMC, IL-2/
IL-15 for another 10-20 days. Dot plots show the phenotype of representative single-cell cultures 
(TCRγδ, TCRαβ and NK clone), harvested after expansion. N=4 independent experiments. (B) A 
Lin-CD127-IEL-derived T and NK cell clone were activated with coated anti-CD3 and anti-CD28 
(both 2,5 µg/ml) or IgG1 (5 µg/ml) for 4h or by a cocktail of PMA/Ionomycin/IL-12 and IL-15 in the 
presence of Brefeldin A (10 µg/ml) for the last 3h. Cells were harvested, stained and analysed by 
flow cytometry for intracellular production of IFNγ or Granzyme B. (C) Lin-CD127-IEL-derived NK 
cell clone (see Figure 4A) and control peripheral blood NK cells, both expanded in the presence of 
IL-15, were used in a cell-mediated lysis (CML) assay, using 51Cr-labelled K562 and Daudi cells as 
target cells at an effector:target ratio of 25:1. The percentage of specific lysis was calculated based 




While the existence of a CD3- IEL population in the small intestine is well established, the exact 
composition and function of this lymphocyte subset has remained largely unknown. Here, we 
phenotypically characterized four CD3- innate IEL subsets and demonstrated that these are 
all clearly distinct from each other. In agreement with our previous results, two distinct Lin- 
IEL populations and two NK-like IEL populations could be identified based on the differential 
expression of CD127 and CD56. Moreover, co-expression of the IL-7R (CD127), the IL-21R and the 
IL-15Rα distinguished two of these subsets from the two other subsets that typically express the 
IL-15Rβ, indicating that changes in the local cytokine milieu may have profound effects on the 
composition of the innate IEL compartment. 
Furthermore, we observed that the composition and intracellular expression of CD3 chains 
was influenced by age and disease. In particular, while the relative proportion of the innate IEL 
subsets was decreased in CD, the intracellular expression of CD3 chains was markedly increased 
in both Lin-  IEL subsets. In contrast, both Lin- IEL subsets were found expanded in RCDII. Finally, 
we provide evidence that the Lin-CD127- IEL subset in controls and patients with CD contained 
precursors to cNK and T cells as co-culture of Lin-CD127- IEL on the stromal cell line OP9DL1 led to 
the outgrowth of both cNK and T cells in an IL-15 dependent fashion. 
Besides IL-15, the expression of the notch-ligand DLL1 promoted T cell development. Importantly, 
notch-ligands such as DLL1 are expressed in the intestine 23, 24, where they provide differentiation 
signals to intestinal stem cells in the crypts 27, 28 and as such could also play a role in lymphocyte 
differentiation in the intestinal epithelium. Lin-CD127- IEL derived from RCDII patients on the 
other hand failed to develop into T or NK cells, which is likely linked to the premalignant nature of 
these cells.
Intestinal Lin- T cell precursors have been identified in mice and were found mainly in 
cryptopatches in the lamina propria 29. These cells express CD34, CD117 and CD127 (IL-7Rα) and 
gave rise to TCRαβ and TCRγδ T cells 30, 31. T cell precursors with a Lin- IEL phenotype were also 
detected in the mouse epithelium; these express icCD3ε but no to little RAG-1, which may explain 
the restricted TCR repertoire found in non-conventional T cells 32 33. Extensive analysis of Lin- 
subsets suggested a stepwise differentiation process of maturation, which include intermediary 
T cell precursors with a phenotype matching that of the human Lin-CD127- IEL described in our 




Evidence for the existence of T cell precursors in the human intestine is scant. In line with our 
current data, MacDonald and colleagues reported that human intestinal CD3- cells contain T 
cell precursors. In murine reaggregate thymic organ cultures and in transplanted SCID mice, 
this population gave rise to mature T cells 11, 12.  The exact innate subset and developmental 
requirements of these T cell precursors, however, was not determined. 
In fact, TCR rearrangements 11, 34  and preTα 12, 34-36 were detected in intestinal IEL and CD3- 
cells. Furthermore, RAG-1 expression has been demonstrated in CD3- IEL 6, 34-36, as well as the 
expression of TdT 36, but to a variable degree 37. In line with the latter observation, we did not 
detect significant intracellular TdT protein expression in duodenal biopsies while such expression 
was evident in CD34+ cells in the thymus (data not shown). As it is now clear that innate IEL 
contain different subpopulations (ref. 18 and this study), which depending on the age and disease 
status of the donors were present in variable numbers, this may explain the conflicting results 
in previous studies. Our current results thus extend those previous observations as they provide 
further evidence for the existence of T cell precursors in the Lin- IEL compartment in the duodenal 
epithelium. 
Furthermore, our data indicated that the majority of Lin- IEL developed into cNK cells in the in 
vitro culture system used. In humans, NK cell precursors have so far been described in secondary 
lymphoid tissue as lymph nodes 38 , tonsils 39, liver 40, in the uterus 41, the thymus 42 and as CD117+ 
cells the lamina propria of the intestine 43, but not in the intestinal epithelium.
A confounding factor could be the outgrowth of contaminating NK and/or T cells in the in vitro 
differentiation system. Several observations argue against this possibility. First, we used a strict 
gating strategy throughout our studies, which showed no T cell contamination (0+/-0%) and very 
few CD56Low cells were detected after the sort (2,5+/-3%). Second, culture of Lin-CD127- IEL from 
RCDII patients did not lead to T cell outgrowth, even though T cells were present before the FACS 
sort. Third, bulk sorting of intestinal Lin-CD127- IEL followed by culture with ‘feeder mix’ – optimal 
culture conditions for mature T and NK cells – did not yield any outgrowth of T or NK cells in 
four independent experiments (data not shown). Finally, the observation that notch-signaling 
augmented T cell differentiation points to the fact that T cells arising from Lin-CD127- IEL were 
derived from notch-dependent pre-T cells and thus not from contaminating mature T cells. 
It is well known that T-IEL numbers, both TCRαβ+ and TCRγδ+ are elevated in patients with CD 
compared to controls 3, 19. We observed that Lin-CD127- IEL isolated from CD patients displayed 
increased expression of intracellular CD3ε and CD3γ and yielded higher T cell numbers compared 
to Lin-CD127- IEL from non-celiac controls. Moreover, we found outgrowth of both TCRαβ+ and 
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TCRγδ+ cells in bulk cultures as well as at the clonal level. Thus, it is tempting to speculate that 
in CD Lin-CD127- IEL are more prone to give rise to T cells due to local alterations, like changes 
in the cytokine milieu induced by the gluten-specific T cell response. For example, the well-
known upregulation of IL-15 in CD 44 would impact on the IL-15β+ Lin-CD127- IEL 18, 44, 45 while 
IL-21 produced by gluten-specific T cells in the lamina propria 46 could drive proliferation and/
or differentiation of the IL-21R+ Lin-CD127+  IEL. RCDII on the other hand presents with a massive 
expansion of Lin-CD127- IEL that express extraordinarily high levels of intracellular CD3 chains, 
which by itself is known to block T cell differentiation 47 and this may explain our observation that 
Lin- IEL from RCDII patients did not develop into cNK or T cells in the OP9DL1 based differentiation 
system.
Interleukin-15 plays an important role in CD and RCDII as it is upregulated in the intestinal 
epithelium and has potent proliferative and anti-apoptotic effects 44, 45, 48, 49. In particular, patients 
with RCDII have a massive increase in the Lin- IEL numbers 17 and in approximately 50 % of these 
patients, malignant transformation leads to enteropathy associated T cell lymphoma, a usually 
fatal complication 50. Cell lines isolated from such patients are IL-15 responsive and treatment with 
anti-IL-15 has therefore been suggested to be a potential treatment option. Our current data, 
however, indicate that next to an expansion of Lin-CD127- IEL, Lin-CD127+ IEL are also frequently 
expanded in RCDII. As the former express the IL-15Rβγ while the latter express the IL-7R, IL-21R 
and IL-15Rα, but considerably less IL-15Rβ, treatment with anti-IL-15 by itself is unlikely to be 
sufficient. Intriguingly, the simultaneous presence of IL-15Rα Lin-CD127+ IEL and IL-15Rβ Lin-
CD127- IEL in the intestinal epithelium suggests that the former could present IL-15 in trans to the 
latter. 
Recently, ILC have aroused broad interest, as these cells constitute minor cell populations in the 
intestine, but exert major roles in the healthy intestine and in inflammatory intestinal diseases 
51. Three types of innate lymphoid cells, ILC1, ILC2 and ILC3, have been described in recent 
years, each with distinct functional features. ILC2 and ILC3 express CD127/IL-7Rα and ILC1 are 
either CD127+ 13 or CD127- 10. Most ILC subsets reside in the lamina propria but evidence for the 
existence of intraepithelial ILC1 subset was recently obtained 10. In fact, this ILC1 population could 
be identical to the intraepithelial cNK subset described in our studies, as both populations are 
CD56+CD127-. Also, intraepithelial ILC1 express granzyme-B, like the cNK cells derived from Lin-
CD127- IEL (data not shown). Moreover, ILC1 cells share other features with Lin-CD127- IEL, such as 
the expression of CD160, a functional IL-15 receptor and NKp44 (data not shown). Thus, further 




In the colonic lamina propria of patients with IBD, the closely related ILC1 10, 13 and ILC3 14 
populations are expanded, as well as ILC1 in the ileal epithelium 10, while innate IEL are reduced 
in the duodenal epithelium of celiac disease patients. This suggests that these innate cell types, 
depending on their localization, play distinct roles in disease pathogenesis. 
In conclusion we provide evidence for the complexity and plasticity of the innate intraepithelial 







SUPPLEMENTARy FIGURE 1 (RELATED TO FIGURE 1). Flow cytometry data for 
the heatmap of Fig1C. Graphs depict the percentages of cells expressing Nkp80, CD94, CD16, KIRs 
(a cocktail recognizing KIR2DL1/KIR2DL2/KIR2DL3/KIR2DS1/KIR2DS2/KIR3DL1), CD122, CD117, 
LAT, CD5, CD160, Nkp46, IL21R, IL15Rα, CD244 and CD18. This data was used to generate the 
heatmap in Figure 1C. The percentage of T cells,  conventional NK (cNK) , CD127+ NK, Lineage-
negative (Lin-) and Lin-CD127+ expressing the marker of interest (y-axis) in blood (n=3-10) and 
duodenal IEL (n=3-8) samples is shown.
SUPPLEMENTARy FIGURE 2. COMPOSITION OF IEL SUbSETS IN RCDII 
PATIENTS. IEL were isolated from duodenal biopsies from adults with refractory celiac disease 
II (RCDII). IEL were stained with antibodies to CD45/CD14/CD19/CD3/CD7/CD56/CD127 and 
analyzed by flow cytometry. The percentages of Lineage-negative CD127-(Lin-CD127-), Lin-CD127+ 
IEL, conventional NK (cNK) and CD127+NK and T cells, gated as in Fig.1A is depicted calculated 
from all CD45+ cells measured. The numbers on the y-axis indicate the patients analyzed.
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The thymic environment primarily supports T cell maturation, but thymic NK cells and NK cell 
precursors have also been identified. We recently identified a CD34-CD103+Lin-CD127- population 
in the small intestinal epithelium that contained NK and T cell precursors. 
Given the presence of NK/T cell precursors and CD103+ cells in the thymus, we here examined the 
existence, phenotype and NK/T cell differentiation potential of thymic CD34-CD103+Lin-CD127- 
(now referred to as thymic CD103+Lin-CD127-) cells.
Thymic CD103+Lin-CD127- cells were phenotypically similar to thymic NK cells: CD5-, Nkp46+, KIR+. 
In contrast to mature NK cells, however, the cells lacked CD16 and CD56.  Furthermore, thymic 
CD103+Lin-CD127- cells were devoid of markers commonly used to identify T cell precursor stages 
such as CD3, CD4, CD8, CD34 and CD1a, but a significant proportion of cells expressed CD3ε 
intracellularly. 
Upon culture with OP9DL1, thymic CD103+Lin-CD127- cells primarily developed into mature NK 
cells in an IL-15-dependent fashion. However, in clonogenic assays single CD103+Lin-CD127- cells 
gave rise to mixed populations of NK cells, immature and mature T cells and undifferentiated Lin- 
cells.
In conclusion, this study shows that human CD103+Lin-CD127- thymocytes resemble thymic NK 
cells and contain bi-potential NK/T cell precursors.
AbbREvIATIONS
IEL- Intraepithelial Lymphocytes, Lin- Lineage,  DN- Double-negative, DP- Double-positive, PBMC- 






T and NK cells share a common progenitor that derives from hematopoietic stem cells in the 
bone marrow. These progenitors can differentiate into NK cells locally, but they can also seed the 
thymus to differentiate into T cells. In the thymus, the precursor cells are initially Lineage-negative 
(Lin-): they lack markers for all mature lineages such as T, B, myeloid and NK cells. The earliest T 
cell progenitors are Lin-, CD34+, CD1a- and CD4-CD8- (double-negative or DN). Subsequently, these 
DN thymocytes mature via an immature single-positive (ISP CD4+) and a double-positive (DP) 
stage into CD4+ or CD8+ SP T cells that exit the thymus. Rearrangement of the TCR loci takes place 
from the earliest DN stage (DN1) to the DP CD3- stage and culminates in the expression of TCR/
CD3 complexes on the surface of DP CD3+ thymocytes. With this progression along the T cell path, 
CD34 is lost together with the potential to differentiate into NK cells. The latest stage at which 
thymocytes developing into T cells can still become NK cells is the second DN stage (DN2), when 
the cells are still CD34+.
A subset of DN and CD8 SP thymocytes expresses CD103 (αE), which together with the integrin 
β7 forms a receptor for E-cadherin, expressed on thymic epithelial cells 1. The function of these 
CD103+ thymocytes is currently unclear. 
We recently described a CD103+ and CD34- Lineage-negative (Lin-) cell population in the 
epithelium of the small intestine. Despite the lack of CD34, this population still had the capacity to 
develop into T and NK cells in in vitro differentiation assays. In the current study, we characterize a 
similar population in the thymus, and show that these CD34-CD103+Lin-CD127- thymocytes (now 
referred to as thymic CD103+Lin-CD127-) harbor bipotential T/NK cell precursors.  
        
MATERIALS AND METHODS
Human specimens
Thymus was obtained as surgical tissue discards from children undergoing cardiac surgery. 
Informed consent was given for all human specimens after medical ethical commission approval 
and in accordance with the local ethical guidelines of the ErasmusMC and in accordance with the 





Thymocytes were isolated as described 16. OP9 or OP9-DL1 cells were irradiated (1500 RAD) 
and plated at 5000 cells/well in 96-well plates. Lineage-negative (Lin-) cells were sorted from 
CD3-depleted (anti-CD3 MACS beads, Miltenyi, Bergisch Gladbach, Germany) thymocytes as 
CD34-CD103+Lin-CD127- [CD45+CD14-CD19-CD3-CD7+CD56-CD127-CD103+CD34-] or as CD34+CD1a- 
[CD45+CD14-CD19-CD3-CD34+CD1a-] and plated at 1, 100 or 1000 cells/well onto OP9 or OP9-
DL1. These co-cultures were maintained in Iscove’s modified Dulbecco’s medium (IMDM; 
LonzaVerviers, Verviers, Belgium) containing 10 % pooled normal human serum (NHS), 5 ng/ml 
human IL-7 (Peprotech, Rocky Hill, NJ, USA), 10 ng/mL human SCF, 10 ng/ml Flt3L and if stated 10 
ng/ml IL-15 (all R&D systems Europe, Abingdon, UK) for up two weeks. Clonal CD103+Lin-CD127- 
thymic cells were sorted at 1cell/well on 100.000 mixed irradiated allogeneic PBMC, 1 μg/ml 
phytohemagglutinin, 20 Cetus u/ml IL-2 (Proleukin, Chiron corporation, Emeryville, CA) and 10 
ng/ml IL-15 (‘feeder mix’). Clones were maintained on IMDM/10% NHS containing 10 ng/ml IL-15 
and 20 Cetus units/ml IL-2 and restimulated with ‘feeder mix’ when appropriate.
Flow cytometry
Fluorochrome-labelled antibodies for CD3ε, CD4, CD5, CD7, CD16, CD45, CD56, CD103, CD117, 
CD122, CD14, CD19, CD34, KIR3DL1 (DX9) and TCRγδ were from BD Biosciences (San Jose, CA, 
USA). KIR2DL2/DL3/DS2 (GL183), KIR2DL1/2DS1 (EB6), CD244, and NKp46 were from Beckman 
Coulter (Fullerton, CA, USA). TCRαβ was from Biolegend (San Diego, CA, USA). Anti-CD127, CD45 
and CD160 were from eBioscience (San Diego, CA, USA) and CD8 from Invitrogen (Bleiswijk, The 
Netherlands). Cells were incubated for 30 minutes with fluorochrome-conjugated antibodies for 
surface staining, and subsequent intracellular staining was done using the permabilisation kit from 
eBioscience. Cells were acquired on a LSRII or on a FACSAriaII (BD Biosciences) for cell sorting. 
Results were analyzed using FlowJo V10 software, and 4-GraphPad.  Unsupervised hierarchical 
clustering of flow cytometry measurements was done using the complete clustering method with 
the Euclidean distance measurement. The result was plotted in a heatmap using the heatmap.2 
function from the R gplots package.
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THE HUMAN THyMUS CONTAINS CD103+LIN-CD127- CELLS THAT 
RESEMbLE THyMIC CNK CELLS
We recently identified a Lin-CD127-  IEL population in the human intestinal epithelium with NK 
and T cell differentiation potential: [CD45+SSClowCD14-CD19-CD3-CD7+CD4-CD8-CD56-CD127-CD34-
CD103+] 2. Given the reported presence of CD103+ DN cells in the thymus 1, we  considered the 
possibility that cells with this Lin-CD127-  IEL phenotype were also present in the thymus. 
Indeed, flow cytometric analysis of human thymocytes  (Figure 1A) revealed a distinct population 
of CD103+ cells within Lin-CD127-  thymocytes (referred to as CD103+Lin-CD127- thymocytes from 
now on). Like Lin-CD127- IEL, these CD103+Lin-CD127- thymocytes lacked surface expression of 
CD4, CD8, CD34 and CD1a, and a sizeable fraction expressed intracellular CD3ε (Figure 1A).  
Using an expanded set of surface markers, we compared the phenotype of CD103+Lin-CD127- 
thymocytes to Lin-CD127- IEL and other lymphocyte subsets within the intestinal epithelium, the 
blood and the thymus.  Unsupervised hierarchical clustering analysis of the results showed that 
CD103+Lin-CD127-  thymocytes most resembled conventional thymic CD3-CD56+ NK cells (cNK, 
Figure 1B). Similar to thymic cNK cells, CD103+Lin-CD127-  thymocytes expressed NKp46, CD244 
and killer cell immunoglobulin-like receptors (KIRs). However, CD103+Lin-CD127- thymocytes were, 
by definition, CD56-. Also they less frequently expressed CD160 and CD16 and expressed lower 
levels of CD122 (IL-2/15Rβ) than thymic cNK cells. 
These experiments revealed several notable differences between CD103+Lin-CD127-  thymocytes 
and Lin-CD127- IEL. While CD103+Lin-CD127- thymocytes expressed CD160, CD122, and CD16 at 
lower levels than Lin-CD127-  IEL, they did express KIRs. Finally, CD103+Lin-CD127- thymocytes did 
not express intracellular TdT (Figure 1C), expressed during rearrangement of the TCR locus.  
In summary, the human thymus contains CD103+Lin-CD127-  cells that are similar to, but distinct 





FIGURE 1: THE PHENOTyPE OF CD103+LIN-CD127- THyMOCyTES. (A) 
Human thymocytes were stained with antibodies to CD45/CD14/CD19/CD3/CD7/CD56/CD127 
and analyzed by flow cytometry. A representative plot for the gating strategy for (1) T cells, 
(2)  innate CD3-CD7+ thymoctes including CD56+CD127- conventional NK (cNK), (3) Lineage-
negative (Lin-) CD127-,  and (4) Lin-CD127+ cells is depicted. Each plot shows the cells gated in the 
previous plot. A representative plot for the expression of CD4, CD8, CD34, CD1a, and intracellular 
(ic) CD3 by CD103+Lin-CD127- is depicted in the lower panel (thymic Lin-CD127- phenotype). 
(B) Thymocytes, duodenal intraepithelial lymphocytes (IEL) and PBL from peripheral blood 
were stained with a standard panel of antibodies against CD45/CD14/CD19/CD3/CD7/CD56/
CD127, gated as in (A) and combined with antibodies detecting CD160, Nkp46, CD122, CD16 
KIR ( a cocktail recognizing KIR2DL1/ KIR2DL2/ KIR2DL3/ KIR2DS1/ KIR2DS2/ KIR3DL1), CD244 
and analyzed by flow cytometry. A heatmap was generated from the flow cytometric data by 
unsupervised hierarchical clustering. The heatmap depicts the z score generated by the average 
percentages of cells expressing the above-mentioned markers or the average mean fluorescence 
intensity (MFI) of the marker per subset (see color key). Analyzed cell populations were: T cells; 
conventional NK (cNK); Lin-CD127+ and Lin-CD127- cells from thymocytes, IEL and PBL; CD127+NK 
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from IEL and PBL. Thymic Lin-CD127- were additionally stained for CD103 (Lin-CD127- thymus). (C) 
Thymocytes were stained, analyzed and gated as described in (A). A histogram depicts the TdT 
expression of CD103+Lin-CD127- and CD34+ thymoctes. The percentage of TdT+ positive cells is 
indicated in the histogram. The cell count is depicted on the y-axis.
IL-15-DEPENDENT DIFFERENTIATION OF CD103+LIN-CD127- 
THyMOCyTES INTO NK CELLS
Our previous results indicated that Lin-CD127- IEL contain precursors to NK and T cells (Chapter 
4). To test the ability of thymic CD103+Lin-CD127- cells to develop into NK or T cells, we made use 
of OP9DL1-based stromal developmental assays, optimized for T cell differentiation 3. Because 
thymic CD103+Lin-CD127- cells showed similarities to NK cells, including the expression of CD122 
(IL-2/15Rβ), we first tested the effect of IL-15, a critical factor in  NK cell differentiation 4-6. 
In the absence of IL-15, FACS-sorted thymic CD103+Lin-CD127-  cells cultured on OP9DL1 in the 
presence of SCF, IL-7 and Flt3L did not expand within two weeks (Figure 2A). In the presence 
of IL-15 however, cultures starting from 100 and 1000 thymic CD103+Lin-CD127-  cells yielded 
thousands of CD45+ cells within the same time frame. Under these conditions, thymic CD103+Lin-
CD127- yielded comparable numbers of CD45+ cells as thymic CD34+CD1a- cells, the earliest T/NK 
cell progenitors in the human thymus 6 (Figure 2A). 
Upon co-culture with OP9DL1 in the presence of IL-15, CD103+Lin-CD127-  thymocytes developed 
into CD3-CD56+ cNK cells (Figure 2B). In line with this, many of these NK cells expressed 
intermediate or high levels of CD8α. In contrast, under identical culture conditions CD34+CD1a- 
thymocytes yielded a mixture of Lin-, NK and T cells (Figure 2B and data not shown). Lin- cells 
derived from CD34+CD1a- thymocytes had often acquired CD4 and occasionally CD8α (Figure 2B), 
suggesting that they had differentiated into CD4+ ISP. 
Thus, under conditions that allowed differentiation into the NK as well as the T cell lineage, 




FIGURE 2. CD103+LIN-CD127- THyMOCyTES ARE IL-15-DEPENDENT AND 
DEvELOP INTO NK CELLS ON OP9DL1. (A) Human thymocytes were stained with 
antibodies to CD45, CD14, CD19, CD3, CD7, CD56, CD127, CD103, CD4, CD8, CD34, CD1a and 
analyzed by flow cytometry. CD34-CD103+Lin-CD127- (CD4-CD8-) and CD34+CD1a- thymoctes 
were sorted at 100 cells/well or 1000 cells/well on OP9DL1. Sorted cells were co-cultured with 
FLT3L, SCF, IL-7 with or without IL-15 (-IL-15), harvested and analyzed by flow cytometry. The 
graph depicts the amount of CD45+ (# of CD45+) after 1 and 2 weeks of OP9DL1 co-culture with 
IL-15 (+IL-15) or without IL-15 (-IL-15). (B) A representative FACS plot depicting the phenotype of 
CD103+Lin-CD127- and CD34+CD1a- cells, obtained after a one week culture of 1000 FACS-sorted 
cells on OP9DL1 in the presence of FLT3L, SCF, IL-7 and IL-15 after 1 week of co-culture. Gates 
were set on CD45+ cells. The phenotype of CD3-CD7+ cells is shown in the right panel with respect 
to CD56, CD127,CD4, CD8, CD103 and CD34 expression.
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THyMIC CD103+LIN-CD127- CELLS CONTAIN bIPOTENTIAL NK/T CELL 
PRECURSORS 
In an effort to obtain thymic CD103+Lin-CD127- clones, we cultured single CD103+Lin-CD127- 
thymocytes with irradiated mixed allogeneic feeder cells, phytohemaglutinin (PHA), IL-2 and IL-15. 
After expansion, most of these cultures contained a mixture of cells that had retained the CD3-
CD56- phenotype, CD3-CD56+ NK cells and CD3+CD56- T cells (Figure 3A). A minority of cultures 
contained CD3-CD56- and CD3-CD56+ cells or CD3-CD56+ cells only (Figure 3C). While a fraction 
of CD3-CD56+ NK cells, like peripheral blood NK cells, expressed  CD8α, the CD3+ T cells arising 
from single CD103+Lin-CD127- thymocytes had not fully differentiated (Figure 3B). Most T cells 
expressed neither CD4 nor CD8, and only a small minority expressed CD4. 
What’s more, approximately half expressed the TCRαβ, but the other half of the CD3+ cells was 
TCR-negative. This suggested that these CD3+TCR- cells expressed a pre-TCRα/TCRβ complex. 
As single CD103+Lin-CD127- thymocytes yielded mixed cultures of Lin- cells, NK cells and immature 
and mature T cells, these results formally demonstrated that CD103+Lin-CD127-  thymocytes 




FIGURE 3. CD103+LIN-CD127- THyMOCyTES HARbOR bI-POTENTIAL 
NK/T CELL PRECURSORS. Human thymocytes were stained and analyzed as described 
in Fig.1A and CD34-CD103+Lin-CD127- (CD4-CD8-) thymocytes were sorted at 1 cell/well on mixed 
irradiated allogeneic PBMC and cultured in the presence of 10 ng/ml IL-15 and 20 U/ml IL-2. After 
3-4 weeks, the resulting cultures were analyzed by flow cytometry. Gates were set on CD45+ cells. 
(A) The graph depicts the FACS sort gate used to isolate CD103+Lin-CD127- thymocytes (sort) and 
the expression of CD3 and CD56 on one of the cultures resulting from the expansion of a single 
CD103+Lin-CD127- thymocyte (after culture). (B) Analysis of the expression of CD4, CD8, TCRαβ 
and TCRγδ  by the CD3-CD56- (Lin-), CD3-CD56+ (NK) and CD3+CD56- (T) cells present in the culture 
depicted in Figure 3A. (C) Overview over the percentages of CD3-CD56- (Lin-), CD3-CD56+ (NK) 





This study shows that human CD103+Lin-CD127- thymocytes resemble thymic NK cells and contain 
bipotential NK/T cell precursors. This finding is surprising for several reasons. 
First, CD103+Lin-CD127-  thymocytes did not express CD34, expressed on developing lymphocytes 
with the potential to develop into NK as well as T cells. Although CD3-CD4-CD8-CD34bright 
thymocytes are capable of differentiating into NK and T cells, CD3-CD4-CD8-CD34dim thymocytes 
have already lost the ability to differentiate into T cells 6. Second, using a single-cell culture 
protocol similar to ours, a previous study identified CD3-CD4-CD8-CD56-CD5-CD34- thymocytes, 
encompassing  CD103+Lin-CD127-  cells, as committed NK cell precursors without T cell potential 7. 
Third, KIR expression frequencies on CD103+Lin-CD127-  thymocytes were comparable to those on 
thymic conventional NK cells (cNK). Since acquisition of KIR is a late event in NK cell differentiation 
8, it is likely that a subset of CD103+Lin-CD127-  thymocytes was already committed to the NK cell 
lineage. Finally, although T cell differentiation is usually notch-dependent 6, 7, 9, 10, in the case of 
CD103+Lin-CD127- cells T cell development did not require notch-signaling, as it occurred using 
irradiated PBMC, but not in the presence of OP9 cells expressing the notch-ligand DL1. 
In conclusion, our results indicate that CD103+Lin-CD127-  thymocytes are an unconventional 
thymocyte subset that contains – most likely KIR-negative - cells with the ability to differentiate 
into NK cells and into T cells in a notch-independent fashion.
Given the above, it is challenging to place the CD103+Lin-CD127-  thymocytes in previously 
described NK and T cell developmental pathways. An unusual feature of these cells is the fact that 
many express intracellular (ic) CD3ε. As icCD3ε can be induced by notch-signaling 11 the presence 
of icCD3ε may reflect ongoing notch-signaling in the thymic environment or represent a relic 
of previous T cell lineage differentiation events 12. As notch-signaling was not required for T cell 
development of CD103+Lin-CD127-  thymocytes, these cells most likely had already undergone 
TCR rearrangement prior to expansion. This would place these cells somewhere between the 
CD34+ DN3 and CD34- DN4 stage of thymic T cell differentiation, when the cells are going through 
the final steps of the TCR rearrangement process. However, in that case one would have to 
postulate that CD103+DN3/DN4, unlike regular DN3/DN4 cells, still have the capacity to develop 
into NK cells. This is not inconceivable, as thymic NK cells express icCD3ε 13, 14 and TCR transcripts 
15, suggesting that they can derive from later stages of T cell development. 




In conclusion, our studies identified a novel thymocyte population that does not easily fit in the 
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WHAT IS ALREADy KNOWN AbOUT RCD AND CD3- IEL?
In recent years, the pathological mechanisms leading to small intestinal damage in CD have been 
elucidated, in particular the nature of the pro-inflammatory gluten-specific T cell response in the 
lamina propria (LP) and the receptor-ligand interactions leading to cytotoxicity of intraepithelial 
lymphocytes (IEL) towards enterocytes in the epithelium. However, refractory celiac disease 
(RCD), where gluten removal does not lead to remission of celiac symptoms, is incompletely 
understood. Aberrant IEL, which massively expand in the epithelium of RCDII patients, have been 
demonstrated to participate actively in cytotoxicity towards the epithelium 1, 2 and IL-15 has 
been shown to be a major factor that drives the expansion of such cells 3. It is currently unknown 
whether IL-15 is solely responsible for the outgrowth of these cells in RCDII. Moreover, the origin 
of aberrant IEL has also remained elusive, but it was suggested that they could originate from CD3- 
IEL 4. Several studies focusing on CD3- IEL have indicated that this population is heterogeneous 
and contains functional NK cells 5, ILC1 6, as well as IEL with unknown functions, which express 
numerous NK cell receptors 5, 7-9. While it is clear that T cell development predominantly takes 
place in the thymus 10, evidence for T cell differentiation in the intestine has been presented 11, 12. 
Such extrathymic, intestinal T cell development, however, is subject of a long standing debate and 
intestinal NK cell development has only been described to occur in the lamina propria 13. 
WHAT IS ALREADy KNOWN?
• IL-15 induces the expansion and survival (anti-apoptotic effects) of aberrant IEL;
• Aberrant IEL were postulated to be either derived from mature T-IEL or from an ill-  
  defined CD3- IEL population;
• CD3- IEL are heterogeneous, express a variety of NK cell receptors and consist of    
 functional NK cells and ILC1;
• CD3- IEL harbor T cell precursors, the phenotype and developmental requirements of    
 which have not been elucidated;





HOW DID OUR STUDIES CHANGE THE CURRENT UNDERSTANDING OF 
RCD AND IEL?
DC-INDUCED ExPANSION OF AbERRANT IEL LINES FROM RCDII 
PATIENTS 
In Chapter 2 we outline our studies on the effect of blood-borne cell types on aberrant IEL lines 
from RCDII patients, which demonstrated that dendritic cells (DC), prominent cell types of the 
intestinal innate immune system, could induce proliferation and had anti-apoptotic effects.  As 
in recent years it has been demonstrated that IL-15 can induce proliferation 3, 14 and has anti-
apoptotic effects on aberrant IEL 15, our results thus indicate that multiple factors can contribute 
to the expansion of aberrant IEL in RCD. 
In active CD lesions, increased numbers of macrophages and DC have been demonstrated, which 
is likely the result of the ongoing inflammation 16. Until now no studies for RCD patients have 
been conducted, but it is likely that due to the severe intestinal inflammation in these patients 
increased numbers of cells of the monocytic lineage can also be expected. Hence, increased 
frequencies of monocytic cells, such as DC, could contribute to the expansion and subsequent 
dissemination of aberrant IEL into the underlying LP, the site where most DC reside. 
As our studies made use of cell lines derived from RCDII patients, we can only hypothesize that 
such proliferative effects indeed happen in situ. It remains to be investigated to what extent DC 
can contribute to the expansion of aberrant IEL, why aberrant IEL are particularly sensitive to 
DC-induced proliferation and if all DC subsets are equally stimulatory for aberrant IEL. Moreover, 
the sensitivity towards DC-induced proliferation could reflect the stage of malignancy, as not all 
aberrant IEL lines were equally responsive to stimulation with DCs. Nevertheless, regular T-IEL 
lines showed no proliferative effect in DC co-cultures. It therefore needs to be investigated, if the 
response to DC correlates with malignant transformation, or the localization of aberrant IEL in 





PLASTICITy OF THE INNATE IEL COMPARTMENT: AbERRANT IEL LIKELy 
ORIGINATE FROM LIN-CD127- IEL
The appearance and expansion of aberrant IEL is a characteristic feature which distinguishes RCDI 
from RCDII. RCD is a severe complication of CD and possibly due to long-term gluten exposure in 
patients that are not properly diagnosed with CD 17. Evidence for an involvement of the gluten-
specific T cell response in the development of RCD is the fact that these patients are often 
HLA-DQ2 homozygous 18 which leads to stronger gluten-specific T cell responses 19. Aberrant IEL 
in RCDII patients are considered pre-malignant, as these cells show the same phenotype and 
monoclonal TCR rearrangements as the malignant cells detected in the enteropathy-associated 
T cell lymphoma (EATL) 20. In order to understand the mechanisms driving the expansion and 
malignant transformation of these aberrant IEL, knowledge on their origin is essential. It has been 
hypothesized that aberrant IEL either originate from mature T cells 21 or from a physiological CD3- 
population 4.  
In Chapter 3 we present evidence that aberrant IEL in RCDII can be characterized as Lineage-
negative (Lin-) CD127-IEL (Lin-CD127- IEL), that these cells were indeed present in non-RCDII 
individuals and that Lin-CD127- IEL shared important features with their aberrant IEL counterparts. 
Though the use of multicolor flow cytometry and the explicit phenotypical characterization 
of aberrant IEL as Lin-CD127- IEL, it now became feasible to refine the common phenotype of 
aberrant IEL described by several groups 3,14,15, 20-25 and to investigate its physiological counterpart 
in depth.
 
First described in EATL patients by Spencer et al. 4, the CD3- IEL population has been further 
investigated (as CD3-CD7+) in the following years. Since this IEL population lacks receptors for 
adaptive lymphocytes, such as CD3/TCR (or B cell markers) we termed this population “innate 
IEL”. Previous studies have analyzed the expression of various NK and T cell markers, as well as 
adhesion molecules and markers of early progenitor cells on this innate IEL population (Table 
1). Whereas the majority of innate IEL expressed the IL-2/15Rβ (CD122) 7, 8, the markers CD56 7, 
8, CD16 7-9 and CD94 7, 8 were only expressed by some innate IEL.  Killer-cell immunoglobulin-like 
receptor (KIR) expression was not detected 7, 8 and innate IEL did not stain for the T cell marker 
CD5 7, 9, but were partially icCD3ε+ 5. Our studies validated and further defined the expression 
pattern of these markers on innate IEL subsets. As suggested by previous studies, innate IEL 
reflected a phenotype reminiscent of immature lymphocytes, therefore early progenitor 
markers such as TdT, CD34 and c-kit (CD117) were tested, but not detected 5.  In line with the 




expression was detected on a subset of Lin-CD127+ IEL (Chapter 4). Together these studies clearly 
demonstrated that the innate IEL population is heterogeneous and harbors functional NK cells 
5, but also harbors other (immature) cell types. In fact, on the basis of the expression or absence 
of the NK cell receptor CD56 and the IL-7R (CD127), we were able to define four subpopulations 
within CD3-CD7+ innate IEL. These include 1.) conventional NK cells (cNK) or ILC1 (CD56+CD127-) 
-in this thesis referred to as cNK-, 2.) CD127+ NK (CD56+CD127+), 3.) Lin-CD127- (CD56-CD127-) 
and 4.) Lin-CD127+ (CD56-CD127+) IEL (Figure 1). Our results further support the finding that T-IEL 
expressed a distinct phenotype as that of innate IEL (Table 1, Chapter 4). 
Moreover, our studies revealed that Lin-CD127- IEL were present in high frequencies in young 
children without CD, while in CD patients the frequencies of these cells were significantly 
decreased in comparison to non-CD controls, supporting previous findings which demonstrated 
that in CD the innate IEL population is reduced in comparison to controls 4, 5, 7, 8, 26, 27. In contrast, 
we observed that in RCDII patients Lin-CD127- IEL and Lin-CD127+ IEL are massively increased 
(Chapter 4). In Chapter 4 we conclude that both disease and age influence the composition of the 
distinct innate IEL subsets (Figure 1). Our results therefore extend early findings by MacDonald et 
al., in which the authors noted a steady increase in T-IEL and changes in CD3- IEL with age 11, 12, 28, 29.
As Lin-CD127- IEL lacked lineage markers (CD14/CD19/CD3/CD56/CD34) and the IL-7R (CD127), 
Lin-CD127- IEL were neither of monocyte, B, T or NK cell lineage, nor innate lymphoid cells type 
2 or 3 (ILC2, ILC3), as these ILC are defined as Lin-CD127+. ILC are innate-like lymphoid cells that 
have attracted great attention in the last years. Even though these cells compose minor cell 
populations at mucosal sites, they are notably important in the immune response to bacteria and 
viruses, as well as for tissue remodeling 30, 31. Intestinal ILC were mainly described to reside in the 
LP. We postulated that Lin-CD127- IEL were distinct from their ILC counterparts, due to the lack of 
CD127 expression (LP- ILC1/ILC2/ILC3 are CD127+) and the absence of CD56 expression, which is 
expressed by intraepithelial ILC1 6 (Table 2). In fact, as intraepithelial ILC1 show large phenotypic 
overlap with cNK -described in our studies- these cell types could be identical. So far ILC1 were 
the only ILC population described to reside in the epithelium 6. How Lin-CD127- IEL and the 
additional innate IEL subsets described here are positioned in relation to the newly described ILC 
family requires further investigation. For this detailed studies defining the expression of cytokine 
receptors and cytokine production, along with an analysis of transcription factors will be crucial 30, 
31 (Figure 2, Table 2).  
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FIGURE 1. HETEROGENEITy OF THE IEL COMPARTMENT. Intraepithelial 
lymphocytes (IEL) are composed of CD3+ T cells (T-IEL) and a diverse innate IEL population (CD3- 
IEL), which includes conventional NK cells (cNK), CD127+ NK cells, Lineage-negative (Lin-) CD127- 
and Lin-CD127+ IEL. The composition changes rigorously during celiac disease and refractory 
celiac disease type II. The pie chart below indicates the mean % of the IEL subsets from all CD45+ 
lymphocytes; the colors of the chart correspond to the colors used to discriminate the different 





FIGURE 2. INNATE LyMPHOID CELLS AND LIN-CD127-IEL: A COMPARISON. 
This figure is adapted from Sonnenberg et al. 31 and describes the main findings for ILC subsets, 
their localization in the intestine and the important cytokines for ILC physiology. Note that ILC1 were 
the only ILC subset described to reside in the epithelium so far 6. Their phenotype is elucidated on 
the right hand site of the graph in comparison to our findings on Lin-CD127-IEL, which are depicted 
as the white cell in this cartoon (Lin-). Due to the functional and phenotypical overlap of cNK (as 
described in this thesis) and ILC1, described by Fuchs et al. 6, these cell types could be identical and 
are therefore depicted together.
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Multicolor flow cytometry allows simultaneous analysis of multiple markers on small subsets 
of cells in suspension. However, this approach has the drawback  that only a limited number 
of markers can be simultaneously analyzed. The choice of markers to be analyzed therefore 
can influence the type of relationship which is revealed by hierarchical clustering (Chapter 4). 
Furthermore, cells might up- or downregulate certain markers, depending on stimuli in situ or 
in vitro. This could be the case for cytokine receptors such as CD122, IL-15Rα or CD127 or for 
NK cell receptors such as CD56. In fact, some Lin-CD127- IEL lines, which were generated from 
4 RCDII patients (P1-P4) (described in Chapter 3), showed intermittent plasticity during cell 
culture. The cell line P4, for example,  temporarily up- or down-regulated CD127 expression. 
It was also notable that cell line P3 was infrequently tested positive for CD56 while negative 
at other moments. Upon repeated sorting of CD127- or CD56- cells from these cell lines, the 
marker-negative sorted cells showed the same functional characteristics as their marker-positive 
counterparts and reacquired CD127 or CD56 expression in culture (data not shown). Hence, 
some plasticity was observed in long term culture for these two cell lines, while the other two 
cell lines showed a stable Lin-CD127- IEL phenotype. In light of this, one has to be careful to ex 
vivo distinguish independent cell subsets, as in situ cells might in fact change their phenotype 
depending on the local milieu. The studies described in Chapter 3 and 4, which provided 
evidence that Lin-CD127- IEL represent aberrant IEL -as their overlapping phenotype and IL-15 
responsiveness suggests- therefore need to be interpreted carefully. More work is needed in 
order to precisely define the capacity to up- or down-regulate certain receptors for innate IEL 
subsets, hence the kinship of distinct innate IEL subsets needs to be investigated. 
Deep profiling of the IEL subsets, described in this thesis, from different patient cohorts and 
tissues through microarray or RNA sequencing would result in an improved and unbiased 
comparison of these cell subsets. This could generate a broad knowledge of their phenotypical 
and possible functional relationship. Of particular interest would be the expression of 
transcription factors, cytokines and cytokine receptors under steady-state (directly isolated ex 
vivo) and after incubation with certain cytokines, relevant for CD disease etiology (IL-15 or IL-21).
In conclusion, our studies have refined and further characterized the heterogeneous innate IEL 
population. By investigating the phenotype of four different innate IEL subpopulations, we could 
extrapolate the similarities and dissimilarities of the IEL subsets (Chapter 4). Furthermore, our 
studies clearly demonstrated that the innate IEL population is diverse and harbors a Lin-CD127- IEL 
population from which aberrant IEL could originate (Chapter 3). The IEL compartment therefore 
has to be considered a diverse, complex lymphocyte compartment with various subsets -each 




marker CD3+ CD3- REF
CD8 85,0% 89,0% +/- 10,0% CD8aa 10,0% 1,2,3,5
CD5 100% gd:CD5- - - 1,2
CD2 96,9% 72,0% 55,1% 25,2% 55,0% 1,2,3,4
CD69 97,0% 97,0% 97,0% + 97,0% 1,3,5
CD38 91,0% 98,0% + 1,3
CD122 9,2% 91,5% 92,0% 1,3
CD56 25,0% 44,7% 44% 1,3
CD16 4,3% 0,5% 12,6% - 12,0% 1,2,3
CD94 31,3% 30,0% 16,2% 24,0% 1,3
CD28 25,5% 25,0% 0,5% - 1,5
CTLA-4 5,0% - 5
CD25 3,6% - - 1,3
HLA-II high 39,0% low 2,0% 1,5
CD71 - - - - - 1,3,5
KIR3DL1 - - 1
KIR2DL1 - - 3
CD44 + + 95,0% - - - 1,3,5
CD161 70,0% 98,0% 3
Perforin 5,0% 5,0% 75,0% 75,0% 3,5
CD94L 6,0% 5,0% 5
CD94 + 97,0% + 95,0% 3,5
CD18 43,7% 0,0% 3
ICAM-I 33,2% 34,0% 85,6% 86,0% 3,5
VLA-4 33,1% 41,1% 3
VCAM-I 14,6% - 3
CD1 14,5% 5,0% 26,0% <1% 4,5
icCD3ε 100,0% 10-25% 5
CD117 2,0% - 5
CD10 3,0% - 5
TdT - - 5
CD34 - - 5
CD80 - - 5
CD86 4,0% 10,0% 5
CD31 57,0% - 5
TNFR1 5,0% <1% 5
TNFR2 61,0% 31,0% 5
CD30 - - 5
CD70 - - 5
TAbLE 1. THE PHENOTyPE OF CD3+ AND CD3- IEL References (REF): 1 Eiras et 
al. Cytometry 1998 7 2 Jarry et al. Eur J Immunol 1990 9 3 Eiras et al. Scand J Immunol 2000 8 4 
Lundqvist et al. Int Immunol 1995 32 5 Leon et al. Gastroenterology 2003 5
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named ILC1 ILC3 ILC1 ILC3 Lin-CD127- Lin-CD127+ cNK CD127+NK
REF 1 2 thesis
CD4 ND ND - - - - - -
CD25 ND ND low low - - - -
CD56 + + - +/- - - + +
CD117 ND ND - + - + - -
CD127 - + + + - + - +
Nkp44 + + - + + + + +
Nkp46 + + - +/- +/- +/- + +
CCR6 - + + ND ND ND ND ND
CD16 ND ND - ND - +/- (+/-) +/-
CD94 + - - - - - (+/-) (+/-)
Granz. B + +/- - - +/- +/- +/- +/-
CD160 + - ND ND + + + +
CD122 + - ND ND + - + -
Tbet + - +/- - ND ND ND ND
RORγt - + - ND ND ND ND ND
CD244 + - ND ND +/- +/- +/- +/-
CD103 + + + + +
site IEL LP LP LP IEL IEL IEL IEL
disease CrD↑ CrD↑ CD↓ CD↓ CD↓ CD↓
TAbLE 2. LIN-CD127-IEL IN COMPARISON WITH ILC1 AND ILC3 SUbSETS. 
References (REF): 1 Fuchs et al. 2013 6 2 Bernink et al. 2013 33, CrD- Crohn’s disease, CD- Celiac 
Disease
DEvELOPMENT OF LIN-CD127- IEL IN THE INTESTINE AND THE THyMUS
As Lin-CD127- IEL resembled immature cells, we hypothesized that these cells could represent 
NK and/or T-IEL precursors. In Chapter 4 we present evidence that Lin-CD127- IEL from celiacs 
and non-celiacs can indeed differentiate into cNK and T-cells, while Lin-CD127- IEL derived from 
RCDII patients did not. In Chapter 5 we investigate the developmental potential of the thymic 
counterparts of Lin-CD127- IEL, and observed that these harbor bipotential T/NK cell precursors.  
 
Human NK cells are thought to develop mainly in the bone marrow, and  NK cell development in 
secondary lymphoid tissue has so far been described for lymph nodes 34, tonsils 35, the liver 36, the 
uterus 37, the thymus 10 and the LP of the intestine 13. Our studies demonstrated that Lin-CD127- 
IEL primarily developed into cNK cells in vitro, which is the first evidence that NK cell precursors 
can reside in the epithelium of the small intestine (Chapter 4).     
 
T cells primarily develop in the thymus from immature CD34+ progenitor cells which egress the 
bone marrow and seed the thymus for maturation into TCRαβ or TCRγδ T cells. Human T and NK 
cells share a common progenitor, which in the thymus still expresses CD34 10. During maturation 
cells loose CD34 expression and develop either into NK or T cells. Nevertheless, our studies 
(Chapter 5) show that single thymic CD103+Lin-CD127- cells, which lack CD34, could still give rise 
to NK and T cells and are therefore bipotential precursor cells. The intestinal counterpart on the 




It remains to be investigated whether thymic CD103+Lin-CD127-  cells could indeed egress from 
the thymus and home to the intestine, as suspected by the expression of the epithelial homing 
marker CD103 38, 39. Recent thymic emigrants have been reported to express CD103 40 which 
indicates that thymic CD103+Lin-CD127-  cells could indeed exit the thymus. Nevertheless, CD103 
expression could also reflect their thymic intraepithelial localization, similar to intraepithelial 
lymphocytes in the intestine 41.  
Studies with humanized mice and/or athymic mice could elucidate if intestinal Lin-CD127- IEL 
are indeed derived from the thymus. Vital cell labeling such as with BrdU and injection of thymic 
Lin-CD127- IEL into humanized mice could demonstrate if these thymic cells indeed home to the 
intestine and can give rise to T and NK cells in situ.
Whether T cell development indeed can take place in the intestine is the subject of long standing 
debate. In mice, evidence both in favor and against intestinal T cell development has been 
provided. In studies with RAG2 transgenic mice, where fluorescence indicates recent and past 
RAG transcripts, no RAG2-expressing lymphocytes were found in the intestine 42. Nevertheless, 
while athymic mice have severely reduced numbers of T cell in the intestine, residual T cells 
are still present 43, 44. Hence, intestinal T cell development cannot be excluded, but is thought 
to have a minor contribution to the T cell pool in mice 45.  Studies on human intestinal T cell 
development are scarce and no direct evidence for in situ T cell development has been presented. 
MacDonald and colleagues were the first to demonstrate that CD3- T cell precursors reside in the 
human intestine and they provided evidence that these cells might be precursors for T cells 11,12. 
Moreover, studies have indicated that CD3- cells can rearrange TCR genes 11, 46, express pre-Tα  47 
or enzymes which are essential for TCR rearrangements, such as recombination activating gene 
1 (RAG-1) 32, 46, 47, as well as terminal deoxynucleotidyl transferase (TdT) 48 (Table 3). In contrast, 
other authors claim that TdT is virtually undetectable 49. Due to the small numbers of cells that 
can be isolated from intestinal biopsies, we were not able to detect RAG transcripts Lin- IEL and in 




These data demonstrate conflicting evidence concerning RAG and TdT expression in the human 
small intestine. This evident discrepancy could be explained by the detection limit of the 
technique applied, as the frequency of the CD3- population varies, depending on the age and 
disease condition of the individual (Chapter 4). A significant reduction of innate IEL in CD could 
explain why less RAG expression was found in CD patients compared to controls 47. Besides this, 
most studies have analyzed complete biopsy material, the entire IEL/LP, or CD3- population 
(Table 3). Thus, as it is likely that only a small subset of cells expresses RAG and/or TdT and that 
this expression is also tightly regulated in the intestine, the detection is problematic. The use of 
sensitive techniques to analyze RAG and TdT expression and TCR rearrangements in single or a 
few cells is therefore needed to confirm our findings for Lin-CD127- IEL and thymic CD103+Lin-
CD127- cells. 
  
Strikingly, while Lin-CD127- IEL numbers were reduced in CD patients, the frequency of  icCD3-
expression within Lin-CD127- IEL was strongly increased and this may relate to the elevated levels 
of T-IEL in patients with CD. Moreover, this is in accordance with the elevated T-IEL frequencies 
generated in culture from Lin-CD127- IEL from CD patients. In contrast, differentiation of Lin-
CD127- IEL into T or NK cells was impaired in patients with RCDII, likely due to the pre-malignant 
state of the Lin-CD127- IEL (Chapter 4).       
Thus, our results indicate that IEL maturation can take place in the intestine and that local clues, 
such as inflammation, can alter the differentiation and expansion potential of innate IEL subsets. 
Depending on the triggers in situ the IEL compartment could therefore swiftly adapt to the 
environmental needs. Selective expansion has already been described for human ILC subsets, 
Author Type compartment Intestine donor
RAG1+ Lundqvist 1995 CD3- IEL Small adults
Bas 2003 CD3- IEL/LP small adults
Bas 2009 CD3- IEL small children
Williams 2004 biopsy all small children 1-2yrs
PreTα+ Howie 1998 cells IEL/LP fetal fetus
Bas 2003 cells IEL/LP small adults
Bas 2009 CD3- IEL small children
TCR 
rearrangement+
Howie 1998 cells IEL fetal fetus
Williams 2004 cells IEL/LP small children 1-2yrs
Gunther 2005 CD3- LP fetal fetus
TdT+ Williams 2004 biopsy all small children 1-2yrs
TdT- Taplin 1996 cells IEL small adults
TAbLE 3. EvIDENCE FOR HUMAN INTESTINAL T CELL DEvELOPMENT. 
References: Lundqvist et al. 1995 32, Bas et al. 2003 46, Bas et al. 2009 47, Howie et al. 1998 12, 




which under inflammatory conditions were found in higher frequencies in the intestinal LP or 
epithelium 6, 33, 50, 51. In fact, IL-15, but also other common γ chain cytokines such as IL-21 or IL-7 
could influence IEL plasticity.
T-cell differentiation from Lin-CD127- IEL was augmented by the expression of the notch-ligand 
DLL1, which is present in the small intestine 52. The role of notch signaling has been extensively 
described for T cell development in the thymus 53 and for intestinal stem cell differentiation 54. 
Thus it is likely that notch-ligands, such as DLL1 could also influence the lineage decisions of 
immature IEL precursor cells in situ. Depending on the localization of DLL1 and the IEL precursor 
cells, the strength of the signal and the interplay of other confounding factors (such as common γ 
chain cytokines) could influence IEL maturation, an issue that deserves further attention. In fact, 
DeSmedt and colleagues have demonstrated that notch-signaling can induce icCD3 expression 
in developing NK cells 55. As higher frequencies of icCD3+ cells are found in CD patients and even 
further elevation is seen in RCDII patients, intestinal notch-signaling could thus play a role in the 
induction of CD3 expression in CD and RCD. It is not known whether icCD3+ and icCD3- innate 
IEL subsets possess distinct functions or represent different cell types. In fact, the functional role 
of intracellular CD3 expression in innate IEL is obscure. In humans, icCD3+ NK cells are present 
in the fetal liver 56 and we could also detect them in the fetal intestine (data not shown), but 
they form only a minor population in blood. It has been suggested that icCD3 expression could 
be a remnant of organ-specific ligand-receptor interactions, such as notch signaling 57. Also, it 
has been proposed that in the intestine icCD3 expression might ensure survival or initiate TCR 
rearrangements, possibly even independently from the pre-TCR 58. Hence, it can be hypothesized 
that icCD3 expression could discriminate between distinct developmental stages in innate IEL. If 
icCD3 expression is an indication of maturation towards the T cell lineage, icCD3+ could indeed be 
pre-T-IEL while  icCD3- IEL could be immature or pre-NK cells (Figure 3).    
Due to technical restraints, we could not investigate this hypothesis. One possibility to study 
progeny-descendant cell relationships is the use of barcoding. Such experiments have been 
designed to tag individual cells with unique barcodes that pass on their specific barcode to 
their progeny, thus allowing tracing of cell differentiation at a single cell level 59, 60. Alternatively, 
studies in mice would allow cell manipulations and fate mapping experiments. Such fate mapping 
techniques could be designed to trace CD3 expression in the precursor as well as the progeny 
(icCD3+ non-T) cells due to the stable expression of fluorescencent proteins. These experiments 




FIGURE 3. HyPOTHESIS OF THE DIFFERENTIATION OF LIN-CD127- 
IEL INTO NK AND T CELLS bASED ON OUR STUDIES. Lin-CD127- IEL can 
differentiate into NK cells or TCRαβ or TCRγδ T-IEL. Based on our findings that icCD3 expression 
is higher in Lin-CD127-  IEL in celiac disease (CD) patients than non-CD controls and T cell 
differentiation from Lin-CD127-  IEL was found to be elevated, we assume that the icCD3+ cells 
constitute pre-T cells and the icCD3- cells pre-NK cells. No further T or NK cell differentiation 
was detected from Lin-CD127- IEL in RCDII patients. This suggests that in RCDII -through as yet 




Further evidence from mouse models suggested that overexpression of CD3ε in immature 
thymocytes by itself could act as an proto-oncogene, resulting in a developmental block in T cell 
differentiation 61 and lymphoma development 62 . While the exact mechanism how CD3ε can act 
as an oncogene is unclear, it is striking that in aberrant IEL of RCDII patients extraordinary high 
levels of icCD3 expression are found, well above the level present in conventional T cells. In this 
respect it is important to note that disturbed notch-signaling is involved in more than half of all 
T-ALL lymphoma subsets 63. Thus it is possible that disrupted notch-signaling could also play a 
role in the upregulation of icCD3 chains, expansion and transformation of aberrant IEL in RCDII 
patients. 
 
Our studies on primary intestinal cells pointed out technological limitations. The cell amounts 
which can be isolated from biopsies or the thymus are small, and sorting by flow cytometry 
yields the danger of impurity of the sorted cells. Therefore we have addressed the issue of cell 
contamination in various experiments (Chapter 4) and concluded that the chance of mature 
T cell contamination was negligible, while the chance of NK cell contamination was very low. 
Nevertheless, we could not exclude contamination completely, as flow cytometric sorting is 
not 100% pure, and purity could vary between each analysis. In conclusion, flow cytometry has 
proven to be a sensitive method to analyze rare subsets of cells and isolate these for further in 
vitro assays. Nevertheless, barcoding experiments or studies in mouse models are essential to 
investigate the underlying mechanisms and to confirm our data on human primary cells.  
The in vitro studies described in Chapter 4 on the developmental potential of Lin-CD127- IEL 
were performed with the mouse stromal cell lines OP9 and OP9DL1, as a convenient tool for the 
generation of T cells from precursor cells 64. Despite the presence of essential components for T 
cell differentiation, this cell culture system has some drawbacks. First, no equivalent human cell 
line exists and no positive/negative selection takes place in OP9/DL1 stromal cultures, as these 
cultures lack the complexity of thymic stromal niches. As OP9DL1 only expresses HLA-I, only CD8+ 
cells can be generated 64, in line with our observation that the T-cells generated from Lin-CD127-
IEL consistently expressed CD8 (Chapter 4). Furthermore, we did not detect any intermediate 
stages of T cell development (such as double-positive T cells) when culturing Lin-CD127- IEL on 
OP9DL1. This could be due to the relatively long time span of 2 weeks before analysis. Hence, at 
the time of analysis T cell maturation could have already been completed. Due to the low growth 




In summary, we provided evidence that Lin-CD127- IEL, the putative precursor population for 
aberrant IEL in RCDII patients, can generate NK and mature TCRαβ and TCRγδ T-IEL (in the 
presence of IL-15 ), whereas T-cell generation was augmented by notch-signaling. This maturation 
was influenced by disease state, as T-IEL differentiation frequencies were higher in CD patients 
and no further development was observed in cells from RCDII patients. This could imply a 
developmental block in Lin-CD127- IEL in RCDII, reflecting the pre-malignant nature of these cells. 
Which triggers influence the (block of) differentiation, expansion and transformation of these 




WHAT ARE THE NEW FINDINGS?
In this thesis we investigated if, next to IL-15, other factors contribute to the expansion of aberrant 
IEL in RCDII, by exploring the effects that potential intestinal bystander cells could have on 
aberrant IEL lines. Furthermore, we investigated the origin of aberrant IEL. In order to do so, we 
defined distinct subsets of the CD3-IEL population and investigated their phenotype, plasticity and 
the developmental capacity of cells from the intestine and the thymus. The main findings are:
• Dendritic cells induced expansion and anti-apoptotic effects in 
 RCDII cell lines (Chapter 2);
• Aberrant IEL are likely derived from a subset of innate CD3-IEL, characterized as 
  Lineage-negative (Lin-) CD127- IEL (Chapter 3);
• The innate IEL population was heterogeneous, contained four subsets, which could   
 be distinguished on the basis of CD127 and CD56 expression (Chapter 3); each with a   
 distinct cytokine receptor profile: CD127- IEL expressed IL-15Rβ, CD127+ IEL the IL-15Rα  
 and IL-21R  (Chapter 4) ;
• Lin-CD127- IEL were dependent on IL-15: they expressed IL-15Rβ, responded to IL-15 by  
 proliferation (Chapter 3) and required IL-15 for outgrowth and development 
 (Chapter  4); 
• The innate IEL populations demonstrated plasticity, which was shaped by age, and   
 disease state, both in celiac and refractory celiac disease (Chapter 4);
• Lin-CD127- IEL harbored NK and notch-dependent T cell precursors: cells isolated from  
 non-CD controls mainly generated NK cells, while higher frequencies of T cells   
 were detected in cultures of CD patients. In contrast, Lin-CD127- IEL from RCDII patients  
 had no differentiation potential (Chapter 4);
• A similar CD34-CD103+Lin-CD127-  population was found in the thymus (Chapter 3), but  
 in contrast to the intestine this contained bipotential NK/T precursors (Chapter 5)
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DIRECTIONS FOR FUTURE RESEARCH
Our studies shed light on the diversity and plasticity of CD3- innate IEL subsets and challenged 
our understanding of the composition of the IEL compartment. They further demonstrated 
how knowledge of a premalignant cell population in a rare disease, such as RCDII, can lead 
to the identification of a novel physiological cell population. It brought up the concept, that 
IEL maturation can be influenced by disease. Nevertheless, several questions still need to be 
answered: 
PLASTICITy: WHAT IS THE ExPRESSION PROFILE OF INNATE IEL 
SUbSETS IN HEALTH AND DISEASE?
To gain further insight into the physiology and relationship of the different innate IEL populations 
in healthy versus diseased tissues, unbiased approaches such as microarray or RNA sequencing 
should be performed. Preferably at the single cell level. It is challenging to generate sufficient 
amounts of RNA for such an analysis, nevertheless it should be technically feasible to perform 65. 
These high throughput technologies could yield crucial information with regard to the expression 
of transcription factors (TF), cytokines and cytokine receptor in these innate IEL subsets; and how 
such innate IEL respond to specific stimulation, for example to cytokines. Furthermore, it could 
indicate which markers can be used to further differentiate these subpopulations and which 
alterations are linked to the developement of intestinal diseases like CD, RCD and inflammatory 
bowl disease (IBD). Alternatively, a comprehensive analysis could also be performed with the 
use of a Cytometer coupled to a Time-of-flight analysis (CyTOF). In the near future a CyTOF is 
expected to allow simultaneous analysis of up to 100 markers simultaneously 66, 67. Thus, the 
following issues could be addressed:
• What is the expression profile of innate IEL subsets in health and disease?
 Parallel sorting of T-IEL, innate IEL subsets from healthy, CD and RCDII biopsies (or other  
 gastrointestinal diseases) and subsequent microarray or RNA sequencing analysis   
 (focusing on TF, cytokine responsiveness)
• How do cytokines alter the expression profile of the different subsets?
 Parallel sorting of IEL subsets after incubation with cytokines (such as IL-15, IL-21, IL-7)  
 and subsequent microarray, RNA sequencing or CyTOF analysis (focusing on TF,   




DIFFERENTIATION: HOW ARE LINEAGE DECISIONS OF LIN-CD127-IEL 
AND INNATE IEL REGULATED?
We have provided evidence that Lin-CD127- IEL can differentiate into T and NK cells. This needs 
to be further investigated and validated. Moreover, it needs to be determined which factors 
influence lineage decisions. Two important candidates which could play a role and have been 
discussed are IL-15 and notch-ligands, such as DLL1.  Which cell types express IL-15 and notch-
ligands (these could be enterocytes, goblet cells, DC) and where are IL-15 and DLL1 (co-)localized? 
Is there a differential expression, when comparing CD/RCDII with non-CD controls? Hence, these 
questions could be studied as follows:
• What is the lineage relationship of Lin-CD127-IEL with T and NK cells?
 IEL could be tranduced with a barcode library and transduced Lin-CD127-IEL could be   
 subsequently sorted onto OP9DL1. After differentiation T and NK cells can be   
 sorted and the barcodes in both populations are analyzed by a microarray platform. 
 According to the barcodes recovered the lineage relationship can be calculated.
• Which factors influence lineage decisions of Lin-CD127-IEL?
 - To study the interaction of lymphocytes with IL-15 and notch-ligands, such as DLL1,   
 histology on small intestinal biopsies could shed light on the presence and localization of  
 DLL1 and IL-15 in different patient cohorts;
 - Fate mapping experiments in mice with stable expression of fluorescent CD3 proteins  
 could discriminate icCD3+ innate IEL subsets to investigate the role of CD3 chains in T/  
 NK cell differentiation;
 - The addition of different soluble factors, such as cytokines (IL-7, IL-21) or supernatants  
 of activated gluten-specific T cells to Lin-CD127-IEL onto OP9DL1 could evaluate if such  
 factors can influence lineage decisions;
 - Co-culture of Lin-CD127-IEL on human intestinal epithelial cultures (e.g. organoids)   
 could indicate if (and which) intestinal cells can also provide differentiation signals for T/ 
 NK cell development 
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TUMORGENESIS: WHICH ONCOGENES CAUSE MALIGNANCIES OF LIN-
CD127-IEL IN EATL?
As discussed above, the overexpression of icCD3ε could potentially lead to transformation. It 
needs to be investigated how (i) notch-signaling can induce icCD3 expression 55 and (ii) how 
overexpression of CD3ε leads to tumorigenesis 62. This could be elucidated as follows:
• Which factors can act as an oncogene driving the transformation of aberrant IEL 
 into EATL? 
 - DNA sequencing could yield information on whether certain mutations, SNP, or   
 chromosomal translocations such as those previously described for Chromosome 1q (68  
 and data not shown) can be detected. Implications of these mutations could be tested  
 in vitro; 
 - Overexpression of CD3 chains by retroviral transduction of primary cells (IEL,   
 thymocytes) could determine if and how high copy numbers of CD3 chains    
 induce uncontrolled cell growth and differentiation arrest in immature cells.
WHAT ARE THE IMPLICATIONS FOR FUTURE THERAPIES?
Our studies thus demonstrated that the small intestinal epithelium not only harbors T-IEL, but also 
a diverse innate IEL compartment, which exhibited plasticity and differentiation potential. What’s 
more, our studies highlighted the idea that CD can profoundly influence not only the composition, 
but also the developmental capacities of IEL. The failure to further differentiate seems to be an 
important hallmark of the premalignant nature of Lin-CD127-  IEL in RCDII patients and future 
studies need to investigate which factors can influence maturation, expansion and transformation 
of IEL subsets. This knowledge may ultimately lead to the development of diagnostic tests, aiming 
at detecting derailed IEL maturation before the development of a full blown lymphoma and 
classifying CD patients at risk of developing RCDII or RCDII patients at risk to develop EATL. If we 
understand the different maturation stages of innate IEL in the healthy gut, in CD and in RCDII, 
this knowledge could help us understand which triggers lead to expansion and transformation. 
This information could then be used to further predict clinical outcome in RCDII or responsiveness 
to the treatment of the lymphoma. Such a ‘scaling’ of aberrant IEL maturity has already been 
suggested to predict clinical outcome in RCDII 24 and calls for further investigation. 
Our studies have also shown, that RCDII patients harbor expanded Lin-CD127- and Lin-CD127+ IEL 
populations, both likely responding to different cytokines. Treatment with anti-IL-15 therefore is 
probably not sufficient in these patients, as this would risk the selective expansion of Lin-CD127+ 




of the common γ chain receptors (including IL-15 and IL-7), such as Jak3 or STAT5 inhibitors. 
Increased Jak3 and STAT5 phosphorylation has been demonstrated in IEL from RCDII patients, 
compared to controls 15.
Ultimately, by understanding the distinct developmental stages and their implications for cell 
survival and function, specialized treatment and intervention strategies could be developed to 
prevent malignancy. Knowledge of the confounding factors leading to transformation of Lin-IEL in 
RCDII will generate cues for an optimized treatment of EATL. It is now becoming clear that EATL 
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COELIAKIE EN REFRACTAIRE COELIAKIE
Coeliakie is een darmziekte die veroorzaakt wordt door gluten: eiwitten uit tarwe, rogge en gerst. 
Deze gluten eiwitten worden door immuuncellen als lichaamsvreemd herkend en dit heeft een 
ontsteking in de darm tot gevolg. Deze herkenning van gluten gebeurt alleen bij mensen die een 
genetische dispositie hebben: ze zijn HLA-DQ2 of HLA-DQ8 positief.  HLA-DQ2 en -DQ8 binden 
fragmenten van gluten die door afbraak ontstaan en deze complexen kunnen  immuuncellen 
activeren.
Coeliakie patiënten mogen hun leven lang geen gluten eten omdat elke keer dat zij dat doen de 
immuuncellen geactiveerd worden. Dit heeft een onsteking, dus schade in de darm als gevolg. 
Een glutenvrij dieet leidt bij de meeste coeliakiepatiënten tot herstel van de darmschade en het 
verdwijnen van de klachten. Echter bij een klein aantal coeliakie patiënten werkt het glutenvrij 
dieet niet zodat, ondanks het strikt volgen van een glutenvrij dieet, de darm nog steeds ontstoken 
is. Deze patiënten worden refractaire coeliakie (RC) patiënten genoemd. Tot nu toe weet men niet 
waarom deze patiënten niet beter worden hoewel ze een glutenvrij dieet volgen. 
HET IMMUUNSySTEEM vAN DE DUNNE DARM
Omdat veel RC patiënten afwijkende immuuncellen in hun dunne darm hebben, zijn deze 
immuuncellen in dit proefschrift nauwkeurig onderzocht. De darm bevat het grootste aantal 
immuuncellen van het lichaam. Deze zijn ervoor verantwoordelijk om aan de ene kant tegen 
bacteriën en virussen te vechten maar aan de andere kant tegelijkertijd ook tolerant tegen 
voedingstoffen te zijn. De immuuncellen die in de darmwand zitten (zogenaamde intra-epitheliale 
lymfocyten) zijn meestal T-cellen, die direct contact met ‘buiten’ hebben. Daarom bezitten 
deze belangrijke functies om de darm te beschermen. Bij coeliakie is het aantal intraepitheliale 
lymphocyten sterk verhoogd en deze kunnen epitheliale cellen vernietigen en zo aan het ziekte 
proces bijdragen.  
Maar het is ook bekend dat er niet alleen maar T-cellen in de darmwand zitten. Hoewel de exacte 
identiteit en functie(s) van deze andere cellen nog grotendeels onbekend is, is het wel duidelijk 
dat de aantallen van juist deze cellen bij refractaire coeliakie sterk verhoogd is.  Omdat zij sterk 
afwijken van de ‘gewone’ darmcellen worden zij ‘aberrant’ genoemd. Deze afwijkende cellen 
kunnen zich aanzienlijk snel vermenigvuldigen. Vaak ontsporen zij en ontwikkelen zich tot een 
lymfoom (kanker). Tot nu toe is deze lymfoom heel slecht te behandelen. Verder is niet bekend 




In dit proefschrift hebben wij onderzocht wat de oorsprong van deze ‘afwijkende’ cellen in 
RC patiënten is en hoe zij zich ontwikkelen. Hiervoor hebben wij darmcellen (intra-epitheliale 
lymfocyten) van refractaire coeliakie patiënten vergelijken met cellen uit de darm van ‘gewone’ 
coeliakie patiënten, en met cellen van patiënten die geen coeliakie of RC hebben (controle groep). 
Wij hebben onderzocht wat deze aberrante cellen nodig hebben om te delen en hebben deze 
cellen uitgebreid gekarakteriseerd om te kunnen bepalen hoe afwijkend deze cellen in vergelijk 
met ‘gewone’ cellen uit de controle groep echt zijn.
HOOFTSTUK 1: INLEIDING
Hooftstuk 1 geeft een algemene inleiding over het immuunsysteem, deze gaat met name over 
het immuunsysteem in de darm. Er wordt samengevat wat er tot nu toe bekend is over intra-
epitheliale lymfocyten bij gezonde individuen, coeliakie en refractaire coeliakie patiënten. 
HOOFDSTUK 2: DENDRITISCHE CELLEN INDUCEREN DELING vAN 
AbERRANTE CELLEN 
Onze studies met aberrante cellen uit de darm van RC patiënten laten zien, dat deze cellen gaan 
delen als zij contact hebben met andere immuuncellen, namelijk dendritische cellen. Deze reactie 
is specifiek voor aberrante cellen, omdat ‘gewone’ darmcellen niet gaan delen bij contact met 
dendritische cellen. Eerdere studies hebben aangetoond dat er veel dendritische cellen in een 
ontstoken darm zijn. Contact van aberrante celen met dendritische cellen zou dus  (onder andere) 
vermoedelijk tot expansie van aberrante cellen leiden- een kenmerk van RC.
HOOFDSTUK 3: ‘AbERRANTE’ CELLEN zIJN EEN NATURLIJKE 
CELPOPULATIE
In hoofdstuk 3 gaan we in op de vraag waar aberrante cellen vandaan komen. Een hypothesis 
postuleert dat aberrante cellen ontspoorde rijpe T-cellen zijn, een andere dat ze al aanwezig zijn 
in een gezond individu, maar in een zo kleine hoeveelheid dat ze daarom nog niet ontdekt zijn. 
Om te onderzoeken of deze cellen inderdaad aanwezig zijn, hebben wij eerst een uitgebreide 
karakterisering van deze cellen uit darmbiopten van refractaire coeliakie patiënten uitgevoerd. 
Nadat wij wisten hoe deze cellen er precies uitzagen, hebben wij gekeken of er soortgelijke 
cellen in darmbiopten van ‘gewone’ coeliakie patiënten en de controle groep te vinden zijn. Wij 
hebben ontdekt dat zulke cellen juist veel voorkomen bij kinderen zonder coeliakie, en minder 




refractaire coeliakie zijn, maar een normale fysiologische celpopulatie zijn.  In refractaire coeliakie 
kunnen deze ‘natuurlijke’ cellen zich vermeerderen en uiteindelijk ontsporen en zo tot een 
lymfoom leiden. Omdat deze cellen kenmerken van zowel T-cellen als ook van NK-cellen (natural 
killer cells) hebben, hebben wij aangenomen dat zij onrijpe cellen zouden kunnen zijn, die zich 
nog niet tot rijpe T- of NK-cellen hebben ontwikkeld.
HOOFDSTUK 4: HET LyMPHOCyTEN COMPARTIMENT IN DE DARM IS 
DIvERS
Studies over cellen in de darmwand waren tot nu toe voornamelijk gericht op één celtype, 
namelijk de T-cellen. Omdat wij uit onze studies in hoofdstuk 3 weten dat er ook andere cellen 
zijn (die kenmerken van zowel T- als NK-cellen bevatten) wilden wij weten hoeveel en welke 
verschillende celtypen er überhaupt in de darmwand zitten. 
In hoofdstuk 4 laten wij zien dat het intra-epitheliale lymfocyten compartiment heel erg divers is 
en dat dit er bij coeliakie en RC patiënten anders uit ziet dan bij de controle groep. Wij vonden 
dat er naast T-cellen ook nog vier verschillende subtypes van (niet T-)cellen in de darmwand 
zitten, die wij innate lymfocyten noemen. Dit zijn de door ons beschreven cellen uit hoofdstuk 3, 
NK-cellen en cellen die verder nauwelijks bekend zijn en deel uitmaken  van de innate lymfocyten 
in de dunne darm. Verder zagen wij leeftijdsafhankelijke veranderingen in dit compartiment in 
individuen uit de controle groep. Dit betekent dat darmcellen sterk beïnvloed worden door zowel 
leeftijd van het individu, als ook door ziekte, zoals coeliakie.
ONRIJPE CELLEN KUNNEN NOG vERDER ONTWIKKELEN
De meeste immuuncellen in de darm zijn rijpe cellen (rijpe T-cellen), die zich niet meer verder 
kunnen ontwikkelen. Over potentiële onrijpe of voorlopercellen is minde bekend. In hoofdstuk 3 
hebben wij cellen beschreven die kenmerken van zowel T- als ook NK-cellen hebben en dus onrijp 
zouden kunnen zijn. Zulke onrijpe cellen zijn in de mens nauwelijks beschreven en tot nu toe 
slechts bij muizen aangetoond. Om te onderzoeken of de door ons beschreven cellen inderdaad 
onrijp zijn, hebben wij deze cellen uit de darm geïsoleerd en in kweek (in vitro) getest of zij zich 
verder kunnen ontwikkelen (hoofdstuk 4). 
Een van de bevindingen in dit hoofdstuk is dat deze cellen uit de controle groep (geen coeliakie of 
RC patiënten) zich voornamelijk tot NK-cellen differentiëren. Bij coeliakie patiënten ontwikkelen zij 
zich meer tot T-cellen en bij RC patiënten kunnen deze cellen zich niet meer verder ontwikkelen. 
Uit deze studies hebben wij geconcludeerd dat zulke cellen inderdaad onrijpe cellen zijn. 
Refractaire coeliakie zou dus als gevolg van een ontwikkelingsstop kunnen ontstaan. Welke 
factoren deze ontwikkeling kunnen hinderen en of de huidige bestaande therapie voor onrijpe 
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cellen zou kunnen toegepast worden, is het doel van toekomstig onderzoek. 
HOOFDSTUK 5: vERGELIJK vAN ONRIJPE CELLEN UIT DE THyMUS 
MET DE DARM
In hoofdstuk 5 beschrijven wij een vergelijkbare celpopulatie in de menselijke thymus die in 
tegenstelling tot de darm tegelijkertijd T- en NK-cel kan worden (in de darm worden deze cellen 
óf T-cel óf NK-cel). Deze celpopulatie in de thymus is dus nog onrijper omdat zij nog alle twee de 
kanten uit kan gaan.
HOOFDSTUK 6: WAT WIJ GELEERD HEbbEN/KUNNEN LEREN OvER 
INNATE LyMFOCyTEN EN HUN ONTWIKKELING
In hoofdstuk 6 worden onze studies over de darm- en thymuscellen samengevat en onze 
resultaten vergeleken met de resultaten van andere studies. Tot nu toe is er nog weinig bekend 
over innate lymfocyten in de darm. Door onze studies weten wij nu dat dit compartiment divers 
is en hoe wij het kunnen onderscheiden. Dat biedt belangrijk perspectief voor vervolgonderzoek 
naar de functie van deze cellen in het darmepitheel. Ook hebben wij laten zien dat het hier 
mogelijk voorlopercellen betreft. Dit laatste is een controversieel onderwerp omdat het 
onduidelijk is of er (in de mens) überhaupt ontwikkeling van onrijpe cellen in de darm kan plaats 
vinden. 
Vervolgstudies zijn dus noodzakelijk om meer inzicht in de functie van deze innate lymphocytten 
in het darmepitheel te verkrijgen. Als wij meer over de cellen in de darmwand weten – zowel T 
cellen als innate lymfocyten- waar ze vandaan komen, tot welke cellen ze kunnen ontwikkelen en 
door welke factoren dit beïnvloed wordt- dan kan dit er toe bijdragen dat we darmziektes beter 
kunnen behandelen. Het uiteindelijke doel is om een effectieve therapie te ontwikkelen voor 
patiënten met refractaire coeliakie. Vervolgonderzoek zou er ook aan kunnen bijdragen dat we 
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